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Summary 
Pulmonary arterial hypertension (PAH) is a rare but devastating disorder of the 
pulmonary vasculature characterised pathologically by progressive intimal 
obliteration and vascular remodelling leading to increased pulmonary vascular 
resistance (PVR) and elevation in pulmonary arterial pressure (PAP), and clinically 
by functional impairment from breathlessness and ultimately death from right 
ventricular failure. Whilst the initial insult occurs in the pulmonary circulation, it 
is increasing recognised that survival relates to the ability of the right ventricle 
(RV) to adapt to this increased afterload. Despite a number of therapeutic 
advances in recent years, long-term survival remains poor, quality of life impaired 
by functional limitation and progression to RV failure often inevitable.  
In contrast, pulmonary hypertension (PH) related to chronic lung disease is 
relatively common, but is usually mild in severity with largely preserved RV 
function. The development of PH is however associated with greater functional 
impairment and worse survival and at present other than referral for lung 
transplantation there are no therapeutic options. Severe PH associated with lung 
disease is relatively rare, but shares many of the characteristics with PAH with 
more severe RV dysfunction and significant morbidity and mortality. It is also 
increasingly recognised in data from large PH registries, that increasing overlap 
exists between the two conditions, and what represents PAH with co-morbid lung 
disease (and therefore should receive specific PAH therapies) and what is PH 
secondary to lung disease (and therefore should not) increasingly muddied. 
What is clear is the critical role the RV plays in determining outcome in PH, but 
despite this studies on the impact of current therapies on RV function are few, 
and improvement or preservation of RV function is not an accepted clinical 
endpoint in pharmaceutical trials. Current methods of monitoring patient 
response to therapies are suboptimal, such as the established and commonly 
employed six minute walk distance (6MWD). The complex anatomy of the RV 
makes assessment of its function by modalities such as echocardiogram difficult. 
The development of simple, reproducible measures of RV function will both 
improve monitoring of PH patients but also facilitate acceptance of routine 
assessment of RV function in both clinical practice and pharmaceutical trials, and 
hopefully establish the optimal approach to RV dysfunction in PAH. Cardiac 
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magnetic resonance imaging (CMR) is particularly suited to interrogating RV 
function, and has recently been established in the literature to provide prognostic 
significance in a number of disease states including PAH. At present, however, it 
is unclear what the optimal method of assessing RV function is, with a number of 
indices assessed by varying modalities associated with prognosis and therapeutic 
response in PAH. Recently research interest has developed in the potential utility 
of RV-arterial coupling in PH. From physiological principles, this metric of RV 
function has potential superiority over commonly employed indices such as RVEF 
or right atrial pressure (RAP) as it is less preload dependent. Its clinical use 
however is limited due to the need for instantaneous pressure-volume loops at 
varying levels of load in its derivation. It is however possible to estimate non-
invasively by CMR. The aim of the work described by this thesis was to provide 
clarity on the optimal method of determining and monitoring RV dysfunction in 
PAH patients, and contrast this to patients with severe PH associated with lung 
disease treated with PAH therapies, where the aetiology of PH differs and utility 
of CMR to characterise RV function has not been explored. 
In chapter 3 PAH therapies given to severe PH/lung disease patients resulted in 
improvements in 6MWD (average ∆6MWD 24m, p=0.032), and NTproBNP (average 
∆NTproBNP -396pg/mL, p=0.008), but to a lesser extent than IPAH patients. CMR 
imaging demonstrated that RV dysfunction (assessed by RV ejection fraction 
(RVEF), stroke volume (SV) and increased RV volumes) was prevalent, predicted 
prognosis in both conditions, and could be used to detect PH in lung disease by 
either measures of pulmonary vascular stiffness (relative area change of main 
pulmonary artery – RAC MPA) or RV mass (RVM).  
In Chapter 4, invasive pressure (Ees/Ea-P) and non-invasive volume (SV/ESV) 
estimates of RV-arterial coupling (determined by right heart catheterisation and 
CMR) were compared to other metrics of RV function in normal subjects, PAH and 
PH associated with lung disease patients as prognostic variables. Severe PH/lung 
disease patients displayed impaired RV adaptation in comparison to IPAH subjects, 
Ees/Ea-P 1.07 versus 1.37mmHg/mL, p=0.020. RV-arterial coupling estimated by 
the pressure method did not predict survival, but when estimated by the volume 
method (SV/ESV) did. Both RVEF and SV/ESV were independent predictors of 
outcome (HR 0.958, p=0.006 and HR 0.329, p=0.002 respectively). Invasive 
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measures of RV function therefore provided no prognostic advantage over the 
more patient acceptable CMR. 
Finally in chapter 5, improvement in RV-arterial coupling assessed by CMR 
(SV/ESV) was seen after commencing PAH therapy (0.461 to 0.616, p=0.036). 
Survival was poorer in those with a fall in either RVEF or SV/ESV during therapy, 
with no superiority of either method of determining prognosis (Logrank p=0.002 
for both). Change in RV function poorly related to change in 6MWD but closely 
related to change in NTproBNP. ∆NTproBNP but not ∆6MWD was an independent 
predictor of survival (HR 1.622 p=0.024 and HR 0.995 p=0.129 respectively) and 
therefore a useful monitoring tool of RV function and therapy response for the 
clinic.  
The results described in this thesis therefore suggest that RV function to predict 
outcome in patients with PH during treatment follow up is best determined by 
CMR imaging of RVEF or SV/ESV, with no clear benefit of re-evaluating invasive 
haemodynamics or pressure estimates of RV-arterial coupling. 
Chapter 1 – Introduction 
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The term Pulmonary Hypertension describes a group of diseases characterised by 
an elevation in Pulmonary artery pressure (PAP) and Pulmonary vascular resistance 
(PVR). Clinically, patients develop symptoms of breathlessness, peripheral 
oedema and exertional syncope with evidence of right ventricular (RV) dysfunction 
and ultimately die as a result of RV failure. In recent years development of a 
number of disease specific therapies has led to improvements in morbidity and 
survival. Despite this, PAH remains a devastating disease with progressive 
functional limitation, high symptom burden and mortality. Until relatively 
recently the RV had been less studied than other aspects of PAH, and relatively 
poorer understanding of the mechanisms of RV failure, prognostic implications of 
specific changes in RV structure and function or the effects of PAH specific therapy 
on the RV exists. Furthermore, how best to assess or monitor RV function is unclear 
with a number of invasive parameters, such as RAP, imaging modalities such as 
echocardiography or cardiac MRI or biomarkers currently linked to prognosis. 
1.1 Structure and function of the normal right heart and 
pulmonary vasculature 
 
1.1.1 Pulmonary Circulation 
The pulmonary circulation is a highly compliant, high flow low pressure system 
which favours pulmonary gas exchange (1). The low pressures prevent fluid moving 
out in to the interstitial space and allow the right ventricle to perform at low 
energy cost. The pulmonary circulation is characterised by an inflow pressure, the 
pulmonary artery pressure, an outflow pressure, left atrial pressure and 
pulmonary blood flow which is approximately equal to systemic cardiac output 
(CO). Mean pulmonary artery pressure (mPAP) is flow dependent and in normal 
subjects increases by 1mmHg for every 1mmHg increase in Left atrial pressure 
(LAP). LAP is approximated by wedged pulmonary artery pressure (PAWP) to allow 
estimation of pulmonary vascular resistance. The normal distribution of  vascular 
resistances is 60% arterial and 40% capillary plus venous resistance (2). In health, 
the pulmonary arteries exhibit low basal smooth muscle tone and the PVR is only 
around 1/20 of systemic vascular resistance (3). 
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The pulsatility of the pulmonary circulation is more significant than that of the 
systemic circulation, which effects the energy transmission from the right 
ventricle to pulmonary arteries. Pulmonary arterial pulse pressure, the difference 
between systolic and diastolic pressures, is in the order of mPAP (in comparison 
to the systemic circulation where it is less than half the mean), and flow varies 
across the cardiac cycle from a maximum at mid systole to virtually zero in 
diastole (1). The distensibility of pulmonary resistive vessels has been shown to 
approximate to 2% of diameter change per mmHg of distending pressure over a 
range of species (4). This distensibility coefficient has been shown to decrease 
with ageing, chronic hypoxic and probably displays gender differences (5-7). The 
distal arteries and arterioles hold most of the capacitance properties of the 
pulmonary circulation, with the proximal lung vessels accounting for as little as 
20% of total vascular compliance (8). At lower mean pressures the compliance and 
pulsatile components of the pulmonary circulation constitute a larger fraction of 
the total afterload of the right ventricle, with some suggesting the pulsatile load 
may account for between one third and up to 50% of the total (9, 10). The study 
of the pulmonary arterial circulation as a steady flow system is therefore an 
oversimplification.  
Tight correlation exists between systolic, diastolic and mean pulmonary artery 
pressure which persists in diseases of the pulmonary vasculature (11). Clinically 
this is of relevance as it allows the estimation of mPAP from systolic PAP (sPAP) 
using the formula mPAP = 0.6 x sPAP + 2 (12). sPAP may be calculated using the 
Bernouilli equation from the tricuspid regurgitant pressure gradient (TRPG) which 
can be determined non-invasively by echocardiogram (13). The product of PVR by 
pulmonary artery compliance (SV/PP) remains constant at 0.7 in both health and 
disease of the pulmonary vasculature which explains this tight relationship (14, 
15). The exception to this is proximal pulmonary artery obstruction which may 
occur in diseases such as proximal chronic thromboembolic pulmonary 
hypertension (16) or experimentally with pulmonary banding models of pulmonary 
hypertension (17). This hyperbolic relationship explains why right ventricular 
afterload may already be markedly increased despite minimal rise in calculated 
PVR in early pulmonary vascular disease.  
The normal value for mPAP derived from a study of 55 healthy young adults is 
around 13mmHg (range 6-16 mmHg) (18-21). Ageing is associated with an increase 
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in PVR which is more marked on exercise than at rest and probably relates to an 
increase in arterial stiffness. The exact limits of normal pulmonary pressure as 
they relate to age is unknown due to the small number of measurements in older 
healthy individuals. The slight increase in mPAP but more significant decrease in 
CO has been shown to lead to a doubling of PVR over five decades of age (22, 23). 
A more recent review showed a small change in mPAP with age, from 12.8± 3.1 
mmHg in healthy subjects <30 years compared to 14.7 ± 4.0 mmHg in those ≥50 
(24). Sex has been shown not to influence pulmonary haemodynamics after 
correction for body dimension.(1, 24) 
Pulmonary blood flow increases in an approximate linear fashion from non-
dependent to dependent areas of the lung. The vertical height of an average 
human lung is approximately 30 cm, the difference in pressure of a corresponding 
vertical column of blood is 23 mmHg which is considerable in the context of the 
mean pressure of the pulmonary circulation (i.e. 6-16 mmHg quoted earlier) (25). 
Gravity dependent influences on arterial, venous and alveolar pressures result in 
the inequality of perfusion distributed from top to bottom of the upright lung 
reported by West to describe three zones of blood flow in the human lung (25). In 
zone 1 at the top of the lung, alveolar pressure (PA) exceeds both venous (PVP) 
and arterial pressures (PAP). In this zone pulmonary blood flow may occur only in 
systole or perhaps not at all with resultant poor gas exchange. The extent of zone 
1 may extend in conditions of low flow or increased alveolar pressure, such as 
occurs with mechanical ventilation with positive end expiratory pressures. In zone 
2, the midzone of the lung, arterial pressure exceeds alveolar pressure, which in 
turn is greater than venous pressure (PAP> PA>PVP). Under these conditions driving 
pressure for flow is the gradient between PAP and PA. In zone 3 at the bottom of 
the lung, PVP exceeds PA so the driving pressure for pulmonary blood flow is the 
PAP-PVP gradient. In the supine lung, the lung is almost completely in zone 3, 
although there is still measurable increase in blood flow from non-dependent to 
dependent areas. 
Active regulatory mechanisms are able to some extent to influence the passive 
gravity dependent distribution of pulmonary blood flow. Hypoxic pulmonary 
vasoconstriction (HPV) was first reported by von Euler and Liljestrand (26). The 
response is found in mammals and birds but with significant inter species and 
individual variability. The systemic and pulmonary circulations are polar opposites 
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in their response to hypoxia. In the systemic circulation vasodilation occurs in an 
attempt to improve tissue oxygenation. In the pulmonary circulation, a decrease 
in PA02 causes an increase in vascular tone, resulting in vasoconstriction and 
diversion of pulmonary blood flow away from underventilated alveoli, to 
preferentially perfuse well ventilated areas of the lung in an attempt to maintain 
ventilation-perfusion (VQ) matching and therefore oxygenation of arterial blood. 
HPV increase in PVR is mainly effected by pre-capillary arterioles although small 
pulmonary veins also undergo vasoconstriction and contribute to approximately 
20-30% of the increase in PVR (27, 28). HPV is enhanced by factors including 
acidosis, reduced mixed venous Pa02, repeated hypoxic exposure and decreased 
lung segment size, and inhibited by alkalosis, hypercapnia, pulmonary vascular 
and alveolar pressures, nitric oxide and vasodilating prostaglandins and drugs 
including calcium channel blockers (29). The response is biphasic with 
vasoconstriction followed by vasodilation in more profound hypoxia. The 
mechanism of sensing the low PA02 is not yet identified. It is thought that a 
decrease in PA02 inhibits smooth muscle cell voltage gated potassium channels 
leading to membrane depolarisation, calcium influx and resultant cell shortening 
(30). In the presence of continued alveolar hypoxia or widespread VQ mismatch, 
HPV may lead to group 3 PH (secondary to chronic lung disease) or high altitude 
PH. 
In addition to HPV regulation, pulmonary vascular tone is attenuated by mediators 
including endothelium derived vasodilators nitric oxide and prostacyclin and the 
vasoconstrictor endothelin. These mediators have been the focus of development 
of potential therapies for PH. Several other circulating mediators including 
serotonin, histamine and angiotensin II have been shown to affect vascular tone. 
Finally, the pulmonary circulation is highly innervated by adrenergic, cholinergic 
and non-adrenergic non-cholinergic (NANC) nerve endings. However the role 
played in the regulation of pulmonary circulation appears minor. The innervation 
is mainly proximal which may suggest a role in proximal vascular compliance (31). 
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1.1.2 The right ventricle 
Until relatively recently the importance of right ventricular function was poorly 
appreciated. Galen described the right ventricle (RV) as a passive conduit through 
which part of the circulating volume of blood passes to the lungs for nourishment 
with the remainder thought to seep through invisible pores in the interventricular 
septum for the formation of vital spirit (32). In the 13th century Ibn Nafis disputed 
the existence of these septal pores, instead for the first time suggesting that blood 
must pass through the lungs from the RV to the LV. 300 years later Michael 
Severtus came to the same conclusion in his theological treatise Christianismi 
Restitutio. William Harvey in 1628 has often been accredited with the origins of 
the role that the RV plays in the pulmonary circulation (33-35). Harvey was the 
first to develop an experimentally based model of the circulation based on 
detailed measurements and calculations that allowed him to conclude that the 
blood recirculated rather than previous speculations of Galen that blood was 
produced in the liver and consumed by the tissues and organs (3). Even in the 
1940s the idea that a functioning RV was not essential to maintain pulmonary 
circulation was accepted after several studies in dogs showed that cauterisation 
of the RV did not lead to changes in systemic venous or pulmonary arterial 
pressures (36, 37). These studies were in open pericardial models and therefore 
did not explore the influence of ventricular interaction. Studies using RV models 
between 1950-1980 demonstrated that the RV was necessary for maintenance of 
pulmonary blood flow (38, 39). However these studies did not achieve widespread 
acceptance as the models used were met with criticism (35). In 1982 in an animal 
model with intact pericardium it was demonstrated that RV infarction lead to drop 
in cardiac output suggesting the importance of RV function (40). Since then the 
importance of the role the RV plays in both exercising healthy individuals and in 
many disease states has become well recognised (41-43). 
The RV and outflow tracts develop embryologically from the anterior heart field 
while the remaining chambers of the heart arise from the primary heart field with 
resultant differences in genetic makeup and cellular physiology (44). The RV is the 
dominant chamber in the foetus, with equable wall thickness and force generated 
by RV and the LV in early life. During the first year of life the RV involutes and 
increases its compliance. The muscle mass of the RV is approximately 1/6 of the 
LV and under normal loading conditions a 5 mmHg pressure gradient across the 
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pulmonary circulation is sufficient to maintain cardiac output and therefore 
minimal RV contractile function is normally required with 1/4th the stroke work of 
the LV (34). The RV is a thin walled crescent shaped chamber, normally less than 
1-3 mm in thickness whose volume is slightly greater than that of the LV. The RV 
may be divided into an inflow tract, the sinus (body) region with a trabeculated 
muscular apex and a smooth walled conus or outflow tract. The RV free wall 
constitutes the anterior border of the RV, lying anterior to the LV and 
interventricular septum (IVS). Under normal loading conditions, the IVS is concave 
towards the RV in both systole and diastole. Short axis cross sections through the 
RV from apex to base vary from a triangular contour at the apex to a crescentric 
appearance at the base which explains the difficulty with using 2D imaging 
techniques to interrogate RV size and function in this complex geometric shape. 
The sinus contains in excess of 80% of total RV volume with different fibre 
orientation compared to the conus. In addition, timing of contraction differs 
between the compartments. Contraction occurs sequentially from the apex 
towards the conus in a peristaltic fashion using predominantly longitudinal fibres 
in a bellows type movement suited to the low impedence pulmonary circulation 
(45, 46). In contrast, the longitudinal and circumferential muscle fibres of the LV 
allow for a more cylindrical contraction. As a result of the larger RV chamber size, 
under normal conditions, RVEF is lower than LVEF, quoted between 40-76% 
dependent on imaging modality used (47-49). 
The RV largely receives its blood supply from the right coronary artery in 
approximately 80% of the population. The lateral wall is supplied by the marginal 
branches with the posterior wall and inferoseptal region supplied by the posterior 
descending artery. The anterior wall and anteroseptal region are supplied by 
branches of the left anterior descending artery. Unlike the LV, where myocardial 
perfusion is largely limited to diastole, the RV intramyocardial pressure remains 
below aortic root pressure throughout the cardiac cycle and therefore continuous 
coronary flow occurs (50). The RV displays relative resistance to irreversible 
ischaemia in comparison to the LV, probably as a consequence of its lower oxygen 
consumption, more extensive collateral blood supply and ability to increase 
oxygen extraction. 
Both ventricles are encircled by spiralling muscle bundles in a complex interlacing 
fashion forming a functionally single unit. Ventricular interaction occurs not only 
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as a series indirect interaction but also directly as a result of the shared IVS, 
continuity between the muscle fibres and shared pericardium (51). During systole, 
LV contraction influences pressure development in the RV. Pericardial constraint 
means that the compliance of each ventricle is influenced by the volume and 
pressure of the other. Animal models have demonstrated that 20-40% of RV systolic 
pressure and volume ejected is a result of LV contraction. Models of impaired RV 
function with scarring of the RV have demonstrated that the septum is able to 
maintain pulmonary circulation provided that RV dilatation does not occur. 
Ventricular interaction becomes of significance in disease states such as 
pulmonary hypertension where LV diastolic filling is impaired by both series effect 
and the direct effect of leftward septal bowing as a result of RV pressure and 
volume overload (52).  
Right ventricular function is determined by preload, a measure of RV filling, 
afterload and contractility. Under normal filling conditions, an increase in preload 
results in increased contractility and cardiac output (53). In addition to chamber 
compliance, heart rate and the afore mentioned LV filling and pericardial factors, 
RV filling is influenced by negative pressure of respiration to a greater degree than 
the LV because of its thin free wall and connection to systemic veins (21). The RV 
has a limited ability to compensate for increased afterload, acutely the normal 
RV is unable to generate pressures that exceed 40-60 mmHg (54). Right ventricular 
response to an increase in filling is the Frank-Starling mechanism. Increasing 
ventricular end diastolic volumes with greater sarcomere length at the beginning 
of contraction, results in a greater force of contraction due to alteration in 
myofilamental sensitivity to calcium as a result of stretch (55). Consequently 
stroke volume increases in response to increased venous return. Similarly an acute 
increase in RV afterload in pathology such as pulmonary embolism which results 
in an increase in RVEDV in an attempt to compensate and maintain stroke volume 
through the same mechanism, sometimes called heterometric adaptation. In 
addition, other compensatory mechanisms exist to maintain SV to a certain extent 
in the face of an increase in afterload. An increase in myocardial contractility 
(inotropy) occurs in the acute setting by activation of the sympathetic nervous 
system. B-adrenergic receptor stimulation, located on the cardiac myocytes leads 
to increased contractility through an increase in intracellular free calcium. 
Additionally, sympathetic activation enhances rate of lusitropy (relaxation) as a 
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result of faster re-uptake of calcium ions by the sarcoplasmic reticulum and a 
resultant quicker release of calcium from the myofilaments (35). The RV also 
adapts through a continued progressive increase in cardiomyocyte contractile 
force over the 10-15 minutes following the acute rise in contractility as a result 
of the Frank-Starling mechanism, known as the Anrep phenomenon. This 
mechanism involves stretch related release of angiotensin II and endothelin (56) 
and results in a progressive decline of RVEDV and pressure after the initial increase 
in response to afterload, so called homeometric autoregulation.  
1.1.3 Cardiac MRI in the normal right ventricle 
The role of Cardiac magnetic resonance (CMR) imaging is well established in the 
evaluation of wide range of cardiovascular diseases, both acquired and congenital. 
It is non-invasive, does not involve the use of ionizing radiation and assessment of 
ventricular volumes and function can be obtained without the need for contrast 
administration. Over the last two decades it has become recognised as the gold 
standard for assessing left and right ventricular structure and function with 
accuracy demonstrated in broad range of diseases (57-62). It is particularly suited 
to the morphology of the right ventricle (RV) the complex structure and 
contractile pattern of which makes accurate assessment by 2D methods such as 
echocardiogram more difficult. The high resolution, 3 dimensional images 
obtainable by CMR avoid the need for any geometrical assumptions and have been 
shown to have superior interstudy reproducibility for right ventricular volume and 
mass in comparison to echocardiography, making CMR an attractive modality for 
monitoring ventricular function (63-65). CMR is not without limitation. It is less 
suitable for haemodynamic measurements than echocardiography due to more 
limited temporal resolution. It is expensive and less widely available in clinical 
practice. Incompatibilities with some ferrous implants such as cardiac pacemakers 
or aneurysm clips exist (66). Claustrophobia, body habitus, long scan times and 
need for repetitive breath-holds for acquisition of images to reduce respiratory 
motion artefact may limit tolerance in some patients. However with advancing 
technology it is now possible to perform single breath-hold and real-time 
acquisitions with adequate resolution (67, 68).  
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1.1.3.1 MRI theory 
Magnetic resonance imaging relies on the physical properties of hydrogen nuclei 
(protons). Protons have an intrinsic spin which when the human body is brought 
into a high strength magnetic field align with the direction of this field. 
Application of a radiofrequency (RF) pulse can excite these spins and perturb their 
alignment, with vector components in line with the magnetic field (longitudinal 
magnetisation) and perpendicular to the field (transverse magnetisation). These 
spins gradually return to their resting state (relaxation) and in the process create 
RF signals that are used to create an image. 
1.1.3.1.1 MR system components 
An MRI system consists of a main magnet, three gradients coils and an integral RF 
transmitter. These components each generate a different type of magnetic field 
which when applied to a patient in combination produce spatially encoded MR 
signals that are used to firm images. The scanner itself is composed of a 
superconducting resistive electromagnet (made of niobium, low resistance wire) 
bathed within supercooled (around -2500) liquid helium. The main magnet 
generates a strong constant magnetic field. The patient is positioned within the 
bore of the magnet where the strength of the field, Bo, defines the normal 
operating field strength of this particular MRI system. Bo is measured in units of 
Tesla (T) with 1T equal to approximately 20,000 times the earth’s magnetic field. 
Typically a field strength of 1.5T is employed in CMR. A reference co-ordinate 
system of three orthogonal axes, x, y and z are used to define the magnetic field 
direction, with the z axis parallel to the direction of Bo (69).  
Smaller gradient coils are housed in the inner circumference of the main magnet. 
A gradient magnetic field that can be rapidly switched on and off is generated by 
each of the three coils. Each coil generates a magnetic field in the same direction 
as Bo but with a strength that changes with position along the x, y or z direction 
according to which coil is applied. This gradient field is super-imposed onto Bo so 
that its strength increases (or decreases) along the direction of the gradient field.  
A RF magnetic field is generated by the RF transmitter coil mounted inside the 
gradient coil closest to the patient. It has a smaller amplitude than the other 
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magnetic fields but oscillates at a characteristic frequency in the megahertz range 
which is determined by the field strength of the main magnet.  
The static magnetic field and the RF field combine to generate MR signals that are 
spatially localised and encoded by the gradient magnetic fields to create an MR 
image. 
The machine is housed within a copper lined room to deflect external radiowaves 
that would interfere with process and external RF sources which create artefact 
in the image. 
For cardiac imaging, the MR signal is received by the phased array chest coil. This 
separate RF receiver coil is placed on top of the patient’s chest. Several 
component coils within are arranged to maximise MR signal strength whilst 
minimising interference i.e. aimed to optimise signal to noise ratio. 
1.1.3.1.2 Origin of MR signal 
The origin of the MR signal used to generate images is from water or fat within 
patients’ tissues, or more specifically hydrogen nuclei (consisting of a single 
proton) within free water or lipid molecules. Protons possess an intrinsic property 
known as nuclear spin that gives rise to a small magnetic field for each proton. 
Under normal circumstances the spins are randomly orientated. When the 
externally applied Bo field is applied, protons align either towards or against the 
direction of the field. The majority of proton spins align in the same direction as 
Bo as this is more energetically favourable direction of alignment. This excess 
combines to form a net magnetisation which is a key determinant of maximal 
signal intensity that can be generated and used to create images. The greater the 
applied field strength Bo the greater the size of net magnetisation. 
Generation of a MR signal from the net magnetisation is achieved by the 
application of the RF transmitter coil described earlier to create RF magnetic field 
and delivery energy to the population of protons. This field is applied at a specific 
frequency, known as the Larmor frequency (wo ) determined by the equation wo = 
γ x Bo . The constant γ is the gyromagnetic ratio which has a value of 
42.6MHz/Tesla for the proton. At 1.5T, the Larmor frequency is approximately 
64MHz. This is also known as the resonant frequency as protons only absorb energy 
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(or resonate) at this characteristic frequency, or precession frequency. The RF 
field is normally applied as short pulses, known as a RF pulse. 
1.1.3.1.3 Radiofrequency pulses 
By applying a RF pulse at the precession frequency protons are made to absorb 
energy and alter net tissue magnetisation, a process known as excitation. When 
the RF pulse is switched off protons will relax back to a low energy state (and 
orientate with Bo ), emitting detectable RF energy which can be used to construct 
MR images. However, as net magnetisation is in the longitudinal plane (aligned 
with the main magnetic field), changes is proton alignment cannot be detected. 
MR systems overcome this by producing magnetisation in tissue protons in the 
transverse plane. 
Before the RF pulse is applied, net magnetisation is aligned along the z axis in 
direction of Bo. When RF pulse is switched on, net magnetisation moves away from 
alignment with Bo field and rotates around it. This oscillating field is applied as a 
rotating field at right angles to Bo in x and y vectors, rotates at same frequency as 
Larmor frequency and therefore appears as additional static field. As a result net 
magnetisation follows a spiral path from alignment with Bo (z axis) towards 
rotational motion in x and Y axes. The greater the amount of energy applied by 
the RF pulse, the greater the angle net magnetisation makes with Bo field (z axis). 
This angle of precession is known as the flip angle and is dependent on both 
amplitude and duration of the RF pulse. A 90⁰ pulse will convert all longitudinal 
magnetisation into detectable transverse magnetisation and is therefore referred 
to as the saturation pulse. This pulse is used to initiate spin echo-based pulse 
sequences described in section 1.1.3.1.8. Low flip angle RF pulses are those <90⁰, 
with a proportion of net magnetisation transferred from z axis to xy plane. This 
produces a lower MR signal, but can be repeated more rapidly as some of the 
magnetisation remains along the x axis immediately after the pulse. This is the 
pulse used to generate signal in gradient echo pulse sequences. A 180⁰ pulse is 
known as an inversion pulse and are used to prepare net magnetisation before 
application of excitation pulse and in black blood pulse sequences. They are 
applied when magnetisation is at close to equilibrium and converts excess 
population of proton spins from aligned to ant-aligned with the Bo field. Because 
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the net magnetisation remains in longitudinal phase this pulse does not result in 
detectable signal. 
1.1.3.1.4 Relaxation 
Once the RF pulse is turned off the tissue magnetisation vector drifts back from 
transverse plane into longitudinal under the influence of the main magnetic field. 
This process is relaxation. During relaxation RF energy is released and detected as 
a MR signal in the transverse receiver coil. There are two distinct relaxation 
processes that relate to the two components of net magnetisation described 
above, longitudinal (z) and transverse (xy) components. T1 relaxation describes 
recovery of the z component along its longitudinal axis to original equilibrium 
state. Transverse relaxation (T2) is responsible for the decay of the xy component 
as it rotates about the z axis, causing a corresponding decay of the observed MR 
signal. Both occur at the same time but in human tissues T2 relaxation is typically 
a faster process. 
The rate of relaxation is an important determinant of tissue contrast. Relaxation 
is rapid in tissues containing large amounts of bound water. These water molecules 
are in close proximity to macromolecules such as proteins which restrict 
movement of the smaller water molecules where their association makes energy 
transfer more efficient. 
Relaxation is slower in free water solutions containing randomly orientated and 
rapidly tumbling water molecules where energy transfer is less efficient due to 
the less structured environment. The molecular environment of the water protons 
undergoing excitation therefore has significant influence on rate of RF energy 
release and therefore the MR signal receive from different tissues.  
T1 relaxation (sometimes referred to as T1 recovery) describes the recovery of 
longitudinal magnetisation after RF pulse. T1 relaxation time is a constant for a 
given tissue within a given MR field strength. The time taken for T1 relaxation is 
dependent on the efficiency with which RF energy can be dissipated from the 
excited protons to the surrounding tissues, and the strength of the main magnetic 
field. The rate at which energy is released to surrounding molecular structure is 
related to the size of the molecule that contains the hydrogen nuclei and rate of 
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molecular motion known as the tumbling rate. As molecules tumble or rotate they 
give rise to a fluctuating magnetic field which is experienced by the protons of 
adjacent molecules. When this fluctuating field is close to Larmor frequency, 
energy exchange is more favourable. Lipid molecules are of a size that have a 
favourable tumbling rate close to this frequency and therefore adipose tissue has 
one of the fastest relaxation rates and shortest T1 relaxation time of body tissues 
(~260msec in 1.5T field). Larger molecules have slower tumbling rates 
unfavourable for energy exchange leading to longer relaxation times. Free water 
smaller molecular size has a fast tumbling rate which is also unfavourable and has 
a longer T1 relaxation time (around 3 seconds). It therefore takes a relatively long 
time to receive adequate MR signal back from pure water solution. Most MR 
sequences aim to detect signals in under 1 second and therefore free water 
solutions (such as CSF) appear dark and adipose tissues appear bright on images 
that rely on T1 contrast. 
Muscle, liver, brain and viscous fluids such as pus contain variable proportions of 
free water and larger macromolecules. The tumbling rates of water molecules 
adjacent to large macromolecules are slowed down towards Larmor frequency 
shortening the T1 time. Therefore characteristic T1 relaxation times of these 
tissue lie in the spectrum between free water and adipose tissue. Conversely when 
free water content of these tissues increases for example by inflammation, T1 
time increases.  
T2 relaxation describes the decay (or dephasing) of transverse magnetisation 
produced by the RF pulse. Net magnetisation is a result of sum of whole population 
proton spins. Immediately following an RF pulse, spins rotate together in a 
coherent fashion so as they rotate they continuously point in the same direction 
in the xy plane. The angle they point is known as the phase angle and at this stage 
are described as being ‘in phase’. Over time, the phase angles spread out, there 
is loss of coherence and spins no longer rotate together and are said to move out 
of phase. The net magnetisation is therefore reduced and the signal the receiver 
coil detects gradually decays. There are two causes of loss of coherence. 
Interactions between neighbouring protons cause a loss of coherence described by 
T2 relaxation. While the applied magnetic field Bo is constant, the magnetic 
moment of one proton is able to slightly modify the magnetic field experienced 
by its neighbour. As protons are moving rapidly and randomly the effects are 
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transient and random. The Larmor frequency of individual protons therefore 
fluctuates in a random fashion leading to loss of coherence of the proton 
population which is known as de-phasing. T2 relaxation therefore relates to the 
amount of spin-spin interaction that takes place. 
If T2 decay was automatically translated in to T1 recovery the use of individual 
terms would be unnecessary. However, rate at which transverse magnetisation is 
lost (T2 relaxation) is greater than rate at which longitudinal magnetisation 
returns (T1 relaxation) in most tissues. T1 and T2 relaxation times for pure water 
are similar. Free water contains small molecules relatively far apart and moving 
rapidly and therefore spin-spin interactions are infrequent leading to long T2 
relaxation times. Water molecules bound to large macromolecules are slowed 
down and more likely to interact so water based tissues with high macromolecular 
content such as muscle tend to have shorter T2 times. Lipid molecules are of an 
intermediate size but interactions between hydrogen nuclei on long carbon chains 
(J-coupling) causes a reduction of T2 relaxation to an intermediate value. Rapidly 
repeated RF pulses used in turbo or fast spin echo sequences can reduce J-coupling 
resulting in increased signal intensity from fat as a consequence of the increase 
in T2 relaxation time. 
Additional decay (or loss of coherence) occurs if there is inhomogeneity in the 
magnetic field which are constant in time, due to either inconsistences in the 
structure of the electromagnet or paramagnetic material in the imaged tissues 
such as ferrous joint replacements or foreign bodies. If the field varies between 
locations then so does the Larmor frequency. Protons at different spatial locations 
will rotate at different rates causing further dephasing so that the MR signal 
decays more rapidly. T2* relaxation describes the total decay of transverse 
relaxation as result of T2 relaxation and these inhomogeneities. 
1.1.3.1.5 MR echoes 
Most MR imaging measures the MR signal in the form of an echo as the gradient 
fields employed to localise and spatially encode the MR signals causes additional 
de-phasing that disrupts free induction decay. Gradient echoes are generated by 
application of magnetic field gradients to produce a change in field strength along 
a particular axis. This causes rapid dephasing of proton spins along the direction 
39 
 
of the gradient and transverse magnetisation rapidly drops to zero. A second 
gradient with a slop of equal magnitude but applied in the opposite direction 
reverses the amount of de-phasing resulting in recovery of FID signal to generate 
the gradient echo at the echo time TE. If the second gradient continues to be 
applied the FID signal de-phases and disappears. 
Spin echos are generated by application of 180⁰ refocusing pulse after the 90⁰ 
excitation pulse. This has the effect of causing proton spins that have de-phased 
as a result of magnetic field inhomogeneities to come back in to phase causing FID 
to increase and therefore increased signal intensity reaching a maximum at TE. 
Imaging based on spin echo is therefore less effected by field inhomogeneities 
caused by metallic artefacts. 
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Figure 1.1 Black Blood contrast images 
A Sagittal and B Axial images commonly employed for cardiac morphology using fast spin echo 
sequences with black blood double inversion preparation pulses. Images have intrinsic black blood 
contrast due to blood flow through the image slice and bright appearance from tissues (when T1 
weighted). Adipose tissue as shown above particularly bright due to very short T1 relaxation time.   
 
  
A 
B 
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1.1.3.1.6 Magnetic field gradients and spatial localisation 
The MR signal produced by the tissues as described can then be localised and 
encoded by applying three magnetic field gradients to produce an image. The 
applied magnetic field gradient causes the strength of the magnetic field and 
therefore the Larmor frequency to depend on position along that gradient field 
direction. Protons at the stronger end of the magnetic field gradient will therefore 
spin faster than those at the weaker end.  
Slice selection gradients (GS) are first used to identify the slice of tissue to undergo 
excitation by the RF pulse. A magnetic field gradient is applied at the same time 
as the RF pulse to alter the procession frequency along a section of tissue protons. 
The frequency of the RF pulse corresponds to a Larmor frequency at a chosen 
point along the direction of the applied gradient. This causes resonance only in 
protons that cuts through that point effectively defining a slice of tissue. The 
orientation of the slice is determined by the direction of the applied gradient. The 
transmitted RF pulse compromises a small range of frequencies rather than just a 
single frequency which determines slice thickness. 
Following slice selection a phase encoding gradient (GP) is applied which induces 
protons to rotate at different frequencies according to their relative position along 
the gradient. Where the gradient increases magnetic field strength the protons 
acquire a higher frequency of procession and where the gradient decrease the 
magnetic field a lower frequency. The protons also change their relative phase 
according to position along this gradient. When the gradient is switched off the 
protons will have changed their relative phase by an amount determined by their 
position along the gradient and can therefore determine their location within the 
tissue slice. This is known as phase encoding and direction of the gradient as phase 
encoding direction.  
Following GP the frequency encoding gradient (GF) is applied in a direction at right 
angles to it and similarly causes protons to rotate at different frequencies 
depending on their position along the direction gradient. GF is applied for a longer 
period and at the same time the signal is measured. The signal is comprised of a 
range of frequencies corresponding to Larmor frequencies of proton spins at 
different locations along the gradient.  
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These separate magnetic field gradients are therefore applied in a three step 
process to localise the MR signal in three dimensions. Slice orientations are 
determined by re-assigning each of the gradients to a different axis, for example 
images obtained in a trans-axial plane occur when GS is applied along the z axis, 
GP along the y axis and GF along the x axis as shown in figure 1.1B. Angled slices 
can be obtained by combining gradients along two or more axis to perform each 
of the localisation tasks. This ability of MRI to define slice orientation along any 
axis is a key strength in obtaining functional imaging of cardiac structures.  
1.1.3.1.7 Image reconstruction 
This frequency encoded signal must then be reconstructed to produce images. The 
Fourier transform is a mathematical tool that analyses the time dependent MR 
signal and transforms it into its different frequency components. The amplitude 
of each frequency component can be mapped onto a location along the frequency 
encoding gradient to determine the relative amount of signal at each location. 
The field of view (FOV) in the frequency encoding direction is defined by the 
operator.  
The phase changes cannot be decoded by this process. The Fourier transform can 
only analyse a signal that changes over time. To enable this multiple signal echos 
are generated by repeating the three step gradient field process, each time 
applying the same slice selection and frequency encoding gradient, but a different 
amount of phase encoding by increasing the slope (or strength) of GP for each 
repetition by equal increments or steps. For each step the signal echo is measured, 
digitised and stored in a raw data matrix. The time interval between each 
repetition is called the repetition time TR. Once all the signals for a defined 
number of phase encoding steps are complete they can be analysed together by 
Fourier transform to decode both frequency and phase information. 
TR is set by the operator and determines how fast MR images are acquired but 
also affects image contrast. The spatial resolution and number of pixels in the 
reconstructed image is determined by the number of phase encoding steps used. 
The greater the number of repetitions however the longer the image acquisition 
time. 
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The MR signals derived from each phase encoding step are stored in a raw data 
matrix known as K space. Just as each pixel occupies a unique location in an 
image, each point of an MR signal belongs to a particular location in k space which 
is represented by a 2D grid of points of which x axis represents frequency encoding 
direction and y axis phase encoding direction. There is an inverse relationship 
between image space and K space whereby if coordinates of the image represent 
spatial position x and y, the c-ordinates of K space represent 1/x and 1/y. Data 
points at the centre of K space (low spatial frequency) contribute mostly to signal 
intensity and image contrast while those arising from points near the edge of K 
space (high spatial frequency) to fine detail or edges and define spatial resolution 
of the image. To reconstruct an image that is accurate representation of the 
imaged subject it is important that the whole range of spatial frequencies is 
acquired and whole of K space filled. For standard CMR protocols this is done by 
filling k space with equally spaced parallel lines of signal data, line by line known 
as Cartesian acquisition. Each line represents a separately sampled MR signal 
during a phase encoding step. Once K space has been filled the Fourier transform 
analyses the digitised information and reconstructs this into a MR image. 
1.1.3.1.8 Pulse sequences and image contrast 
Pulse sequence is a timed series of RF pulses and magnetic field gradients which 
provides raw data to fill k-space – the “echo”. The two broad families of pulse 
sequences are spin-echo and gradient echo. 
In Spin echo sequences, a 90⁰ RF pulse is applied to the selected slice so that 
resting longitudinal (z) magnetisation is entirely flipped to the transverse (XY) 
plane. The transverse magnetisation begins to de-phase when a 180⁰ RF pulse is 
applied. This causes transverse magnetisation to partially rephrase and produces 
a spin echo, filling one line of K-space. This rephrasing 180⁰ pulse can be repeated 
multiple times to acquire multiple lines of K-space, known as fast or turbo-spin 
echo. Image quality for this sequence is high at the expense of long acquisition 
time to fill K-space. The excitation angle is fixed at 90⁰ and therefore TR and TE 
control the influence of tissue’s T1 and T2 relaxation times. T1 weighted spin echo 
sequences have a short TR and short TE and characterised by bright fat signal and 
low fluid signal. They are useful for anatomical imaging where contrast is high 
between fat, muscle and fluid. In cardiac imaging, TR is determined by subject 
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heart rate and set to one RR interval and TE is short to minimise T2 weighting. T2 
weighted spin echo sequences are characterised by long TR and TE. Long TR allows 
z magnetisation to recover to equilibrium for most tissues reduce influence of 
differences in T1 relaxation. Longer TE however allows more decay of xy 
component leads to differential signal between short T2 tissues such as muscle 
and those with long T2 such as fluid. These images are characterised by bright 
fluid and useful for characterisation of fluid collections or oedema.  
The two main types of gradient echo pulse sequence used in cardiac imaging are 
spoiled gradient echo and balanced steady state free precession (SSFP).  
Gradient echo pulse sequences use a smaller initial RF pulse typically between 10-
90⁰ and then apply magnetic field gradients to rephrase net magnetisation. TR, 
TE and flip angle control the influence of T1 and T2* relaxation times on the signal. 
The main advantage is that gradient echoes can be produced very quickly with 
short scan times but at the disadvantage of increased susceptibility to artefacts. 
Gradient echo sequences have very short TR values which is attractive for cardiac 
imaging as gives rise to short acquisition times. The TR values are much shorter 
however than T2 relaxation times of blood and myocardium. Transverse 
magnetisation therefore would still exist when the next RF pulse is applied and 
contribute to the signal during the subsequent TR unless destroyed. 
Spoiled gradient echo sequences (Siemens FLASH  - Fast Low Angle Shot) 
incorporate an additional “spoiler” gradient at the end of each TR period to 
destroy any residual transverse magnetisation prior to the next RF pulse (70, 71). 
These are used in both T1 weighted and T2* sequences. 
SSFP gradient echo sequences rather than spoiling transverse magnetisation 
instead ensure it is brought back in to phase at the end of each TR period when 
the next RF pulse is applied. This is then superimposed onto transverse 
magnetisation generated by that RF pulse. After a number of repetitions this 
combines to give a greater signal and results in images with both T1 and T2 
contrast with tissues appearing bright and contrast depending on T2/T1 ratio (72). 
Fluid and fat have highest signal on T2/T1 weighted images with all other tissues 
showing intermediate signal. The increased signal allows for shorter TR and TE 
compared to spoiled sequences but is prone to dark banding artefacts due to field 
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inhomogeneities. The Siemens “unspoiled” gradient echo sequence used in this 
thesis is known as TrueFISP (Fast Imaging with Steady state Procession). 
 
  
 
 
Figure 1.2 'Bright blood ' cine steady-state free procession images 
Examples of b-SSFP sequences images used in assessment of cardiac function. A. Sagital view B. Axial from single-phase scout localiser images. In contrast to figure 
1.1 blood pool (and CSF) appears bright. Images are not T1 or T2 weighted, but signal depends on ratio of T2/T1 in addition to flow. Blood, water and fat therefore all 
appear bright. In this thesis sequence is known as TrueFISP. 
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1.1.3.2 Cardiac MRI sequences 
To acquire an image of the heart unaffected by motion requires an image 
acquisition period of just a few tens of milliseconds. This means limiting both the 
number of phase encoding steps (and therefore spatial resolution) and a short TR 
time. This is achieved at the cost of reduced image quality, but in order to achieve 
acceptable images the acquisition time becomes too long to ‘freeze’ cardiac 
motion. For CMR therefore the MR signals are acquired over multiple heart beats 
synchronising the pulse sequence and therefore signal acquisition to a particular 
time point in the cardiac cycle. 
1.1.3.2.1 Fast imaging techniques 
As described in section 1.1.3.1.8 the attributes of spin echo and gradient echo 
sequences are employed in CMR dependent on the goal of imaging. Spin echo 
technique is ideally suited when goal is to achieve images with a high signal to 
noise ratio and reduce sensitivity to artefacts caused by magnetic field 
inhomogeniety. Fast gradient echo pulse sequences are used where imaging speed 
is of more importance than imaging quality. Flowing blood appears differently 
between the two sequences with spin echo giving intrinsic black blood appearance 
employed in anatomical imaging (see figure 1.1) (73) and gradient echo pulses 
intrinsic bright blood appearance employed in fast cine imaging (see figure 1.2). 
Balanced steady state free procession (b-SSFP) sequences are commonly employed 
for functional assessment (74, 75). Conventional imaging techniques acquire only 
one phase encoding step and therefore one line of k space per heartbeat. TR is 
defined by patients’ heart rate and equal to the R-R interval. It would therefore 
take several minutes to acquire an anatomical dataset. Fast imaging techniques 
acquire more than one line of k space per heart beat leading to shorter acquisition 
times and are known as turbo or fast pulse sequences (76). These sequences 
generate multiple echoes by applying multiple 180⁰ pulses after the initial 90⁰ 
pulse. Turbofactor describes the number of lines of k space filled per heart beat. 
Sequences with very high turbofactor such as that employed in real time or single 
shot acquisitions shortens acquisition time but at the expense of reducing the 
number of cardiac phases within the cardiac cycle and therefore the cine frame 
rate. Imaging therefore suffers from poor temporal and spatial resolution.  
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CMR data acquisition is synchronised to cardiac motion using the electrical activity 
of the heart (77). The magnetic field exerts a significant effect on the ECG, 
resulting in voltage artefact in the ST segment on the ECG. Reliable r wave 
detection is possible using a vector cardiogram (VCG), but reliable ST/T wave 
monitoring is not possible. The VCG can be used for either prospective or 
retrospective gating. 
Prospective triggering is typically used for single phase acquisitions such as static 
image of the heart at a single point in cardiac cycle. Information is acquired at a 
specific interval after the r wave, usually to coincide with diastole when heart 
relatively still. This still imaging approach is typically used in combination with 
turbo or fast spin echo pulse sequence to acquire black blood anatomical images 
shown in figure 1.1.  
Multiphase acquisitions are used to acquire dynamic information such as cine MRI. 
Data is acquired throughout the cardiac cycle and reconstructed with 
retrospective reference to the VCG (78). Typically the cardiac cycle is divided in 
to 20-30 phases with one image reconstructed for each phase and displayed as a 
cine loop. Retrospective gating in combination with a turbo or fast gradient echo 
method is most common approach to bright blood functional cine imaging shown 
in figure 1.2. Most CMR images are obtained during breath holds, typically of 10-
15s duration to minimise image degradation caused by respiratory motion. End-
inspiratory breath hold is more comfortable and tolerate for longer periods. 
However breath hold at end of gentle expiration is usually more consistent 
(minimising slice misregistration) and less likely to provoke ectopic beats. 
Real-time cine MRI can also be acquired by increasing the parallel imaging factor 
and reducing spatial resolution. When applied it is possible to obtain diagnostic 
images in those with very irregular heart rhythms or in patients who are unable to 
breath hold (79, 80). 
In this thesis pulse sequence is known as TrueFISP (Siemens). Resultant images are 
not T1 or T2 weighted, but signal intensity depends on ratio of T2/T1 in addition 
to flow. Blood, water and fat therefore all appear bright. 
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Ventricular volume is determined using a “stack” of contiguous short axis slices 5-
10 mm thick acquired during breath-hold (typically in region of 5-18 seconds), 
ECG-gated cine “bright” blood sequences. This sequence gives good blood-
myocardial contrast to allow tracing of endocardial and epicardial contours on 
end-diastolic and end-systolic frames. Ventricular volume is calculated as sum of 
individual slice volumes (Simpson’s rule). Ventricular mass is determined by 
multiplying myocardial volume by the muscle-specific density for myocardial 
tissue (1.05g/cm3). Inclusion or exclusion of the RV trabeculations as either mass 
or volume is source of interstudy variability (81). 
1.1.3.2.2 Velocity encoding and phase contrast MRI 
Velocity encoded CMR, also known as phase contrast, is a fast and simple method 
of measuring blood flow (82-84). As proton spins flow along a magnetic field 
gradient they acquire a shift in transverse (xy) magnetisation which is proportional 
to the strength of the magnetic field gradient and to flow velocity, which can then 
be determined. Phase maps are generated to enable quantification of flow where 
pixel intensity depends on phase of transverse magnetisation rather than its 
magnitude. First the image is prescribed perpendicular to flow direction through 
the vessel. More than 15⁰ of variation from the true perpendicular will significantly 
underestimate the flow. Secondly an appropriate encoding velocity (VENC) is 
selected. This must be greater than the highest velocity in the flow otherwise 
aliasing artefact (see section 1.1.3.3) will make data unreliable. Typical VENC in 
normal systemic flow ~150cm/s and in right sided flow ~100cm/s but may need 
adjusted in pathological situations, for example severe valve stenosis may require 
VENC set in region of 400cm/s by the operator (85) . Selection of too high a value 
results in underestimation of velocity. Adequate temporal resolution typically 
requires 30 phases in free breathing acquisitions or 20-25 in breath hold. Velocity 
maps are generally displayed using a gray scale (example is shown in figure 1.4) 
with stationary tissue appearing gray, velocities in forward (positive) and reverse 
(negative) directions represented as higher (white) and lower (towards black) 
pixel intensities. Volumetric flow (ml/s) is determined in each time frame by 
multiplying spatial mean velocity (cm/s) of blood flow with the cross sectional 
area of the vessel (cm2) delineated by a region of interest (ROI) drawn by the 
operator at time of post acquisition analysis. 
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By multiplying blood velocity by the cross sectional area of chosen vessel, such as 
the main pulmonary artery, SV can be calculated (86). In addition this can be used 
to quantify intracardiac shunt by comparing aortic and pulmonary arterial flow 
(87). Flow assessment by CMR has the advantage over echocardiography as it can 
be conducted in any orientation or plane whilst accurate echocardiographic 
assessment requires the flow to be parallel to the echocardiographic plane. Phase 
contrast flow is less accurate in the presence of cardiac arrhythmia or turbulent 
blood flow. 
1.1.3.3 MRI artefacts 
Artefacts can degrade image quality and may cause measurements in functional 
imaging to be unreliable (88). Most can only be corrected during image acquisition 
and therefore artefact recognition and adaptation of acquisition protocol where 
possible to resolve. 
Aliasing occurs when the FOV does not enclose all of the region of interest being 
imaged. The region outside the FOV wraps around and is projected at the opposite 
side of the image as shown in figure 1.3. This projected image may cover the 
region of interest. Increasing the FOV or number of phase encoding steps 
(oversampling) often resolves this. Alternatively frequency and phase encoding 
directions can be swapped. In velocity encoded sequences any velocity greater or 
smaller than the defined VENC causes aliasing. Here aliasing appears as black holes 
in the flow sequence and will lead to over or underestimation of the true velocity. 
Correction of the VENC until the velocity encoded slightly exceeds that of the flow 
will eliminate the artefact. 
RF artefact is caused by distortion of the magnetic field by an external RF source 
and characterised by regular striped pattern (sometimes known as zipper artefact) 
across all images irrespective of the MR sequence. This may arise when the door 
to the MRI room is not closed or the isolation of the room damaged. 
Chemical shift artefacts appear at the interface between fat and water based 
tissues. Misregistration of signal as result of difference in frequency resonance 
between fat and water protons in same voxel along the frequency encoding 
direction causes a separation (pixel shift) in the reconstructed image. Dephasing 
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of fat and water protons can cause signal cancellation and also cause chemical 
shift artefact. Increasing the bandwidth reduces the difference between the 
frequency of fat and water protons in one voxel and can diminish this artefact. 
Fat suppression sequences can also be used.  
Dark rim artefacts can be seen in any CMR image at the interface of bright blood 
pool and darker (myocardial) signal. In CMR perfusion imaging this may be difficult 
to differentiate from subendocardial perfusion defects. This can be reduced by 
increasing spatial resolution. 
Inhomogeneity artefacts may arise from presence of implanted metallic foreign 
bodies such as coronary stents, sternal wires or devices. Due to different magnetic 
properties of most tissues the applied field is slightly inhomogenous. This causes 
regional dephasing of protons at boundaries between different tissues. Metallic 
susceptibility artefacts tend to worsen at higher field strengths and limited field 
strengths 1.5T advisable. Intermittent use of a 180⁰ refocusing pulse may rephrase 
the protons and therefore spin echo sequences are less sensitive to susceptibility 
artefact than gradient echo sequences. A saturation band may also be employed 
to suppress signal from the implant. 
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Figure 1.3. 2 chamber view demonstrating aliasing artefact 
Sagittal imaging of 2 chamber view with left atrium (LA) and ventricle (LV) shown, vertebrae indicated 
by V. Region outside the field of view (FOV) shown by arrows in panel A wraps around and is 
projected at the other side of the image, causing interference with the image of the LV. In panel B 
FOV is increased (white arrow) so less wrap occurs and LV can now be seen clearly.  
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1.1.3.3.1 Motion artefacts. 
Ghosting refers to appearance of parallel lines or double contours in the image 
usually as a result of respiratory motion during acquisition. An example is shown 
in Figure 1.4. Coaching of the subject to control breathing will eliminate ghosting, 
if patients struggle with breath-holds in expiration, inspiratory breath-hold can be 
employed or shortened acquisition times to decrease breath-hold duration at 
expense of reduced spatial resolution. 
Trigger artefact causes myocardial borders to become less defined or blurry. An 
example is shown in figure 1.5. Cardiac data acquisition is synchronised to the R 
wave and data collected throughout the cardiac cycle and retrospectively assigned 
to specific phases. As a result the presence of a poor ECG signal or arrhythmia 
impairs data acquisition. The image quality may decline and render the image non 
diagnostic due to difficulty delineating endo and epicardial borders and hence 
calculations of volume or mass unreliable. Arrhythmia rejection software can be 
applied so images obtained during irregular R-R intervals are rejected. Prospective 
triggering can also be used to acquire data during a predefined period of the 
cardiac cycle but as this does not cover the complete R-R interval SV may be 
underestimated. In severe arrhythmia real time imaging can be used with 
limitations as described above. 
Blood flow artefact occurs as a result of protons moving at high velocity near or 
in the selected imaging slice, usually close to outflow tracts or large arteries, 
which can disturb the homogenous steady state magnetisation. This can be 
overcome by improvement (shimming) locally of the homogeneity of the main 
magnetic field. Reducing TR or TE results in a sequence less susceptible for 
turbulent flow artefacts. Alternatively slice selection can be adjusted or the signal 
from passing protons inverted by application of a saturation band across the 
outflow tract. 
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Figure 1.4 Ghosting Artefact 
Example of ghosting artefact caused by respiratory motion during acquisition. Panel A shows the 
axial view with parallel lines caused by multiple contours indicated by arrow. And B corresponding 
phase velocity map which would have been used to determine flow in pulmonary artery (arrow) 
which will be inaccurate due to motion artefact.  
 
A 
B 
  
 
 
Figure 1.5. Trigger artefact caused by arrhythmia. 
Short access views of right and left ventricle used to delineate endocardial and epicardial borders in the analysis of ventricular mass, volume and function. Panel A 
shows clear delineation between myocardium and blood pool. In Panel B, myocardial borders are poorly defined and image blurry as the result of arrhythmia and 
trigger artefact. This can be overcome by use of arrhythmia rejection software or real-time image acquisition. 
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1.1.3.4 Normal Variants in right ventricular structure and function 
LV mass and volumes are known to vary by age, sex and race and are typically 
adjusted for body surface area (BSA) (89-91). Echocardiography and autopsy 
studies have demonstrated significant age and gender related differences in both 
cardiac function and mass in healthy subjects (92-94). Autopsy study has also 
shown subject weight, height and BSA to relate to cardiac mass (94, 95). Over the 
last decade a number of studies have reported normal values for right ventricular 
structure and function but have been limited by small sample size over a narrow 
age range with varying acquisition techniques (47, 64, 96, 97). More recently, the 
multi-ethnic study of atherosclerosis (MESA)-right ventricle study, a multicentre 
prospective cohort study of over 4000 participants without evidence of clinical 
cardiovascular disease at baseline (98), have evaluated a number of patient 
demographics that influence CMR value interpretation.  
Conventional cardiovascular scaling approach uses ratiometric method of dividing 
indices such as RV mass by a measure of body size such as height or BSA. Body 
composition has significant effects on relationship between body mass, surface 
area and cardiac structure as large volumes of adipose tissue in the obese or 
extravascular fluid in heart failure patients are not adjusted for, which have little 
metabolic demand and therefore are unlikely to influence cardiac adaptation 
whose function is to provide efficient circulatory supply of metabolic substrates. 
Fat free mass or lean body mass has been proposed as more appropriate method 
of scaling to body size, however clinical use is limited as accurate measurement 
requires  assessment of body composition using dual-energy x-ray absorptiometry 
(DEXA) or hydrodensitometry (99). Superiority of height indexed over BSA indexed 
LV mass has been demonstrated (100). Height may be preferable to index RV 
parameters to over BSA as it is not affected by volume of adipose tissue.  However 
autopsy study has shown weight or BSA to be superior to height in predicting 
cardiac mass (94) and CMR study has shown worse correlation coefficients in 
healthy subjects between RV mass, volumes and height than weight or BSA, 
although this appears population dependent (47). Fat free mass may also vary 
considerably for subjects of identical height. It is therefore current clinical 
practice to adjust RV parameters for BSA. 
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1.1.3.4.1 Ageing and the right ventricle 
Increasing age in autopsy studies is associated with myocyte loss and decreases in 
LV mass and volume in males but not females (95). Remodelling may occur due to 
age-related hormonal change such as reduced testosterone levels in males, or as 
a result of decreasing levels of physical activity. Absolute and indexed CMR 
derived RV mass and volumes have also been shown to be lower with increasing 
age (101-104). Larger effects are observed in males than females, but significant 
changes have been reported in both albeit not consistently. An approximate 5% 
lower RV mass per decade of increasing age has been reported. Age related 
increase in right ventricular ejection fraction is also seen (about 1% per decade) 
and changes in RV diastolic function defined by decreased early peak filling rate 
(PFRE)  and increased active peak filling rate (PFRA) are also reported, reflecting 
a degree of ventricular stiffening with age (104).  
1.1.3.4.2 Sex differences in right ventricular morphology 
Absolute right ventricular volumes are greater in men than women (101, 105). 
Differences in RV mass have been reported variably (47, 96, 101, 102, 104, 106) 
but in larger cohort studies seems to be higher in males. RV mass has been 
reported as up to 8-15 % lower in females and RV volumes 10-25% lower (101, 102). 
These differences have been shown to persist despite adjustment for BSA (104). 
As previously mentioned, greater age related decline in RV mass and volume is 
seen in men and one study has reported restriction of this decline to the male sex 
(102). In general no gender differences have been reported in RVEF, with the 
exception of the larger MESA-RV study where males had 4% lower RVEF after 
adjustment for age and ethnicity (101). These gender differences are potentially 
hormone related (107, 108). Higher levels of estradiol are associated with better 
RV systolic function in healthy postmenopausal woman taking hormone 
replacement and higher levels of androgens in both males and postmenopausal 
women are associated with greater RV mass, higher stroke volume and larger RV 
volumes (109). 
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1.1.3.4.3 Ethnicity and RV structure 
The influence of ethnicity has been less well studied. Lower RV mass in African 
Americans and higher RV mass in Hispanics in comparison to Caucasians has been 
reported (101). After adjustment for LV mass, lower RV mass in African Americans 
remained significant suggesting a RV specific effect. In the same study, Hispanics 
had larger RVEDV and RVSV, and African-American men had lower RVEDV despite 
adjustment for age and sex. Chinese ethnicity has also been shown to have lower 
RV volumes after adjusting for BSA than Caucasians, although mass was not 
reported in this study (105). 
1.1.3.4.4 Influence of physical activity on RV structure  
Long term high intensity exercise in elite athletes is well documented to cause 
adaptive changes in cardiac structure characterised by increases in LV mass, 
volume and wall thickness with a small number of CMR studies showing increases 
in RV mass and volume, the so called “athlete’s heart”(110-113). Levels of 
physical activity in non-athletes however have also been shown to influence RV 
mass and volumes. The MESA-RV cohort has been used to interrogate levels and 
intensity of activity from household chores to sports and leisure activities (114). 
Higher levels of moderate and vigorous physical activity were associated with 
greater RV mass and volumes after age, body size and gender adjustment, 
although the absolute value was low (1g of RV mass from lowest to highest quintile 
of activity, and 7% increase in RVEDV) which remained significant after adjusting 
for LV size. 
1.1.3.4.5 Obesity 
Obesity is independently associated with increased cardiovascular morbidity and 
mortality and is a growing health problem in the western world. Obesity is 
associated with increases in blood volume, cardiac output and direct infiltration 
of fat in the myocardium, termed the cardiomyopathy of obesity (115, 116). RV 
mass and volumes determined by CMR are higher in obese individuals even after 
adjustment for LV parameters and demographic variables. Chahal et al 
demonstrated a 14 % absolute and 8 % LV adjusted higher RV mass, 16 % higher 
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RVSV, larger RVEDV and slightly lower RVEF in healthy obese individuals without 
reported symptoms suggestive of a sleep disorder (117). Adjustment for LV 
parameters and height suggests these increases could not be attributed to 
increased body size alone. Again, these effects were relatively small, a 5kg/m2 
increase in BMI was associated with 1.3g higher RVM, 8.65ml greater RVEDV and 
0.5% lower RVEF. The BMI related increase in RVM was out of proportion to RVEDV 
suggesting remodelling rather than simply increase in cardiac size. Earlier CMR 
studies in the obese have also shown higher RV mass and volumes but preserved 
RVEF (97). These studies potentially could be limited as subclinical sleep disorder 
was not excluded where nocturnal hypoxic vasoconstriction could result in 
increased RV afterload or directly affect the RV (118). It is however thought 
obesity-related increase in blood volume impacts on cardiac output and ultimately 
adaptive change in RV morphology (119). Additionally obesity results in changes 
in adipokine levels which have effects on RV morphology along with fatty 
infiltration of myocardium and increased mass (120, 121). 
Several large cohort studies have now published age and gender specific CMR right 
ventricular reference ranges for mass, volume and function (101, 102, 104).  
 
1.1.4 Right Ventricular - arterial coupling 
Isolated RV failure can arise as a consequence of intrinsic RV pathology such as 
infarction, but typically occurs as a consequence of pathology of its adjoining 
circuit, either impedence of the pulmonary circulation or disease of the left heart. 
It is therefore intuitive when considering RV dysfunction in PAH, where the 
primary disease is in the pulmonary circulation but the capacity of the right heart 
to adapt to this increased afterload that ultimately dictates outcome and 
functional capacity, to consider the RV-pulmonary artery circuit as a unit. RV-
arterial coupling considers the extent of RV adaptation in context of its afterload, 
represented as a ratio of elastances, contractility (or end systolic elastance - Ees) 
with effective arterial elastance (Ea).  
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1.1.4.1 Right ventricular contractility 
RVEF is the most commonly used measure of RV function and by inference RV 
contractility. Ideally however indices of RV contractility should be independent of 
preload and afterload in addition to being sensitive to change in inotropy and 
independent of cardiac mass. SV is the net result of RV contraction, however it 
too is determined by RV filling (preload) and in addition to myocardial function by 
the afterload that the ventricle contracts against i.e. arterial resistance. 
Ventricular pressure-volume loops allow derivation of load independent measures 
of RV contractility, known as maximum ventricular elastance (Emax), which is 
regarded by many as the gold standard measurement of RV function (122). A single 
pressure volume loop describes the changes in ventricular pressure and volume 
through a cardiac cycle. Unlike the rectangular shape observed in the LV, the RV 
pressure-volume loop is more triangular in a normal RV-pulmonary circulation. The 
cycle can be divided in to four phases; (1) the filling phase, which in the RV is 
described by significant increase in volume with only slight increase in pressure as 
a result of high RV distensibility, (2) isovolumetric contraction which is short due 
to low PA pressures, (3) RV ejection with an early peak in pressure and subsequent 
rapid decline, (4) isovolumetric relaxation from pulmonary valve closure until 
pressure falls to baseline. Multiple pressure-volume loops under different loading 
conditions, such as preload reduction generated in models of isolated RV by IVC 
occlusion, allow identification of end-systolic pressure-volume points of each 
pressure-volume loop. The end-systolic pressure-volume points can be connected 
by a linear line, the end-systolic pressure-volume relation (ESPVR). The gradient 
of this line is the end-systolic elastance (Ees) (123) which approximates Emax. Figure 
1.6 describes derivation of Ees from PV-loop analysis. 
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Figure 1.6. Derivation of Ees from multiple pressure-volume loop 
 
Pressure volume loops at decreasing levels of venous return are obtained by instantaneous pressure 
and volume measurement, usually by IVC occlusion. End systolic pressure points are then 
determined as shown, and Ees is the slope of the gradient line connecting these points, the end 
systolic pressure volume relation. 
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Ees is therefore a load independent measure of ventricular contractility and has 
been shown to increase in response to inotropic agents. A shift in the ESPVR may 
occur with changes in ventricular mass and configuration. 
The generation of multiple pressure-volume loops requires the use of conductance 
catheters which are expensive, is time consuming requiring simultaneous measure 
of pressure and volume, and alteration of loading conditions (i.e. venous return 
to the heart) which may not be safe in unwell patients. It is therefore not an 
attractive modality for clinical use. Single beat methods have been developed, 
initially in the LV but more recently translated to the RV (124, 125). The single 
beat method relies on the derivation of the maximal pressure that the RV could 
generate if isovolumetric contraction occurred, known as Pmax. This point is 
derived by the nonlinear extrapolation of the early and late portions of the RV 
pressure time curve for a single ventricular contraction obtained by standard right 
heart catheterisation. Pmax is then plotted on the pressure-volume plot at end 
diastolic volume. Ees can then be determined as the slope of the line from Pmax to 
ESP. Figure 1.7 describes the derivation of Ees, Ea and Pmax using single beat 
method. 
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Figure 1.7. Derivation of Ees using single beat method. 
 
Panel A shows a RV pressure/time trace over a single cardiac cycle obtained at right heart 
cathetersation. Pmax is calculated from the non linear extrapolation of the early systolic and diastolic 
portions of the pressure curve. Panel b shows a RV pressure/volume trace for a cardiac cycle. Ees 
can be determined by the slope of the ESPVR between Pmax plotted at end-diastolic volume and 
ESP at end-systolic volume.  
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1.1.4.2 Right Ventricular afterload 
The afterload faced by the RV is determined by several components; the steady 
state mean resistance to blood flow, compliance of the system, arterial wave 
reflections that arise as a result of the pulsatile nature of flow, and inertance of 
blood during ejection (126). Clinical measures commonly derived from right heart 
catheterisation such as PVR are therefore not ideal measures of RV afterload. 
Afterload can be defined by RV wall stress that arises during RV ejection. This can 
be approximated by the maximum product of volume and pressure divided by wall 
thickness, by Laplace’s law. This is however problematic in the RV as there is 
considerable variation in RV internal radius due to its complex shape and it is not 
in essence the true sphere to which this law applies (127). Pulmonary artery 
impedence (PVZ) is the ratio of pressure to flow oscillations which can be 
calculated by spectral analysis of pressure and flow waves. Whilst this method 
does provide a comprehensive description of all aspects of RV vascular load, it is 
both difficult to measure and interpret (128). Effective arterial elastance (Ea) is a 
simpler approach to describing the load faced by the RV and incorporates both 
resistive and pulsatile components (129). It is graphically determined on a 
pressure volume loop by dividing the pressure at ESP by stroke volume. This 
method allows matching of afterload to RV contractility (Ees). As contractility 
should be homeometrically adjusted to match its afterload, the adequacy of this 
adaptation can be assessed by the ratio of Ees/Ea, which defines ventricular-
arterial coupling. 
1.1.4.3 Simplified methods for the assessment of right ventricular-arterial 
coupling. 
RV-arterial coupling as a ratio of elastances represents optimal transfer of energy 
from the RV to pulmonary circulation at ratios of 1.5-2 (130). It is, however, also 
possible to determine coupling by a ratio of volumes. Ees can be approximated by 
the formula; 
Ees= ESP/ (ESV-V0) 
Where ESP is the end systolic pressure, ESV the end systolic volume and V0 is the 
volume intercept of the ESPVR line, and approximates to the theoretical volume 
of the unloaded ventricle. 
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And Ea can be approximated by 
Ea = ESP/SV. 
RV-arterial coupling (Ees/Ea) therefore can be determined by ratio of volumes, 
SV/ESV, if V0 is regarded as negligible. 
There are several limitations to using SV/ESV. The first is that ESP-ESV relationship 
is linear and crosses the origin. This is incorrect as the ventricular volume at zero 
filling (ie V0) has to be positive and therefore this method leads to an 
underestimation of Ees. In addition, we assume that Ees coincides with Emax which 
may not be correct (131). SV/ESV however offers a measure of RV function in a 
similar manner to RVEF (SV/EDV) however in a less preload dependent manner. 
Additionally, RV-A coupling can be approximated by pressure measurement 
obtained at RHC and RV volume measurement by CMR (132). Pmax is derived as 
previously mentioned from extrapolation of the RV pressure curve, however ESP 
is approximated by mPAP. Ees is therefore calculated as; 
Ees = (Pmax – mPAP)/SV  
or by further simplification if V0 = 0, Ees = mPAP/ESV.  
Trip et al demonstrated that V0 may vary from-8 to 171 ml, and correlated with 
ventricular volume and therefore could not be regarded as negligible, nor could 
the calculated Ees be preload independent. However, this method has a number 
of limitations raised by the use of surrogate pressures and volumes in addition to 
reliance on a linear extrapolation from the slightly curvilinear ESPVR which may 
result in markedly different pressure or volume intercepts (122). 
  
66 
 
1.2 The right heart and pulmonary vasculature in 
pulmonary hypertension 
1.2.1 Aetiology 
Pulmonary arterial “sclerosis” was first described by Ernst von Romberg in 1891 
but it wasn’t until 1951 that a larger study reported the characteristics of 39 
patients with PAH of unknown aetiology and the term ‘primary pulmonary 
hypertension’ was coined (133, 134). The WHO presented the first definition of 
the disease in 1973 in Geneva, classifying the disease by primary, secondary and 
associated PH (135). Since then, four further world symposia have developed a 
more comprehensive clinical classification system based on 5 main groups of 
pulmonary hypertensive disease initially proposed in Evian France in 1998 (136-
138). The most recent clinical classification from the fifth WSPH held in Nice, 
France in 2013 is shown in table 1-1 
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Table 1-1 Clinical classification of Pulmonary Hypertension (Nice 2013) 
1. Pulmonary arterial hypertension (PAH)  
1.1 Idiopathic (IPAH) 
1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK1, ENG, SMAD9, CAV1, KCN K3 
1.2.3 Unknown 
1.3 Drug and toxin induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV Infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary 
hemangiomatosis 
1″ Persistent pulmonary hypertension of the newborn (PPHN) 
 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and 
congenital cardiomyopathies 
 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases 
 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Haematological disorders: chronic haemolytic anaemia, myeloproliferative 
disorders, splenectomy 
5.2 Systemic disorders: Sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
5.3 Others: tumour obstruction, fibrosing mediastinitis, chronic renal failure, 
segmental PH 
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1.2.2 WHO group I pulmonary arterial hypertension 
The global burden of PAH is difficult to estimate as accurate diagnosis requires 
access to healthcare and specialist diagnostic tools including RHC which is limited 
in many developing countries. The incidence and prevalence from France is 
estimated at 2.4 cases/million annually and 15 cases per million respectively 
(139). In the UK, national audit data from 2013 reports prevalence rates of 
49.2/million and 51.8/million in England and Scotland respectively (140). 
Historical data from Scotland suggests annual incidence of 7.6/million population 
(141). Information regarding the prognosis of idiopathic and familial PAH were 
derived from the National Institute of health (NIH) supported US registry in the 
1980s, based on both prevalent and incident cases, in an era which predated PAH 
therapies. Based on this registry, very poor median survival of 2.8 years from 
diagnosis has been quoted (142, 143). Since that time a number of PAH therapies 
have been developed, and several large national registries have been established 
and reported improved survival in PAH. In the US REVEAL registry 1, 3 and 5 year 
survival rates of 85%, 68% and 57% respectively were observed, with a median 
survival of 7 years (144, 145). This registry is however in a cohort of predominantly 
prevalent patients, which may create survival bias. Data from France and the UK 
of incident PAH cases report similar 1 year survival rates of 88%.  
Prognosis varies depending on the aetiology of PAH and comorbid conditions. 
Prognosis in PAH associated with CHD tends to be better than IPAH, while 
historically CTD associated PAH carried a significantly worse prognosis than IPAH 
prior to availability of therapeutic options. In the 2013 national audit data from 
the UK similar 1 year survival rates of incident cases of CTDPH vs IPAH of 89 vs 
88% were observed. In Ssc associated CTDPH, 1 and 3 year survival rates 78% and 
47% have been reported in comparison to 1 and 3 year survival rates of 92.7% and 
73.3% in IPAH, familial and anorexigen associated disease, both from incident 
cohorts albeit different UK registries (146, 147). In SLE associated disease 1 and 3 
year survival rates were 78 and 74% respectively, and 83% and 66% for rheumatoid 
arthritis, suggesting the aetiology of the CTD also has some influence on outcome. 
PAH is therefore a rare disease but one of significant mortality.  
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1.2.2.1 Pathophysiology 
PAH is a syndrome characterised by progressive pulmonary arterial obstruction 
and remodelling as a consequence of excessive cell proliferation and impaired 
apoptosis, leading to an increase PVR and RV afterload. Remodelling mostly occurs 
in small to medium sized pulmonary arterioles <500µm and involves all three layers 
of the vessel wall. Endothelial dysfunction leads to an imbalance that favours 
vasoconstriction, in situ thrombosis and mitogenesis. Histological appearances are 
of muscularisation of distal and medial pre-capillary arteries, neointimal 
formation, infiltration of inflammatory and progenitor cells, thrombosis in situ and 
formation of complex lesions called plexiform lesions (148). Endothelial cells and 
PASMCs from patients with PAH display a pro-proliferative anti-apoptotic 
phenotype and a glycolytic shift in metabolism which has led to some analogies 
with cancer cells (149). 
A number of growth factors act as mitogens and chemoattractants for SMCs, 
fibroblasts and endothelial cells including FGF-2 and PDGF (150). Levels of 
cytokines and chemokines such as IL-6, TNF and IL-1β are raised in PAH and may 
correlate with severity of disease (151). Monocytes, macrophages, T and B 
lymphocytes are found in plexiform lesions and autoantibodies to endothelial cells 
and fibroblasts have been isolated from the lungs of PAH patients. Inflammation 
therefore is thought to be an important contributor to progression of vascular 
remodelling and may be implicated as a triggering factor in PAH (152). 
Perturbed angiogenesis is suggested by the development of plexiform lesions and 
altered levels of circulating pro-angiogenic progenitor cells in patients with IPAH. 
The precise role that disordered angiogenesis plays however is uncertain (153, 
154). Alterations in the function of K+ and Ca2+ channels have been linked to 
dysregulation of cellular homeostasis, promotion of SMC proliferation and 
alterations in pulmonary vascular tone. In PAH, reduced expression of voltage 
gated K+ channels, specifically Kv1.5 is linked to induction of muscle contraction 
and vascular remodelling due to an imbalance in apoptosis and proliferation (155). 
Finally, roles for insulin resistance, obesity and sex hormones have been linked to 
development of PAH (156, 157). Both idiopathic and familial disease is more 
common in females, however animal studies suggest a protective effect of 
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oestrogens. Further study is required to better understand potential links with 
development of PAH. 
1.2.2.1.1 Endothelial dysfunction 
Endothelial dysfunction is reflected by reduced production of the 
vasodilators/growth inhibitors nitric oxide (NO) and prostacyclin (PGI2), and 
increased production of vasoconstrictor/co-mitogens, such as endothelin-1 and 
thromboxane A2 (158).  
NO is produced in the endothelium by the action of endothelial NO synthase 
(eNOS). In PASMC NO stimulates soluable guanylate cyclase (sGC) to produce cyclic 
GMP (cGMP) which has antiproliferative properties in addition to causing 
vasodilatation. In the pulmonary circulation, the eNOS/NO/sGC/cGMP pathway is 
the principle driver of endothelium mediated vasodilation and focus of 
therapeutic targeting in PAH (159). In PAH, reduced NO bioavailability arises as a 
result of reduced NOS expression, consumption of NO by overproduction of free 
radicals by oxidative stress, and inhibition of NO synthesis (160-162). Additionally 
elevated levels of asymmetric dimethylarginine (ADMA) which is a competitive 
inhibitor of NOS have been found in patients with IPAH. Increased expression of 
phosphodiesterase type 5 (PDE-5) has been shown in both PASMC and the right 
ventricle, which is the enzyme responsible for cGMP degradation (163). PDE5 
inhibition has also been exploited as a therapeutic target in PAH. 
ET-1 regulates vascular tone causing vasoconstriction and inducing cell 
proliferation via ETA and ETB receptors located on PASMCs. ET-1 levels have been 
shown to be elevated in PAH as well as patients with heart failure and COPD (164, 
165). Endothelial cells also express ETB receptor which is involved in release of 
NO and prostacyclin. ET-1 also interacts with matrix metalloproteinases (MMPs) 
causing fibrogenesis. Both selective (against ETA) and nonselective ETRAs have 
been developed as treatments in PAH. 
Overproduction of serotonin by pulmonary artery endothelial cells has also been 
shown in PAH which acts on SMC and fibroblasts to cause vasoconstriction and 
remodelling (166). Abnormal cross-talk between endothelial cells and SMC in IPAH 
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has been linked to enhanced paracrine overproduction of serotonin and other pro-
migratory pro-proliferative mediators (167). 
1.2.2.1.2 Genetic mechanisms 
PAH has a genetic component. Mutations in bone morphogenetic protein type II 
receptor (BMPR2) have been reported in >70% patients with one or more affected 
relatives (heritable PAH) but also 11-40% of those with sporadic IPAH (168-
170).Penetrance is low with only ~25% of carriers developing PAH (171). Most cases 
of familial PAH have loss of function mutations in BMPR2 that promote cell 
proliferation. Modifier genes such as SERT may in part explain the variable 
penetrance, however it seems likely that aberrant BMPR2 function alone is 
insufficient to explain the subsequent development of PAH and lead to second hit 
hypothesis from environmental or comorbid conditions. Mutations in several other 
genes have been discovered, including ALK1 (172), the endoglin gene (173), SMAD9 
(174), Caveolin-1 (175) and K+ channel subfamily K KCNK3 (176). Patients with 
BMPR2 and ALK1 mutations present with higher PVR, and present and die at 
younger age than those without (177, 178). 
1.2.2.2 Diagnosis 
Echocardiography is employed to detect suspected PH in symptomatic individuals 
with breathlessness or signs of RV dysfunction, or as a screening tool in at risk 
populations such as scleroderma. Doppler derived measurements of the peak 
velocity of blood crossing tricuspid or pulmonic valves allow estimation of the 
pressure gradient using a simplified Bernoulli’s equation 
PG= 4x (peak velocity)2 
Tricuspid valve regurgitant jets are more readily acquired and used for this 
purpose. Systolic PAP can then be estimated, as the sum of tricuspid valve 
regurgitant pressure gradient (TRPG) + estimated RAP. The presence of tricuspid 
regurgitation increases as sPAP increases and regurgitant jets are visualised by 
echocardiogram in the majority of PH patients. One study demonstrated TR in 74% 
of patients with PH (179), whilst another has reported appreciable TR jets in 80% 
patients with a sPAP above 35mmHg rising to 96% of those with sPAP >50mmHg 
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(180). RAP can be estimated from inferior vena cava collapsibility index by 
echocardiogram or clinically from assessing the extent of jugular venous pressure 
elevation. Impressive correlation with invasively measured sPAP has been 
demonstrated, with r = 0.89-0.97. There are however a number of limitations, 
reliance on the presence of tricuspid regurgitant jet, operator dependence and 
relatively high standard errors of estimation. Therefore, whilst echocardiography 
has been established as the imaging modality of choice in screening for PH it is 
not sufficient to diagnose PH. 
Right heart catheterisation (RHC) is the gold standard for both diagnosis and 
haemodynamic assessment of patients with suspected PH. For standardisation of 
measurements the pressure transducer is zero levelled at the midthoracic line in 
the supine patient, halfway between the anterior sternum and table surface, 
which represents the level of the left atrium. PH is defined by the presence of 
mPAP ≥25mmHg at rest, however for a diagnosis of PAH, additional haemodynamic 
measurements are required; 
1. Cardiac output (CO) must be normal or low. This is commonly measured 
using the thermodilution method which has been shown to provide reliable 
measurements in patients with very low CO or with severe tricuspid 
regurgitation. 
2. Pulmonary artery wedge pressure (PAWP) < 15mmHg. PAWP provides an 
approximation of left atrial pressure by recording pressure measurements 
with a balloon-tipped pulmonary artery catheter wedged, with the balloon 
inflated, within a branch pulmonary artery. Measurement at end of normal 
expiration minimises the effect of swings in intrathoracic pressure with 
respiration. A PAWP >15mmHg suggests PH secondary to left heart disease 
(group 2 disease). 
3. Raised pulmonary vascular resistance (PVR) ≥ 3 wood units. PVR is 
calculated by (mPAP – PAWP) / CO. 
Additional haemodynamics measurements that are assessed include RAP, 
pulmonary artery or mixed venous oxygen saturations (SVO2) which have been 
shown to have prognostic significance in PH.  
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A resting mPAP ≥25mmHg is required for a diagnosis of PH. As discussed in section 
1.1.1 mPAP increases with ageing, with the upper limit of normal of 20mmHg (24). 
It is unclear how to classify and manage patients with mPAP 21-24mmHg as most 
epidemiological and therapeutic studies have used mPAP ≥25mmHg as threshold 
for inclusion. These modest elevations in mPAP could represent early pulmonary 
vascular disease particularly if the TPG or PVR is high. Whether these patients go 
on to develop more significant pulmonary vascular remodelling and meet current 
diagnostic criteria for PAH is unknown as the natural history of such a group has 
not been widely studied. The exception to this is in scleroderma where screening 
for PH is widely carried out due to the lifetime risk of development of PAH. The 
presence of borderline mPAP is associated with higher risk of developing clinically 
significant PAH (181)  and associated with poorer prognosis when raised TPG is 
also present. The consequence of delaying therapeutic intervention until PAH 
manifests is unknown. Current guidelines recommend close monitoring of patients 
with mPAP 21-24mmHg, particularly if they have an additional risk factor 
associated with PAH. 
Before the 4th WSPH, PH was also defined by the presence of mPAP which rose to 
>30mmHg on exercise in the absence of resting PH. This has subsequently been 
removed from the updated diagnostic criteria. Exercise related mPAP rises with 
age as part of normal age related increase in vascular stiffness. Previous studies 
have not standardised the level, type and posture of exercise and it is therefore 
uncertain what represents a normal valve of exercise mPAP. Additionally, the 
prognostic and therapeutic significance of exercise induced PH with normal resting 
haemodynamics is unknown and further study in this area is required. 
Despite increased awareness of the disease there is often considerable delay 
between the onset of symptoms and the diagnosis. The majority of patients are 
diagnosed with NYHA FC III-IV disease which has been shown to predict poorer 
survival. Data from the REVEAL registry found that 21% of patients had symptoms 
for more than 2 years before diagnosis, and so interest has focussed on striving to 
identify patients with PAH at an earlier stage and commence treatment before 
the development of RV failure. Due to the variable penetrance of mutations 
associated with FPAH, the benefit of genetic screening of asymptomatic relatives 
is uncertain. Furthermore, a monitoring strategy for mutation carriers has not 
been agreed, with some suggesting annual echocardiogram, and others advocating 
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investigating symptomatic relatives only due to lack of evidence for treating 
asymptomatic individuals. In scleroderma, annual screening of asymptomatic 
patients using modalities such as DLCO, biomarkers, echocardiography and RHC in 
those with positive findings or clinical signs is already underway. Focussed 
screening of at risk groups is suggested, but the majority of cases arise in sporadic 
patients in wider populations. Earlier diagnosis therefore relies on increasing 
awareness and education of clinicians who patients are likely to present to, such 
as cardiorespiratory physicians and rheumatologists.  
 
1.2.2.3 Treatment 
Over the past two decades the three major pathways underlying the development 
of PAH, the prostacyclin, nitric oxide and endothelin pathways, have been 
targeted for the development of PAH specific therapies. At the time of the 2nd 
WSPH in 1998, only epoprostenol, an intravenous prostacyclin analogue in addition 
to calcium channel blockers were known therapies. 15 years later at the time of 
the 5th WSPH, the therapeutic options have expanded considerably with 7 
compounds approved, different modalities of administration available and a 
number of drugs under development. These pharmacological discoveries have led 
to considerable reduction in mortality and morbidity (182). Additionally, therapies 
from all three drug classes, prostacyclin analogues, phosphodiesterase-5 inhibitors 
(PDE-5i) and endothelial receptor antagonists (ETRA) have been shown to improve 
exercise capacity, functional status, symptoms and haemodynamics. Whilst some 
have been shown to delay time to clinical worsening, only Epoprostenol is proven 
to improve survival. Newer therapies Macitentan and Selexipag which have 
completed phase III studies in the last 3 years have also shown improvement in 
composite endpoint of morbidity and mortality. Table 1-2 displays current drug 
therapies licensed for use in PAH. 
In addition to vasodilatory effects, ETRAs have been shown to improve pulmonary 
vascular endothelial function and beneficial remodelling in pre-clinical studies 
(183). PDE-5 inhibition has antiproliferative effects and in PAH models enhances 
myocardial contractility as a result of the pressure overloaded RV myocytes 
expression of PDE5 (184). As discussed above, the pathogenesis of PAH is complex 
and in addition to focusing drug development on overcoming vasoconstrictive 
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components, recent interest has arisen in targeting other components of 
pulmonary vascular remodelling, including inflammatory mediators, growth 
factors, BMPR2 mutations, metabolic dysfunction and calcium signalling. 
Preclinical studies into utility of Tocilizumab (an anti-IL-6 monoclonal antibody), 
Rapamycin (HDAC1 inhibitor), Apelin, PPARγ agonists and Rho kinase inhibitors 
such as Fasudil respectively targeting these pathways may provide novel 
therapeutic agents in the future (185). 
Combination therapy because of the 3 signalling pathways involved is an attractive 
prospect for management of PAH. Recent meta-analysis has suggested 
combination therapy reduces time to clinical worsening, and improves 
haemodynamics and exercise tolerance (186). It is unknown if combination 
therapy upfront is of benefit. Current guidance recommends sequential 
combination therapy in those with unsatisfactory clinical response. The suggested 
initial therapy is based on NYHA functional class, with those in FC II treated with 
an oral agent and Epoprostenol reserved for those in FC IV (187). 
 Table 1-2. Drugs approved or completing phase III studies for treatment of PAH in UK. 
 
Drug route Study Outcome Measure Reference 
   6MWD FC Haemodynamics TTCW Survival  
Endothelin Pathway 
Endothelin receptor antagonists (ETRA) 
     
Bosentan Oral BREATHE 1 and 2 + (44) + + + NT (188) 
Ambrisentan Oral ARIES 1 and 2 + (51.4) + + + NT (189) 
Macitentan Oral SERAPHIN + + + NT +* (190) 
NO Pathway 
PDE-5 inhibitors 
      
Sildenafil Oral SUPER-1 + (45) + + - NT (191) 
Tadalafil Oral PHIRST + - + + NT (192) 
Soluable guanylate cyclase stimulator       
Riociguat Oral PATENT 1 and 2 + (35.8,51) + + + NT (193, 194) 
Prostacyclin Pathway 
Prostacyclin analogues 
      
Epoprostenol IV  + + + NT + (195, 196) 
Iloprost Inhaled AIR + + + + NT (197) 
Prostaglandin Receptor Agonist       
Selexipag Oral GRIPHON     +* (198) 
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1.2.3 WHO group 3 PH associated with hypoxic lung disease 
Pulmonary hypertension associated with chronic lung disease is one of the most 
common forms of PH. The true prevalence is unknown as echocardiography is 
known to be unreliable in lung disease patients making accurate noninvasive 
diagnosis difficult in large population based studies (199). It is known, however, 
that the prevalence of PH varies with both the underlying aetiology and severity 
of lung disease, and its development is associated with both exercise limitation 
and worse prognosis. Unlike group I PAH, where development of pharmacological 
therapies has substantially progressed in the last decade, with the exception of 
provision of oxygen therapy there are no proven therapeutic options. 
1.2.3.1 Epidemiology 
1.2.3.1.1 Chronic obstructive pulmonary disease 
Studies in patients with advanced COPD have shown a high prevalence of PH with 
up to 90% having a mPAP >20mmHg. The reported prevalence however varies 
widely, dependent on the definition of PH, methods used to determine pulmonary 
pressures and the population studied. The absence of large epidemiological 
studies means the true prevalence of PH in mild to moderate COPD is unknown. 
Relative to other forms of PH, COPD largely causes modest haemodynamic changes 
at rest with mPAP typically in range 20-35mmHg. However, even moderate levels 
of exercise have been shown to cause further rapid rise in mPAP likely as result of 
impaired vascular distensibility and recruitment (200). The presence of mild PH, 
with mPAP >18mmHg is associated with increased risk of hospitalisation with 
exacerbations (201). During episodes of acute respiratory failure mPAP may rise 
by as much as 20mmHg but return to baseline following recovery of the 
exacerbation (202). The rate of PH progression is normally slow, typically in the 
range of 1-3mmHg/year in small studies with serial RHC in COPD patients (203).  
There have been a number of RHC studies in patients with severe COPD undergoing 
evaluation for lung volume reduction surgery (LVRS) or lung transplantation. 
Scharf et al reported the RHC results of 120 patients with severe emphysema 
screened for participation in the National emphysema treatment trial (NETT) 
(204). 91% had an mPAP >20mmHg with a mean mPAP 26.3 ± 5.2mmHg. Vizza et 
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al observed similar results in 168 patients listed for lung transplantation with mean 
mPAP 25.6mmHg (205). Thabut et al reported a retrospective review of 215 
patients with severe COPD (mean FEV1 23.9% predicted) whom underwent RHC as 
part of evaluation for LVRS or transplantation and found PH was present (using 
traditional definition of mPAP >25mmHg) in 50.2% with mean mPAP of 26.9mmHg 
(206). Cuttica et al found remarkably similar prevalence with a retrospective 
review of 4930 COPD patients listed for transplantation (207). Whilst 48% had 
mPAP ≥25mmHg, 30% had both mPAP ≥25mmHg and PAWP ≤15mmHg highlighting 
prevalence of coexistent pulmonary venous hypertension. Finally, in a large study 
of 998 COPD patients with less severe airflow limitation (mean FEV1 33%) and 
hypoxaemia, mPAP was 20.3mmHg, with a prevalence of PH (defined as mPAP 
>20mmHg) in approximately 50% of patients hospitalised for COPD (208). 
The development of PH in COPD has been shown to have significant prognostic 
relevance, with inverse correlation between mPAP or PVR with survival (209, 210). 
It is suspected that the improved survival of hypoxaemic COPD patients with LTOT 
relates to improvement of pulmonary haemodynamics, although mPAP remains a 
prognostic variable in LTOT treated patients. In recent study, the 5 year survival 
of COPD patients with mPAP >25mmHg was 36.3% in comparison to 62.2% without 
PH. Pulmonary haemodynamics were stronger prognostic variable than either FEV1 
or gas exchange variables (210). 
1.2.3.1.2 Interstitial lung disease 
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung 
disease of unknown aetiology with a median survival of 2.5 to 5 years (211, 212). 
PH has been reported in 8.1% and 14.9% of patients at time of diagnosis (213, 214), 
rising to 20-50% in advanced disease at time of evaluation for transplant and >60% 
with end stage IPF (215-217). Serial RHC has shown progressive PH from a 
prevalence of 38.6% at time of transplant evaluation to 86.4% at time of 
transplantation. Rapid progression of PH has also been reported. Like COPD, the 
PH is usually mild, in a retrospective study of 135 patients, mean mPAP was 
31±6mmHg (218). Shorr et al reported on 2,525 IPF patients listed for 
transplantation (219). Of the 46.1% whom had PH, mean mPAP was 
34.2±9.9mmHg, although 18% had a PAWP >15mmHg suggesting co-existent 
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pulmonary venous hypertension. Poor or even no correlation between lung 
function (219, 220) or HRCT fibrosis score (221) and severity of PH has been 
reported. The development of PH has been associated with more pronounced 
exercise capacity limitation due to circulatory impairment in comparison to IPF 
patients without PH but similar lung function (216, 222). The presence of PH is 
associated with an almost 3 fold increase in the risk of death (220, 223). Both 
echocardiography defined PH (sPAP >50mmHg) and RHC (with even trivial increase 
to an mPAP of >17mmHg) has been associated with poorer survival (213, 220). In 
one study, the 1 year mortality in those with PH IPF was 28% compared to 5.5% in 
those without (220). 
1.2.3.1.3 Combined pulmonary fibrosis and emphysema syndrome 
PH is particularly prevalent in combined pulmonary fibrosis and emphysema 
(CPFE) syndrome with estimates approaching 30-50% of patients. CPFE is 
characterised by predominantly upper lobe emphysema with lower lobe fibrosis in 
association with marked impairment of gas exchange demonstrated by low DLCO 
(224). The incidence is unknown but case series suggest it may compromise up to 
35% of patients with IPF (225). Prognosis is poor, with a 5 year survival of 55% 
(226). Unlike COPD and IPF, often severe PH is seen with markedly reduced DLCO 
but largely preserved lung volumes. At RHC, mPAP >35mmHg occur in 68% and 
>40mmHg in 48% of patients (227). The development of PH is associated with poor 
survival (228) with reduced CI being a strong prognostic determinant. 1 year 
survival of only 60% has been reported (227). 
1.2.3.2 Pathophysiology 
The pathophysiology of PH in patients with lung disease is complex and likely 
arises due to a combination of HPV, vascular inflammation and remodelling, and 
loss of the vascular bed as a result of parenchymal destruction. Chronic effects of 
hypoxia on the pulmonary circulation is the basis of many animal models used in 
the study of pulmonary hypertension therapies. Chronic alveolar hypoxia results 
in a sustained elevation in pulmonary vascular resistance due to vasoconstriction 
and induces vascular remodelling. Whilst undoubtedly one of the initiating factors 
in development of PH in lung disease, the failure of oxygen therapy to 
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subsequently reverse PH suggests the resultant structural changes in the 
pulmonary circulation are the major factor.  
In COPD, autopsy specimens from patients with severe disease have demonstrated 
muscularisation of pulmonary arterioles which can extend to the periphery of the 
lung in precapillary vessels as little as 20µm in diameter (229, 230). 
Muscularisation can also be seen in post capillary veins and venules. Intimal 
hyperplasia has been observed in both mild and endstage COPD. Complex 
plexiform lesions of PAH have not been demonstrated, but reduction in total 
number of pulmonary vessels has been shown in both angiographic and autopsy 
studies (231, 232). The changes in vessel structure are accompanied by endothelial 
dysfunction and alteration in expression of growth factors and antiproliferative 
mediators that favour cell proliferation and vascular contraction. Whilst the 
severity of hypoxaemia has been related to the increase in both PAP and PVR, 
pulmonary vascular remodelling also occurs in non-hypoxaemic mild COPD patients 
(233, 234). Regional hypoxia in under ventilated areas of the lung in absence of 
systemic hypoxaemia may be present in COPD and therefore regional remodelling 
related to HPV may still occur. Tobacco smoke exposure is thought to play an 
important role in development of pulmonary vasculopathy (235). “Healthy” 
smokers without demonstrable airflow obstruction have been shown to have 
intimal hyperplasia, reduced eNOS expression, increased VEGF and inflammatory 
cell infiltrate in pulmonary arteries at a similar level to COPD patients (234, 236-
238). In experimental models, cigarette smoke is known to cause endothelial 
dysfunction, and when exposed to both cigarette smoke and hypoxia, animal 
models are seen to develop more severe pulmonary hypertension and remodelling, 
suggesting a possible synergistic effect (239, 240). This has led to some to 
postulate that smokers are perhaps more susceptible to effects of hypoxia on the 
pulmonary vasculature as a result of pulmonary vascular dysfunction initiated by 
cigarette smoke. The role inflammation plays in the development of PH is poorly 
understood. It is known that systemic inflammation appears to be a risk factor for 
development of PH, with some studies showing a correlation between pro-
inflammatory cytokines such as IL6 and c-reactive protein and PAP (241, 242). 
Additionally hyperviscosity from polycythaemia, compression of the alveolar 
vessels from hyperinflated emphysematous lungs, hypercapnic acidosis related 
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vasoconstriction and increase in PAWP as result of dynamic hyperinflation may 
play a role (243). 
In IPF, vascular remodelling with intimal proliferation and medial thickening in 
both muscularised pulmonary arterioles and veins have been demonstrated in 
pathological specimens consistent with those seen in other hypoxic lung diseases 
(244). In addition to vessel ablation in dense areas of fibrosis, occlusive venopathy 
and vascular remodelling is present in non-fibrotic areas suggesting a potential 
role for other mechanisms (245). Overexpression of inflammatory cytokines and 
growth factors including PDGF and fibroblast growth factor are implicated in the 
pathogenesis of IPF (246, 247). Decreased levels of prostaglandin E2 (PGE2) which 
opposes fibrotic response and may increase expression of TGF-β, has been found 
in bronchoalveolar lavage in IPF patients (247). Additionally ET1, a potent 
vasoconstrictor and smooth muscle mitogen found in increased levels in IPAH, has 
been found in elevated concentrations of IPF patients both with and without PH 
(248, 249). Arterial levels of ET-1 have been shown to correlate inversely with 
Pa02 and directly with PAP in IPF patients (250). PDGF, TGF-β, and fibroblast 
growth factor have been implicated in the pathogenesis of both IPAH and hypoxia 
induced PH suggesting the possibility of common inflammatory pathways in 
parenchymal and vascular remodelling seen in IPF PH and potentially a shared 
therapeutic target (246).  
1.2.3.3 Severe pulmonary hypertension in hypoxic lung disease 
Whilst mild PH in chronic lung disease may be prevalent, severe PH, defined as 
mPAP ≥35mmHg is rare occurring in only 3-5% of COPD patients. These patients 
typically display less severe respiratory function compromise and the PH is 
therefore regarded as disproportionate. Haemodynamic or CMR evidence of RV 
dysfunction more commonly seen in PAH patients is often seen. Severe PH is 
postulated to occur in individuals with excessive HPV response, including those 
with genetic polymorphisms of the serotonin (5HT) transporter gene (251). 
Whether these patients should be managed as Group 3 disease or possibly regarded 
as having co-existent Group I disease is uncertain. Recent data from large national 
PH registries has reported on increasing prevalence of comorbid disease in PAH 
diagnoses with up to 17% having COPD (252). Previous literature on “out of 
proportion” PH in lung disease has been clouded by use of differing levels of mPAP 
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between 35-40mmHg, and varying degrees of lung function impairment in its 
definition. The most recent world congress has suggested classification system in 
efforts to standardise therapeutic trials and also to address the issue of what 
represents comorbid lung disease or group 3 disease (253). A level of mPAP 
≥35mmHg is suggested to define severe PH in lung disease.   
Cuttica et al reported <1% of COPD patients listed for transplant had a mPAP 
>35mmHg at RHC (207). Severe PH was found in 5% of emphysema patients from 
the NETT trial (254), although this is probably an underestimate as severe PH was 
one of the exclusion criteria for the study.  In the studies from France, Thabut et 
al found 13.5% of patients with advanced COPD had severe PH (206), whilst Chaout 
et al reported a prevalence of 5.8% with mPAP >35mmHg and 2.7% mPAP >40mmHg 
(208). The majority however had an alternate cause for PH. In the remaining 1.1%, 
clinically these patients displayed less severe airflow obstruction but more severe 
hypoxaemia, hypocapnia and grossly impaired DLCO. Those with a mPAP >40mmHg 
had worse survival than both those with no PH (mPAP <20mmHg) and those with 
mild-moderate PH (mPAP 20-40mmHg). 
Data on the prevalence of severe PH in IPF studies is limited. Shorr et al reported 
9% of IPF patients had an mPAP>40mmHg (219). Letteri et al whilst not specifically 
reporting on frequency of severe PH, found mPAP ranging up to 46mmHg in the 
cohort with a linear correlation between mPAP and outcome, suggesting greater 
risk of mortality in those with severe PH similar to COPD patients (220). Severe 
PH associated with CPFE is thought to be relatively more common, reported in 68% 
at RHC and 72% by echocardiogram in two small case series (227, 228). 
Severe PH associated with lung disease whilst rare, is therefore a disease with 
severe morbidity and mortality, with some features, such as relative preservation 
of lung function, greater degree of RV dysfunction and haemodynamic 
compromise, that have generated interest in the potential for use of pulmonary 
vasodilator therapies. 
1.2.3.4 Treatment 
Unlike PAH, there are no studies to support the use of pulmonary vasodilator 
therapy in patients with hypoxic lung disease PH. Clinical studies examining the 
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effect of PAH therapies in group 3 disease have however been in small population 
sizes, with poorly defined levels of PH often using echocardiography alone to 
diagnose PH or using mixed populations of lung disease patients with and without 
PH. Management therefore focuses on treating the underlying lung disease, 
excluding an additional aetiology for the PH such as thromboembolic disease and 
consideration of lung transplantation. In COPD, in addition to improving mortality 
LTOT has been demonstrated to stabilise or even slightly improve mPAP. In the 
MRC trial, at 5 years mPAP increased by 2.7mmHg/year in the no oxygen group 
whilst remained unchanged in the oxygen therapy group (255). In the NOTT study, 
mortality was 11.9% in the continuous oxygen group versus 20.6% in the nocturnal 
oxygen group at 1 year (256). In the 117 patients whom underwent haemodynamic 
evaluation at 6 months, mPAP showed a slight rise in the nocturnal oxygen group 
whereas an average decrease of 3 mmHg/year was seen in the continuous therapy 
group. PVR also fell by 11.1% in the continuous oxygen group and rose by 6.5% in 
the nocturnal oxygen patients. Smaller studies have also shown fall in mPAP of 
2.1mmHg per year after initiation of oxygen therapy and long term stabilisation 
of PH in COPD patients receiving LTOT (257, 258). In severe PH with lung disease 
however results are less encouraging. In the NOTT study, those patients with high 
PVR did not demonstrate a survival benefit with continuous oxygen therapy 
whereas low PVR patients did. Additionally autopsy studies show no significant 
difference in structural pulmonary vascular remodelling in those receiving LTOT 
and those not (259). Therefore it would seem that LTOT has the potential to 
stabilise pulmonary haemodynamics, but does not lead to a normalisation of 
haemodynamics or reversal of vascular remodelling. In ILD, there is limited data 
on the use of LTOT and similar benefit has therefore not been demonstrated. The 
use of LTOT is recommended to maintain arterial saturations above 90% as HPV is 
known to play a role in the pathogenesis. 
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1.2.4 The right ventricle in pulmonary hypertension 
Right ventricular failure is the major cause of death in patients with PAH, and it 
is increasingly recognised that both survival and functional status relate to the 
ability of the RV to adapt to the increasing levels of afterload that occur as the 
disease progresses. As a result of sustained elevation in PVR and reduction in 
compliance of the pulmonary circulation that slowly develops in PAH, the RV 
initially undergoes homeometric adaptation characterised by concentric 
remodelling and preservation of systolic and diastolic function. Eventually as the 
disease progresses, the RV cannot maintain adaptive hypertrophy to match its 
afterload, and RV dilates in an effort to maintain SV and maladaptive remodelling 
associated with eccentric hypertrophy and impaired function occurs (260). At this 
point there is no further increase in contractility, or even a decrease may occur 
despite continued elevation in load, and “uncoupling” of the RV from the 
pulmonary circulation. RV dilatation increases wall tension which in turn increases 
myocardial oxygen demand whilst decreasing RV perfusion leading to ongoing 
cycle of further compromised RV contractility and dilatation. Additionally, due to 
ventricular interaction, RV enlargement decreases LV filling due to pericardial 
constraint, which further decreases SV and therefore systemic blood pressure, 
which may add to RV ischaemia from reduced coronary perfusion pressure. 
Prolongation of RV contraction occurs as RV function declines, with resultant 
ventricular asynchrony. The RV free wall continues to contract whilst the LV has 
already relaxed in its early diastolic phase, leading to left ward septal bowing 
which further impairs LV filling (261). This, together with systolic and diastolic RV 
dysfunction and fall in RV SV culminate in the marked fall in CO seen in severe 
PAH. Chronic neurohormonal activation (adrenergic and angiotensin pathways), 
oxidative stress, immune activation and cardiomyocyte apoptosis have also been 
implicated in the progression of RV failure and deterioration in contractility in 
PAH (262-264). Increases in RV volumes leads to functional tricuspid regurgitation 
as a result of annular dilatation which in turn causes RV volume overload, and 
further RV remodelling and annular dilatation. Therefore, once the onset of RV 
functional decline is initiated, a cycle of events is triggered which spirals towards 
RV failure. In comparison to the LV, ventricular enlargement occurs earlier in PAH 
then in the pressure overloaded LV as a result of greater wall stress experienced 
by the thin walled RV. However, significantly less fibrosis occurs often limited to 
the RV septal insertion points and constitutes <10% of the ventricular volume (265, 
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266). This explains why patients whom undergo lung transplantation restore RV 
function despite severe RV impairment prior to transplantation (267, 268).  
 
1.2.5 Monitoring and prognosis in pulmonary hypertension 
Although remodelling of the pulmonary circulation is the cause of PAH, symptom 
severity and survival have been shown to relate to RV function. A number of 
prognostic indices have been identified from both large cohorts from National 
registries and smaller imaging modality studies. Most reflect right ventricular 
function, such as right atrial pressure and cardiac index from haemodynamic 
studies (142, 269), or Tei index and tricuspid annular plane systolic excursion 
(TAPSE) from echocardiographic studies (270-272). Traditional prognostic 
measures for evaluating both severity of disease and treatment response however 
have a number of limitations reflecting the complexity of the geometry of the RV 
with the use of non-invasive tools.  
1.2.5.1 Echocardiography 
Echocardiography, being cheap, portable and widely available is readily employed 
to assess RV function and its use as a prognostic tool in PH has been extensively 
studied. There are however a number of important limitations. The complex 
anatomy of the RV means that accurate measurement of size and volume using 2D 
imaging modality is difficult, and measurements that rely on geometric 
assumptions can be complicated to adopt for RV evaluation by echo. The 
technique is highly operator dependent and hampered by poor acoustic windows 
due to body habitus or in some clinical conditions such as emphysema. 
Inaccuracies and variability may arise from other factors such as patient or probe 
position, image quality or phase of respiration. There is a lack of standardised 
models for calculation of RV volumes and function. Additional, when using echo 
as a monitoring tool, as progressive RV dilatation occurs changes in heart position 
and orientation can be seen that could influence serial measurements (273). 
The most reported prognostic echo parameter of RV function associated with 
mortality is the presence of pericardial effusion. Increased right atrial pressure 
impairs venous and lymphatic drainage of the myocardial and presence of 
pericardial effusion is therefore a reflection of RV dysfunction. Pericardial 
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effusion has been reported in 54% of severe IPAH cases, with larger effusion 
associated with RHF, impaired exercise tolerance and poor 1 year survival (274). 
In prospective study, presence of pericardial effusion was the strongest predictor 
of mortality (270) which has been confirmed by recent data from the REVEAL 
registry (144). However, the studies give no diagnostic criteria and therefore what 
size of pericardial effusion should be considered significant needs further study. 
TAPSE is a measure of the longitudinal movement of the lateral tricuspid annulus 
towards the RV apex and is used to reflect RV systolic function. In the normal RV, 
longitudinal shortening accounts for the greater proportion of RV volume change 
during ejection. TAPSE has been shown to correlate with RVEF (275). In PAH TAPSE 
<1.8cm shown to be associated with RV dysfunction and reduced survival (272). 
TAPSE is influenced by coexistent LV dysfunction (276) and its relationship to RV 
function is less accurate in those with significant tricuspid regurgitation (277). 
The myocardial performance or Tei index is an echocardiography derived measure 
of global RV function (271). It has been shown to have prognostic significance in 
PAH (278), however is influenced by volume loading of the patient, is less reliable 
during tachycardia and interpretation is highly operator dependent. Other echo 
parameters known to have prognostic significance in PH include greater RV 
diameter (279), eccentricity index (270) and right ventricular dysynchrony (280). 
Some RCTs of PH targeted therapies have reported changes in echocardiography 
derived indices in small subsets of patients. Chronic epoprostenol therapy 
improved RV end diastolic area, left ventricular eccentricity index and maximum 
tricuspid regurgitant velocity (281). Bosentan improved ratio of RV to LV end-
diastolic area, left ventricular eccentricity index, Tei index, RV ejection time, SV 
and severity of pericardial effusion in 56 PAH patients after 16 weeks of therapy 
(282). 
1.2.5.2 Right heart Catheterisation 
As previously discussed in section 1.2.2.2 RHC is the gold standard for diagnosis of 
PH. Haemodynamic studies have identified RAP, SVO2, CO and CI, all indices 
reflecting RV function, to be significant predictors of survival (142, 144, 269, 283). 
In addition, mPAP at diagnosis was predictive of survival in the IPAH cohort from 
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the NIH registry in patients before the availability of PAH specific therapies. 
However, as mPAP is a product of both PVR and RV function, rise in mPAP is 
subsequently followed by fall in late disease as the RV fails, and therefore 
relationship between mPAP and survival is lost. It has been demonstrated that RV 
power is distributed approximately 77% for steady state resistance (PVR) and 23% 
pulsatile component (compliance SV/PP) (284). It is known that resistance and 
compliance are inversely related to each other in the pulmonary circulation, and 
therefore in early disease large decreases in compliance are seen for small 
increases in PVR. It is not therefore surprising that measurements of compliance 
at RHC, SV/PP, in patients with IPAH is an independent predictor of mortality 
(285). 
Current management guidelines recommend repeat haemodynamic measurements 
at 3-4 months following addition of new PAH therapy, or at times of clinical 
worsening. Improved survival has been reported in patients with fall in total 
pulmonary vascular resistance of at least 30% (286), or improved CI and mPAP 
(287). However, recent study has shown continued progression in RV failure and 
worse survival in this subset despite improvement in PVR at RHC (288). 
Additionally, RHC is invasive and needs to be performed in centres with 
appropriate expertise. RHC is associated with small risk of morbidity such as 
pneumothorax or cardiac arrhythmia and mortality. A multicentre review of over 
7000 RHC procedures carried out in experienced PH centres reported serious 
adverse events in 1.1%, and mortality rate of 0.055% (289). It is therefore not 
practical or acceptable to patients as a methodology for regular monitoring of 
disease progression and therapeutic response. Research therefore is driven by the 
need for simple, reproducible noninvasive measures of RV function to improve 
management of patients with PAH and explore optimal therapeutic approach to 
treat both the pulmonary circulation and RV as a unit. 
1.2.5.3 Six minute walk test 
Exercise testing in the form of either a walking test or cardiopulmonary exercise 
test in addition to assessing the patient’s functional capacity can provide a 
measure of RV function due to the relationship between cardiac output, oxygen 
delivery and consumption. The 6MWT is commonly employed as it is easy to 
perform, is the commonly accepted end point for studies evaluating treatment 
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effect in PAH, and has been shown to correlate to peak oxygen pulse (which in 
itself correlates to SV), CO, total pulmonary resistance and to fall in proportion 
to worsening FC (290). Absolute 6MWD has been demonstrated to be a strong 
prognostic variable both at diagnosis and whilst on therapy. At baseline, 6MWD 
less than 332m, or <250m with associated drop in oxygen saturations of >10% have 
been shown to predict poor survival (286, 290). Improvement in absolute 6MWD to 
>380m after 3 months of therapy has been shown to confer improved survival. 
However, change in 6MWD does not seem to predict survival benefit, and what 
constitutes a relevant change in order to confer survival advantage is unknown. A 
pooled analysis of 10 placebo controlled drug trials in PAH found that ∆6MWD 
accounted for only 22.1% of the treatment effect and may therefore not be a 
sufficient surrogate end point (291). An average ∆6MWD of 22.4m favouring active 
treatment over placebo was seen across the studies, with a calculated minimum 
of 41.8m corresponding to a significant reduction in clinical events. These studies 
however are confounded by select population for trial entry including a threshold 
minimum distance walked. 
Additionally, 6MWD is influenced by a number of confounders including patient 
motivation, age, weight and comorbidity such as musculoskeletal disease. Recent 
study looking at utility of exercise variables including 6MWT to predict outcome 
in IPAH versus associated PAH found no variable independently predicted survival 
or time to worsening in the associated PAH group, whilst distance walked was of 
significance in those with IPAH (292). Expressing 6MWD as a percent of predicted 
which would take into account confounders such as age and sex confers no 
advantage over absolute distance walked in relation to outcome and therefore 
raises concerns over the reliability of the test as an outcome measure (293). In 
those with IPAH, exercise and respiratory training resulted in mean increase of 
111m in 6MWD compared with controls without any measurable effect on RV 
function (294). Additionally, a ceiling effect may occur whereby in those with 
increasing baseline walk distance treatments that improve haemodynamics and 
symptoms may not translate into further additional significant increment in 
distance walked. This has been demonstrated suggesting reduced sensitivity of the 
6MWD in those PAH patients walking >450m (295). Current guidelines recommend 
treatment goal of achieving 6MWD above 500m, however in practice few patients 
89 
 
will achieve this and better indirect measures of RV function for monitoring 
therapeutic response are needed. 
1.2.5.4 NTproBNP 
BNP is secreted by ventricular cardiomyocytes in response to increased stretch as 
a result of an increase in cardiac wall stress and play important roles in regulation 
of blood pressure, volume and sodium homeostasis. The BNP precursor is split into 
biologically active peptide and the more stable N terminal fragment NTproBNP 
(296). Levels of NTproBNP (and BNP) have been shown to reflect severity of RV 
dysfunction with inverse correlations demonstrated with RVEF and cardiac output, 
and correlates with haemodynamics measurements of mPAP, RAP and total 
pulmonary vascular resistance in PAH (297, 298). Changes in levels have been 
shown to parallel haemodynamics and functional status of PAH patients during 
treatment, and relative change in NTproBNP reflects changes in CMR indices of RV 
structure and systolic function. High NTproBNP levels or in particular increasing 
levels during follow up have been shown to be independent predictors of mortality 
(299-301). There are however no validated cut off levels of NTproBNP and its value 
lies in a change in level on an individual patient basis as an indication of a decline 
in RV function but not the extent of deterioration. 
1.3 Cardiac MRI in pulmonary Hypertension 
CMR offers the opportunity of a more comprehensive approach to the non invasive 
assessment of patents with PH, simultaneously evaluating RV status, vascular 
stiffness, pulmonary blood flow and potentially coupling of the RV-PA circuit. 
Quantification of RV volumes or ejection fraction reflects cardiovascular 
adaptation to chronic pressure overload, however investigation of the RV-PA 
circuit as a whole and coupling of RV contractility to arterial load may provide 
insights into the discrepancy seen in progression of RV dysfunction despite 
improvements in PVR with PH therapies. The high accuracy and interstudy 
reproducibility of CMR derived indices of ventricular structure and function have 
demonstrated superiority over 2D echo, although the interstudy reproducibility of 
RV parameters is lower than that of the LV due to the heavy trabeculation seen 
(64). CMR is therefore ideally suited to non invasive serial monitoring of PAH 
patients in assessing treatment response.  
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1.3.1 Ventricular mass, volume and function 
A number of studies in PAH have demonstrated significantly raised RV end diastolic 
(RVEDV) and end systolic (RVESV) volumes, with impaired systolic function 
determined by reduced RVEF, CO and SV in comparison to normal subjects (58, 
302, 303). Figure 1.1 shows transverse and sagittal MRI images of the RV in a 
normal subject in comparison to a patient with IPAH.  
Increasing RVM has been shown to correlate with mPAP (r=0.75) in IPAH (57). RV 
hypertrophy as previously discussed is an adaptive response to the increased 
afterload in PH. It is perhaps not surprisingly that RVM is not a strong predictor of 
mortality however, as RV failure in late disease is more characterised by 
progressive RV dilatation with reduced contractility. Reduced LVEDV and LV peak 
filling rate but similar LVM have been demonstrated by CMR in patients with PH in 
comparison to healthy controls (304). Using tagged MRI, a non invasive technique 
for interrogating 3D motion and deformation of myocardium, demonstrated 
interventricular asynchrony with prolonged RV contraction in comparison to LV 
(261). This asynchrony led to decreased LV diastolic filling, septal bowing and 
reduced LVEDV. A low baseline SV, RV dilatation (increased RVEDVI) and impaired 
LV filling (reduced LVEDVI) measured by CMR independently predicted mortality 
in 64 patients followed up for 32 months (41). RVM did not have a significant 
relationship to mortality. Mauritz et al demonstrated that progressive RV 
functional decline is characterised by both reduction in longitudinal and 
transverse shortening until a plateau is seen in longitudinal shortening (305). 
Further progressive decline in RV function characterised by reduced transverse 
shortening related to increased LVSB was seen in subsequent nonsurvivors at 4 
years. Transverse shortening is therefore a CMR index that can be used to monitor 
RV functional decline in end stage PAH, which is not assessed by TAPSE at 
echocardiogram.  
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Figure 1.8 Cardiac MRI images of a normal subject in comparison to patient with pulmonary 
arterial hypertension.  
 
Panels A and C display transverse and short axis views in a normal subject whilst panels B and D 
show IPAH patient. In Panel B, gross enlargement of right atrium (RA) and ventricle (RV) is seen, 
with compression of left sided chambers (LA, LV). In Panel D, note enlarged RV (a), small underfilled 
D shaped LV (b), septal bowing (c) and pericardial effusion (d). 
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1.3.2 Pulmonary blood flow and vascular stiffness 
As previously discussed in section 1.1.3, phase contrast velocity mapping is a MRI 
sequence that allows measurement of velocity and flow, or interrogation of flow 
profiles, across valves or within blood vessels. It has advantages over 
thermodilution measures of SV or CO as it is both noninvasive, and, as it is 
averaged over a number of cardiac cycles, also less influenced by changes in SV 
between cardiac cycles and when measured at level of aorta or pulmonary artery, 
not affected by TR. Volumetric RVSV tends to overestimate actual SV in presence 
of considerable TR which can occur in PH patients with RV failure as it is impossible 
to determine what proportion of flow moves back through the tricuspid valve in 
preference to ventricular ejection. In PH however, aortic blood flow or LVSV has 
been shown to more accurately reflect actual SV measured at RHC (306). Phase 
contrast MR flow is known to be less accurate in presence of turbulent blood flow 
which occurs in pulmonary artery in PH patients. Figure 1.2 shows cross section 
view through the main pulmonary artery in a patient with IPAH with demonstrable 
turbulent PA flow. For SV determined by PA flow versus invasive SV determined 
by Fick principle, correlation co-efficients were r=0.71 (mean difference -4.2ml, 
limits of agreement 26.8 and -18.3ml) and for RVSV r=0.73, in comparison to SV 
by LV volumes vs Fick, r=0.95 (mean -0.8ml, limits of agreement 8.7 and -10.4ml). 
In the absence of intracardiac shunt, aortic flow or LV volumes is therefore the 
preferred method for assessing stroke volume in PAH. 
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Figure 1.9 Cross sectional image of dilated pulmonary artery in patient with IPAH.  
 
Turbulent blood flow clearly seen in enlarged main pulmonary artery (MPA) in comparison to aorta 
(Ao). 
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CMR has shown reduced peak systolic velocity and greater retrograde flow in 
pulmonary arteries of PAH patients. Retrograde flow was proportional to 
resistance and inversely to flow volume (307). PA flow, peak velocity and 
distensibility were significantly lower in 25 PAH patients in comparison to matched 
controls (308). Strong correlations between average velocity of pulmonary blood 
flow and mPAP and PVRI have been demonstrated (r= -0.86), suggesting a possible 
role in non invasive diagnosis of PAH (309).  
As previously discussed, it has been shown that an inverse curvilinear relationship 
exists between compliance and mPAP, so large changes in compliance occur at 
small increases of mPAP in early PAH. At a level of a mPAP of 40mmHg little 
further decrease in compliance occurs, i.e. vessels become stiff and indistensible 
(310). Increased stiffness (reduced compliance) causes higher RV pulsatile 
workload, decreased contractile performance and enhanced energy transmission 
to smaller vessels increasing vascular damage. Invasive haemodynamic studies in 
patients with PAH have shown that those with lower SV/PP of <0.81 ml/mmHg, 
had a less than 40% 4 year survival compared with 100% 4 year survival in those 
with value above 2 (285). CMR derived relative area change (RAC) of the proximal 
pulmonary artery can be used to approximate compliance of the proximal 
pulmonary circulation. Vessel wall stiffness can be approximated by  
                            Ln (sPAP/dPAP)/(Δ 2A/A)  
where sPAP/dPAP is the pulmonary artery pulse pressure, and A is the area of the 
vessel (311).  
It has been shown that in pulmonary hypertension, sPAP/dPAP is a linear 
relationship through a wide range of PA pressures, implying ratio is constant (11). 
Therefore, ΔA/A (RAC) is inversely proportional to stiffness (and a measure of 
compliance of PA circulation).  
RAC (by CMR) = (max PA area – min PA area)/min PA area *100% (312, 313) 
Gan et al reported a decrease in RAC (20% vs. 58% in controls) in 70 patients with 
PAH, and the same inverse curvilinear relationship between RAC and mPAP was 
demonstrated (314). Both reduced RAC and SV/PP were predictive of increased 
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mortality. RAC has also been demonstrated to correlate with 6MWD (r2 = 0.61) and 
RAC <20% predicted poor functional status (defined as 6MWT <400m) with 
sensitivity and specificity of 82% and 94% respectively (315). Reduction in RAC has 
been proposed as a marker for early pulmonary vascular disease in a recent study 
by Sanz et al (310). 75 patients with PH were compared to 13 patients without 
resting PH but exercise induced rise in PA pressure (EIPH), and 13 normals. In EIPH, 
despite normal PA size, reduced compliance and capacitance was observed. A RAC 
of <40% had a sensitivity of 93% and specificity of 63% for presence of PH.  
Whilst there is evidence that treatment causes a reduction in PVR, it is unknown 
how disease targeted therapies affect compliance and whether this is a useful 
measure of treatment efficacy. Furthermore, in hypoxic lung disease associated 
with pulmonary hypertension, whilst evidence is growing on cardiovascular risk 
and increased peripheral arterial stiffness in COPD (316), whether the use of RAC 
and measures of compliance in this population is of clinical benefit. 
1.3.3 Diagnosing pulmonary hypertension 
At present the utility of CMR in the diagnosis of PH is lacking, with somewhat 
contradictory studies. Correlations between mPAP or sPAP and CMR derived RVM, 
pulmonary blood flow average velocity and septal curvature have been reported 
(317). One study in 26 PAH patients found superiority of calculated ventricular 
mass index, (VMI - ratio of RVM to LVM), over echocardiography estimated mPAP 
(318). Correlations between VMI and mPAP were stronger with narrower CI than 
for echo. Sensitivity and specificity of VMI using >0.6 as a diagnostic threshold 
were 84% and 71% in comparison to 89% and 57% for echo. Laffon et al applied a 
computerised algorithm to estimate mPAP in 31 patients based on MRI indices 
including blood flow velocity and PA cross-sectional area with patient 
characteristic such as height and found strong correlation with RHC values (r=0.92) 
(319). In contrast, poor correlation between mPAP and 5 MRI indices including 
pulmonary artery acceleration time and the Laffon algorithm was shown in a study 
of 44 PAH patients (320). Significant, if weaker, correlation was still seen for VMI 
(r=0.56) but using the previous threshold of VMI >0.6 resulted in missed diagnosis 
in 9 of the 44, and false negative rate of 20%. 
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1.3.4 Monitoring treatment response 
There are few completed studies of PAH therapies that have used CMR indices as 
endpoints despite clear evidence that RV function rather than degree of PAP 
strongly predicts survival. Reverse remodelling and improvements in RV function 
and pulmonary flow has been demonstrated in CMR studies following lung 
transplantation (321, 322) and endarterectomy for treatment of CTEPH (323). 
Substudies of pharmacological RCTs or small, single centre studies in PAH have 
reported on associated changes in CMR indices. In a small study of 5 patients, 3 
months of Sildenafil decreased RVM, improved RVSV and reversed IVS shift (324). 
In another blinded RCT, sildenafil but not Bosentan lead to a reduction in RVM 
despite similar decreases in PAP, suggestion the possibility of a direct effect on 
the RV by Sildenafil (325). Two studies using the ETRAs Bosentan and Ambrisentan 
in PAH found no improvement in RV ejection fraction, or volumes at 12 months 
(326, 327). CMR was used to assess response to Epoprostenol in 11 IPAH patients 
treated for 1 year. RVSV increased from 34±11 ml to 41±11 ml, p<0.05 with no 
change in RV mass or volumes (302). Change in RVSV related to improvement in 
6MWT suggesting this resulted in functional improvement, a correlation which has 
not been demonstrated with invasive haemodynamic parameters. In 18 systemic 
sclerosis patients treated with Bosentan, CMR has been utilised to demonstrate 
improvement in myocardial perfusion, although these patients did not have PH 
(328). Finally, Van Wolferen et al demonstrated the addition of Sildenafil to 
Bosentan therapy resulted in significant increase in RVEF and CI in comparison to 
baseline in 15 PAH patients (329). 
Increasing RVEDVI or a further decrease in SV or LVEDV at 1 year of follow-up were 
the strongest predictors of mortality and treatment failure in longitudinal CMR 
study in 54 patients with IPAH (41). Significant increases in RVEF, SVI, CI and 
LVEDVI and improvement in RVEDVI were demonstrated at 1 year. Change in RVM 
has not been shown to have prognostic significance, presumably as a result of the 
ambiguous nature of an increase in mass, which could arise as both a consequence 
of concentric hypertrophy representing successful adaptation to afterload or 
eccentric hypertrophy that occurs with RV failure and dilatation. In comparison 
with follow up haemodynamic data at right heart catheterisation, recent study 
has shown that despite haemodynamic improvements with treatment in PVR and 
CI, and stability of 6MWD at 1 year, progressive right ventricular dysfunction was 
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demonstrated by CMR, and the deterioration of RV function was associated with 
poorer outcome regardless of the change in PVR (288). Change in RVEF was 
associated with survival, but change in PVR was not. Therefore it would seem 
reasonable to propose that CMR is a better tool for follow up and monitoring of 
patients with PAH. 
Van wolferen et al have determined by correlation of SV with 6MWD during therapy 
that a > 10ml change in stroke volume is of clinical relevance in PAH (330). This 
could be potential endpoint for future studies in PAH. 
1.4 Thesis outline 
It is apparent that although PAH specific therapy improves PVR, this does not 
necessarily translate into improvements in functional status and mortality unless 
accompanied by a parallel improvement in RV function. In a recent meta analysis 
of studies undertaken to evaluate PAH therapies, treatment was associated with 
a reduction in PVR mediated by reduction in mPAP and increase in SV, but without 
improved contractility, suggesting current therapies have vasodilating effects with 
limited cardiac specific effect (331). Studies have demonstrated that despite a 
reduction in PVR with therapy, progressive RV dysfunction continues. Reduction 
in PVR as a result of PAH therapy in severe PH leads to an increase in CO without 
appreciable change in mPAP and therefore unchanged RV power output which 
perhaps explains this continued spiral of deterioration. This highlights the need to 
evaluate the RV-PA circuit as a whole and CMR offers the unique opportunity to 
study this. RV systolic function traditionally has been evaluated by RVEF, however 
this is preload dependent and gold standard evaluation of RV contractility from 
derived PV loops is invasive, time consuming and not suitable to serial monitoring 
of patients. SV/ESV is a volumetric measure of RV coupling that can be easily 
determined by CMR and is a less preload dependent measure of RV systolic 
function. It is unknown whether this has superior prognostic significance in PAH 
over traditional methods of assessing RV function, and how PH specific therapies 
alter it.  
Whilst response to PH specific therapy in PAH and relationship to prognosis has 
been extensively studied by both functional and biomarker outcomes in addition 
to CMR indices of RV function, there is limited data on treatment of severe PH 
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associated with lung disease where the pathophysiology, whilst sharing some 
common mechanisms described earlier in this chapter, is different. The prognostic 
significance of CMR indices of pulmonary vascular stiffness, RV function and 
coupling to the pulmonary circulation in the latter and its comparison to those 
with PH “in proportion” to lung disease may provide mechanistic insights as to 
why a small subgroup develop severe PH and whether they would benefit from PH 
therapies. 
The aim of this thesis was the explore the utility of CMR to interrogate RV function, 
vascular stiffness and RV-arterial coupling by SV/ESV in patients with PAH and 
contrast this to patients with PH associated with lung disease in whom the 
pathophysiology is different. The thesis is therefore divided into three separate 
but complementary studies described in chapters 3, 4 and 5. 
In chapter 3, I aim to describe the right ventricular characteristics of patients with 
severe PH associated with lung disease in comparison to IPAH (where utility of 
common metrics of RV dysfunction is already established) and PH “in proportion” 
to lung disease, and how CMR may be employed to detect PH, determine prognosis 
and response to PH therapies. 
In chapter 4 I aim to compare invasive and CMR estimates of RV-arterial coupling 
in PAH in comparison to normal subjects and PH associated with lung disease. In 
addition, to determine if CMR estimates of RV-arterial coupling is a superior 
prognostic variable in comparison to commonly implemented metrics of RV 
function in PAH such as RV ejection fraction. 
Finally, in chapter 5 I aim to assess the impact of PAH therapies on RV-arterial 
coupling assessed by CMR, in comparison to other indices of RV function and 
clinical endpoints (such as 6MWD or NTproBNP) and relate this change to survival, 
to determine the optimal method for monitoring the right ventricle in patients 
undergoing PAH therapy. 
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Chapter 2 - Materials and Methods 
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2.1 Patient recruitment 
The patients involved in the studies for this thesis were retrospectively identified 
and included following inpatient diagnostic assessment for the evaluation of 
clinically suspected PH between January 2000 and March 2014 at the Scottish 
Pulmonary Vascular Unit, Glasgow. In total, 325 patients were included across the 
3 studies, 206 underwent CMR and RV pressures traces were available for analysis 
in 125. A flow chart describing patients included in the studies is shown in figure 
2.1. Inclusion criteria thus compromised a diagnosis of PH of either group 1 or 3 
disease after diagnostic assessment according to ESC guidelines. All were incident 
cases and treatment naive. A control group without PH (defined as mPAP 
<25mmHg) whom had undergone diagnostic assessment due to the suspicion of PH 
were also included. Additional specific exclusion criteria were applied for each 
study. These will be discussed in the relevant chapter and a demographic 
description of each study population will be shown. For all studies identical CMR 
exclusion criteria applied. These include ferrous implant such as cardiac 
pacemaker, pregnancy, claustrophobia or tolerability relating to breathlessness. 
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Figure 2.1 Flow chart describing study population for each chapter. 
 
Patients included in Chapter 3 indicated by blue, Chapter 4 in green and Chapter 5 in red. Specific 
inclusion and exclusion criteria will be discussed in methods of each chapter. 
In Chapter 3 clinical characteristics, survival and treatment outcomes of 81 IPAH patients will be 
compared to 124 severe PH/lung disease patients. RV characteristics of 30 mild/mod PH and 12 no 
PH lung disease patients included for comparison. 
In Chapter 4, RV-arterial coupling values will be estimated by invasive pressure and non invasive 
volume methods for 30 IPAH patients, 31 APAH, 42 hypoxic lung disease PH (30 with severe PH) 
and 22 subjects without PH (8 with lung disease).  
In Chapter 5, 52 PAH patients with serial CMR included to examine change in RV function and RV-
arterial coupling with PH therapy. 
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2.1.1 Diagnostic assessment 
During 4 day admission all patients underwent a series of investigations following 
standard diagnostic algorithm for PH (332). These included blood investigations, 
including HIV serology, thyroid function, connective tissue serology and NTproBNP, 
lung function and 6MWT, transthoracic echocardiogram, arterial blood gases and 
CT imaging of thorax. CMR and right heart catheterisation were carried out within 
72 hours. 
Right heart catheterisation was performed using a 7F triple-channel 
thermodilution Swan Ganz catheter (Baxter Healthcare, Irvine, California, USA). 
All measurements were recorded with the patient in a supine position, at rest, 
breathing room air or with supplementary oxygen to obtain peripheral saturations 
above 90%. Measurements carried out included mean right atrial pressure (RAP), 
right ventricular pressure and systolic, mean and diastolic pulmonary artery 
pressures (PAP) and pulmonary artery wedge pressure. Cardiac output (CO) was 
determined by thermodilution, allowing the determination of pulmonary vascular 
resistance (PVR) by the following: (mPAP – PAWP)/CO. Cardiac index was 
determined as CO/body surface area and compliance as SV/ (sPAP-dPAP). Mixed 
venous oxygen saturations were determined from a sample drawn from the 
pulmonary outflow tract. 
2.2 Cardiovascular Magnetic Resonance imaging 
CMR was performed as part of patient’s routine diagnostic assessment. Follow up 
scans were performed as part of two longitudinal studies approved by the West 
Glasgow Hospitals University NHS Trust (as part of EURO-MR project) and West of 
Scotland REC 4 ethics committee, to which patients gave written consent. All 
scans were performed on a 1.5 T MRI scanner (Sonata Magnetum, Siemens, 
Germany) using a previously described protocol (304). Fast cine imaging with SSFP 
sequences (TrueFISP Siemens) was used for functional imaging. Initial scout 
images (shown in Figure 2.2) were obtained to localise the heart within the thorax 
and plan subsequent cine images. All cines were acquired during a breath hold 
typically lasting 5-8s. Total scan time was approximately 40-50 minutes. 
  
Figure 2.2. Initial localiser images in the planning of stack of short axis cines. 
 
The white lines indicate the projection lines to plan the next step in localising. [a] Sagittal view of RV outflow tract. Planning for cross section of PA shown. [b] Coronal 
view, [c] transverse view, [d] vertical long axis view, and [e] short axis view. The line on the coronal view defines the transverse view, and similarly progression to next 
views are displayed. 
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Horizontal long axis (HLA) cines were then planned and acquired using these scout 
images. A series of short axis “stack” of images was then obtained from the HLA 
view from the base of the atrioventricular valve to the cardiac apex covering both 
ventricles with 8-mm SA imaging slices, separated by a 2-mm inter-slice gap as 
shown in Figure 2.3. Imaging parameters were standardised for all subjects, 
TR/TE/flip angle/voxel size/FOV = 3.14ms/1.6ms/60⁰/2.2 x 1.3 x 8.0 mm/340mm. 
 
 
 
 
 
Figure 2.3. Horizontal long axis view (HLA) acquired in a patient with PH 
 
Note the dilated RA and RV with regurgitant flow visible in the RA. The solid white line denotes the 
planned first short axis image intersecting base of the atrioventricular valve. Subsequent dashed 
white lines indicate the propagation of the SA imaging plane towards the apex at 2mm intervals to 
create a stack of images through both ventricles. 
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2.2.1 Volumes and mass 
All CMR images were analysed using Argus analysis software (Siemens, Germany). 
Right and left ventricular volumes and mass were determined by manual 
delineation of endocardial and epicardial borders of end diastolic and end systolic 
images at each slice position on the short axis cines. This method of manual 
planimetry has been well described previously and is regarded as standard method 
for analysis of ventricular volumes and mass. An example of an analysed series of 
images is shown in figure 2.4. By multiplying the individual slice areas by slice 
thickness (8 mm) plus the inter-slice gap (2mm) and applying Simpson’s rule, the 
software calculates ventricular end diastolic and end systolic volumes (RVEDV, 
RVESV, LVEDV and LVESV). Stroke volumes (RVSV & LVSV) are also calculated by 
EDV-ESV. Right and left ventricular mass (RVM and LVM) were determined as the 
product of myocardial volume for each ventricle and the quoted density of cardiac 
muscle (1.05 g/cm3). RV mass was determined as RV free wall mass, while the 
Interventricular Septum (IVS) considered part of the LV in accordance with 
accepted practice (47). For the purpose of this analysis, trabeculations were 
considered part of ventricular volume. All indices of mass and volume were 
indexed to the patients’ body surface area (BSA) and when considered for survival 
analysis adjusted for patient age. 
Imaging was reviewed during acquisition for artefacts described in Section 1.1.3.3 
and adjustments made where possible to rectify, such as patient coaching for 
breath-holding or end inspiratory breath-holds in presence of motion artefact, 
arrhythmia rejection software in presence of image blurring due to arrhythmia, 
alteration of FOV if wrap artefact interfered with region of interest or alteration 
of VENC settings in phase velocity map sequences if aliasing noted. Scans were 
abandoned if patients were unable to breath-hold or in presence of significant 
arrhythmia, or converted to real-time acquisition if CMR imaging was of clinical 
benefit. At time of functional analysis, scans were excluded if real-time sequences 
were used, or if image quality was poor with blurring of myocardial borders.  
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Figure 2.4. An example of planimetry analysis of right and left ventricular volumes and mass 
in a PH patient. 
 
Note the dilated thin walled RV in comparison to the LV. Each row of short axis images represents a 
loop of cine images acquired during one cardiac cycle at consecutive slice positions, beginning at 
the base of the heart, moving apically to cover both ventricles. The first images within each row (or 
slice position) are the end-diastolic images (indicated by the yellow ED at the top of the left-hand 
column) [A] shows one enlarged end diastolic image with endocardial borders delineated in red and 
epicardial in green. [B] indicates the end systolic image at the same slice position with endocardial 
borders shown.  
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2.2.2 Function 
Ejection fraction (RVEF and LVEF) was determined as a percentage (%) using this 
planimetry derived stroke volume measurement. RVEF = RVSV/RVEDV x100 and 
LVEF as LVSV/LVEDV x100. 
2.2.3 Flow mapping 
As described in section 1.1.3.2.2, two Image acquisitions was prescribed 
perpendicular to flow direction through the great vessels (MPA and aorta) with 
image plane just distal to valve leaflet tips. Direction of flow was set (R-L, F-H) 
to determine forward velocity from ejecting heart. Appropriate VENC was set, 
typically 100 - 120 cm/s for MPA and ~150cm/s Aorta with adjustment for 
aliasing/valvular pathology. Image acquisition performed during free breathing. A 
region of interest (ROI) was drawn around the interior surface of the target vessel, 
either cross section of aorta or pulmonary artery, on the first anatomical image. 
This ROI was propagated throughout the anatomical images using a semi-
automatic function within the Argus software. These were then checked visually 
and modified within Argus to approximate the interior surface of the target vessel 
throughout the cardiac cycle. These modifications were then copied onto the 
corresponding velocity images. A second, reference, ROI was then drawn within 
the soft tissue of the chest wall as close as possible to the target vessel and 
propagated throughout the cycle. This was applied for phase correction, to correct 
for background movement of the thoracic contents through the imaging plane 
during respiration. An example of flow map analysis is shown in figure 2.5. 
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Figure 2.5. Magnetic resonance phase contrast flow quantification. 
 
[A] Anatomy image of main pulmonary artery with ROI drawn around the interior surface of the 
vessel. [B] corresponding velocity encoded image. Pulmonary flow images denoted in red and 
aortic in green. 
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 Six SV results were therefore obtained by CMR for each patient, RVSV and LVSV 
from planimetry, and Aortic SV (AoSV) and pulmonary artery SV (PaSV) both with 
and without phase correction. It has previously been shown that in PH, LVSV and 
AoSV (the latter with phase correction) is a more accurate reflection of invasively 
determined SV at RHC than right sided SV (306). This relates to difficulties in 
delineation of endocardial contours in the heavily trabeculated RV, and turbulent 
flow observed in the PA of PAH patients with reverse flow occurring during RV 
ejection. An initial analysis was performed correlating the 6 SV determined by 
CMR with invasive thermodilution determined SV in 134 patients. In our centre 
thermodilution CO is employed whereas most regard Fick method as the gold 
standard invasive measure of CO. This however requires simultaneous arterial 
sampling of Pa02 with an arterial line. The correlations shown here are therefore 
with thermodilution CO, whilst previous published data by Mauritz et al employed 
Fick CO. The use of phase correction resulted in poorer correlations, presumably 
as this is not a true phantom (i.e. motionless) as used in CMR theory where 
stationary objects were used for phase correction. AoSV and LVSV demonstrated 
superiority over RVSV and PaSV. Correlations are shown in figures 2.6 – 2.8. AoSVI 
therefore will be quoted throughout (without phase correction) for SVI. RVEF 
however is generated by the use of RVSV and in order to directly compare the 
superiority of SV/ESV as a measure of systolic function in PH, RVSV will be applied 
in this calculation. 
CMR derived measures of vascular stiffness was determined by the relative area 
change (RAC) of the cross sectional area of both the PA and proximal Aorta. RAC 
was calculated as the difference between maximum and minimum vessel area / 
minimum area and multiplied by 100% (312, 313). 
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Figure 2.6 Correlation of invasive measured stroke volume with cardiac MRI values 
determined by ventricular planimetry. 
 
Stroke volumes determine by left and right ventricular planimetry (LVSVI and RVSVI). Panels a & c 
display correlations between CMR measured and invasive stroke volume index and Panels b & d 
Bland-Altman analysis of difference versus mean (limits of agreement indicated by dashed line and 
mean difference by solid line). Correlation of LVSVI with invasive SVI was superior to RVSVI, r2 = 
0.51, p<0.0001 and r2 = 0.15, p = 0.004 respectively. 
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Figure 2.7 Correlation on invasive Stroke volume with CMR stroke volume determined by 
Aortic flow mapping 
 
Stroke volume determined by flow mapping of the proximal aorta (AoSVI) without (panel a) and with 
(panel c) phase correction shown. Panels b & d Bland-Altman analysis of difference versus mean 
(limits of agreement indicated by dashed line and mean difference by solid line). 
Correlation with invasive SVI for AoSVI without and with phase correction was r2 = 0.71 and r2 = 0.61 
respectively, both p<0.0001. Closest agreement between AoSVI without phase correction and 
invasive SVI was determined. 
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Figure 2.8 Correlation of invasive stroke volume with CMR stroke volume determined by 
Pulmonary artery flow mapping. 
 
Stroke volume determined by flow mapping of the main pulmonary artery (PaSVI) without (panel a) 
and with (panel c) phase correction shown. Panels b & d Bland-Altman analysis of difference 
versus mean (limits of agreement indicated by dashed line and mean difference by solid line). 
Correlation of both methods with invasive SVI similar, r2 = 0.57 and r2= 0.54 without and with phase 
correction respectively, both p<0.0001.
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2.3 Statistical Analysis 
Statistical analysis was performed using SPSS 21 (SPSS Inc, Chicago, IL) and 
Graphpad Prism Version 5.00 (Graphpad Software, California, USA). Continuous 
variables were tested for normality using D’Agostino and Pearson omnibus 
normality test. Normally distributed variables are shown as mean ± standard 
deviation and non-normally distributed variables as median (IQR). Categorical 
variables are described by percentages (number) unless otherwise stated. 
Comparison of characteristics was made using unpaired t-test or Mann-Whitney U 
test depending on data distribution. Comparison of several groups was performed 
using ANOVA or Kruskal-Wallis test with post hoc analysis using Tukey’s or Dunn’s 
multiple comparison test. Comparison between baseline and follow up 
investigations was made by paired t-test or Wilcoxon signed rank test. Comparison 
between categorical variables was made using X2. 
Survival was from date of diagnostic right heart catheter and endpoint as either 
date of death, lung transplantation or censoring. Patients were censored if they 
were lost to follow up or alive at last day of study (05/08/2014). All cause 
mortality was used for survival analysis. Survival predictors were determined using 
Cox proportional hazards regression analysis. Variables with a p-value ≤0.2 were 
considered for multivariate analysis. Indicator variable coding for missing data was 
used for multivariate analysis. A P value <0.05 was considered statistically 
significant throughout.
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Chapter 3 - Right ventricular dysfunction and 
response to PH specific therapy in severe 
pulmonary hypertension associated with lung 
disease 
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3.1 Introduction 
As discussed in chapter one mild to moderate PH is relatively common in patients 
with hypoxic lung disease although the prevalence varies depending on the 
aetiology and severity of the underlying lung disease (204, 207, 219, 220). 
Hypoxaemia has been shown in clinical studies to be the major determinant in the 
development of PH, with patients with relatively normal Pa02 rarely displaying 
pulmonary hypertension at rest even in the presence of severe ventilatory 
impairment (333, 334). Severe PH, defined by a mPAP ≥ 35mmHg, in contrast is 
rare, occurring in 5 -13% of patients and is characterised by relatively preserved 
lung function, gross hypoxaemia and impaired DLCO, and greater RV dysfunction 
(206, 208). The level of PH has therefore often been described in the literature as 
“disproportionate”. Regardless, the development of PH is associated with poor 
prognosis (208, 223, 335), greater functional limitation with little or no 
therapeutic options. 
In contrast to patients with group I PAH where large increases in PVR and right 
ventricular dysfunction is observed, PH associated with COPD is usually mild to 
moderate and right ventricular function and cardiac output are usually in the 
normal range (243). COPD patients with moderate to severe disease but without 
hypoxaemia have been shown to have preserved RV systolic function at rest. In a 
small study of 25 COPD patients with FEV1 41±15%  but a Pa02 10.9 ±1.3KPa, RVEF 
was 53±12% in comparison to 53±7% in normal controls (336). During acute 
exacerbations with evidence of peripheral oedema, decreased RV contractility has 
been demonstrated but only in these circumstances (337). In contrast, in 158 
patients undergoing lung transplantation evaluation, RV dysfunction was present 
in 59%, and in 120 patients with severe emphysema, mean RVEF was reduced at 
34±8% (204, 205) suggesting a greater degree of RV dysfunction in those with end 
stage disease. In the latter study, mPAP and Pa02 were shown to predict RVEF, but 
only explained 13% of the variance, which is perhaps not surprising as RVEF is 
product of complex interaction between preload, afterload and contractility 
which were not evaluated.  
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3.1.1 Prognosis 
The prognostic implications of the presence of PH highlights the clinical 
importance of detection. However, echocardiography, the accepted screening 
tool for PH in the general population has been shown to be less accurate in those 
with lung disease. The accuracy of echocardiography estimated PAP was compared 
to RHC measurement in 374 patients undergoing evaluation for lung 
transplantation, the majority of whom had COPD (199). PH was present in 25% of 
the population, 18% of those with obstructive lung disease and 59% of those with 
ILD. It was not possible to estimate sPAP by echo in 56% of subjects. In 52% of 
cases estimated sPAP was inaccurate (varied by >10mmHg), 48% were misclassified 
as having PH by echo and 13% were missed. The sensitivity and specificity of 
echocardiography for the presence of PH in this population was therefore 85% and 
55% respectively, demonstrating the need for better non invasive screening tools 
in lung disease patients. 
3.1.2 Therapy 
Long term oxygen therapy (LTOT) has been demonstrated to stabilise or decrease 
mPAP in COPD with mild to moderate PH (256-258). However, in those with severe 
PH results are less encouraging (257, 338). The role of PH specific medication in 
those with severe PH is uncertain. Features such as greater haemodynamic 
compromise and RV dysfunction in this subgroup may suggest a role for PH specific 
therapy. Studies to date have been of small sample size, used echocardiography 
to diagnose PH and included those with both mild and severe or even no PH (339-
342). Acute vasodilator studies in COPD patients have raised the possibility of 
worsening hypoxaemia. Blanco et al administered Sildenafil, a PDE-5i to 20 
patients with severe or very severe COPD, 17 of whom had PH at rest with an 
average mPAP of 27 mmHg (range 21 -61 mmHg) at RHC (343). Whilst a fall in 
mPAP was demonstrated, CO was unchanged and increased hypoxaemia occurred 
from increase in VQ mismatch. Acute inhalation of nebulised iloprost in 16 PH-
COPD patients also demonstrated worsening hypoxaemia, although 6 of the 16 had 
PCWP >15mmHg at rest indicating pulmonary venous disease and potential of 
pulmonary oedema as an explanation for increased hypoxaemia (344). Alp et al 
demonstrated a 42% fall in PVR at 1 hour after IV Sildenafil administrated in 6 
patients with severe COPD and PH, and fall in mPAP from 30mmHg to 22mmHg 
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(p<0.001) (345). These studies suggest that PH even when mild in COPD is 
vasoresponsive, however how these haemodynamic effects translate into 
functional or symptomatic benefit is less clear, particularly given concerns 
regarding possible worsening of VQ mismatch in those already compromised by 
chronic lung disease.  
Several studies in COPD with either only a mild elevation in PAP or without PH 
suggest no role for vasodilator therapy with no change in quality of life scores or 
6MWD and varying effects on haemodynamics and oxygenation. Patients with 
COPD have been shown to have impaired resting stroke volume and blunted SV 
response to exercise, with evidence of RV dysfunction and disproportionate rise 
in PAP on exercise (346, 347). In a small study of 18 patients with COPD, 5 with 
PH at rest and 6 with exercise induced PH, Sildenafil administration resulted in 
attenuation of exercise related increase in PAP (348). Rietema et al showed no 
improvement in SV response after sildenafil administration in 15 COPD patients 
(9/15 had PH, average mPAP 22 mmHg) (340). Bosentan therapy for 3 months led 
to no improvement in 6MWD or sPAP but demonstrated a drop in arterial oxygen 
pressure when given to 20 patients with severe and moderate PH (echocardiogram 
estimated sPAP 32 mmHg) (342). In a larger study of 63 patients with severe COPD 
and modest PH on echocardiogram (sPAP 42 ± 10 mmHg) Sildenafil therapy 
resulted in no additional benefit over pulmonary rehabilitation in incremental 
exercise but no deterioration in oxygenation was seen (349). In contrast, Iloprost 
(an inhaled prostacyclin analogue) therapy given to 10 COPD patients with 
echocardiogram evidence of mild PAP elevation increased 6MWD by an average 
49.8m with no deterioration in VQ mismatch (341). In the study described earlier 
by Alp et al, after 3 months of Sildenafil 6MWD increased (from an average of 351 
to 433m) and mPAP fell (from 30 to 25mmHg) but observations were based on only 
5 patients (345). 
Similar lack of clarity exists in the literature on the role of pulmonary vasodilators 
in interstitial lung disease associated PH. As discussed in section 1.2.3.2 similar 
cytokines are implicated in both the pathogenesis of IPF and pulmonary arterial 
disease and the use of ETRAs in particular would seem intuitive. The BUILD1 
(Bosentan Use In Interstitial Lung Disease) study demonstrated no change in 6MWD 
in comparison to placebo in the 49/74 IPF patients completing 12 months of 
Bosentan, but a trend towards prolongation of time to disease progression or death 
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was perhaps suggested (350).There was no controlling for PH between the placebo 
or therapy groups, and patients with sPAP > 50 mmHg on echocardiogram were 
excluded so it is not possible to apply the findings to an ILD PH population. A 
randomised placebo controlled trial of the ETRA Ambrisentan in nearly 500 IPF 
patients (of which 10% had associated PH) was terminated early as interim analysis 
not only suggested a lack of efficacy, but the possibility of increased risk of disease 
progression and hospitalisation related to respiratory exacerbation in the 
Ambrisentan arm (351).  
In 2014 Corte et al reported on 40 IPF patients with associated PH (352). After 16 
weeks of Bosentan no change occurred in 6MWD, mPAP or QOL scores in 
comparison to the placebo group. Although the deterioration in 6MWD in the 
active therapy group was less, -25.9 m vs -53.1 m respectively, this was not 
statistically significant. Whilst the average mPAP of 37 mmHg in the overall cohort 
suggests this population had severe PH, only 25/40 completed the study and 
characteristics of these patients were not reported. Other, smaller studies have 
reported more positive effects. Collard et al reported an increase in 6MWD by a 
mean 49 m after 3 months of sildenafil in 11 IPF patients with PH (353), whilst 
Hoeper et al demonstrated an increase in 6MWD and CO, and a decrease in PVR 
following therapy with Riociguat in 22 ILD patients with an average mPAP 
>30mmHg (although 4 had an alternate aetiology for PH) (354). 
Therapy studies solely focussing on severe PH associated with lung disease are few 
but perhaps more encouraging. Valerio et al treated 16 COPD patients with an 
average mPAP 37 ± 5 mmHg at RHC with 18 months of Bosentan (355). 6MWD 
improved from 256 ±118 m to 321±122 m and mPAP fell (31±6 mmHg) whilst a 
trend towards deterioration in 6MWD occurred in the best standard care group. 
The ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a 
Referral centre) registry reported no survival advantage in 43 COPD patients with 
severe PH treated with pulmonary vasodilators. However this group did 
demonstrate a fall in PVR  of more than 20% in 4 of 7 patients with repeat 
haemodynamic data, but did not evaluate clinical response by commonly used 
outcome measures  such as six minute walk distance or NTproBNP (356).  
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3.1.3 The right ventricle in chronic lung disease. 
Post mortem study has demonstrated links between the degree of RV hypertrophy 
and hypoxaemia in COPD patients (357) and demonstrated that cardiac failure is 
leading cause of death in COPD patients during hospitalisation with acute 
exacerbations (358). Small cardiac MRI studies in COPD with normoxia or only mild 
hypoxaemia and the absence of PH (determined indirectly by preserved PA 
distensibility) have demonstrated increased RV mass, smaller RV volumes, and in 
one fifth, impaired RV function (defined as a RVEF <45%) (336). Marcus et al 
imaged the RV using cardiac MRI in 8 COPD patients with early PH suggested by a 
decreased pulmonary artery acceleration time, and also demonstrated increases 
in RV mass and SV but preserved RVEF (359). Correlations between increasing 
severity of COPD determined by FEV1 and increasing RVM or falling RVEF have 
been shown (360), with only severe COPD patients demonstrating impaired RV 
function and fall in SV. However, no PH screening or control for hypoxaemia was 
performed so it is difficult to attribute the changes in RV to severity of COPD 
alone. In a larger echocardiography study, Hilde et al demonstrated a reduction 
in 9 measures of RV systolic function, including RV fractional area change and 
myocardial performance index, in 72 COPD patients without PH at RHC and an 
average Pa02 9.8KPa (361). In agreement with the former studies, an increase in 
RV wall thickness by 57% in comparison to controls was seen. Whilst RV wall 
thickness correlated with FEV1, this explained only 8% of the variance suggesting 
severity of airflow obstruction is a less significant driver of RV structural changes 
and other mechanisms such as systemic inflammation, increased afterload from 
hyperinflation, endothelial dysfunction or hypoxaemia have a greater detrimental 
impact. As discussed in section 1.2.3.2, it is known that pulmonary vascular 
remodelling occurs not only in advanced COPD, but also in patients with mild 
disease or even to some degree in smokers with normal lung function. RV 
adaptation and hypertrophy in the absence of significant resting hypoxaemia may 
be postulated to occur as a consequence of intermittent increase in PAP on 
exercise or during sleep that has been shown to occur in COPD patients (346, 362). 
Whilst the COPD patients in the study by Hilde et al are regarding as not having 
PH by the accepted diagnostic threshold (mPAP ≥25mmHg), mPAP was mildly 
increased with reduced PA compliance (mPAP 18±3mmHg in comparison to 
accepted normal 14.7 ±4mmHg (24)) indicating early changes in RV structure at 
subclinical levels of PH. 
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In populations of patients with end stage pulmonary disease undergoing 
assessment for lung transplantation, prevalence of RV dysfunction is higher, 
reported at 66% in one case series, with the prevalence higher still (94%) in those 
that also had pulmonary hypertension (205). In end stage IPF patients, 
echocardiographic indices of RV dysfunction have been shown to be independent 
predictors of mortality, whilst mPAP was not in a population with a PH prevalence 
of 29%, but moderate-severe RV dysfunction in only 11% (218). Biernacki reported 
largely preserved RV function (average RVEF 39% and normal CI) and pressure 
volume relationship in 100 hypoxaemic COPD patients with mPAP 26mmHg (range 
10-60 mmHg, 72% with PH) in comparison to controls (363). On exercise, RVSP 
increased significantly, but no detriment in RV contractility occurred. RVEF 
correlated with PVR, but no relationship to Pa02 or FEV1, and surprisingly mPAP 
which may reflect use of less accurate radionucleotide ventriculography to 
determine RV function (363). Turnbull, using MRI derived RV free wall volume as 
surrogate for RVM, in COPD patients with average mPAP of 30mmHg demonstrated 
good correlation with mPAP and PVR (r=0.72 and 0.67 respectively) (364). CMR 
indices of RV structure or function may therefore have a potential role in 
detection of raised PAP in patients with chronic lung disease. 
3.1.3.1 Biomarkers: 
BNP or its precursor NTproBNP have been shown to predict survival in COPD 
patients both during acute exacerbations (365, 366) and in stable disease (367, 
368), predict risk of hospitalisation or need for intensive care (369) and been 
postulated as a screening tool to identify those with co-existent PH (370). Levels 
of NTproBNP during exacerbations of COPD have shown to relate to both left and 
right ventricular dysfunction but not sPAP or severity of lung disease (371). Chang 
et al reported on 244 COPD patients with an average FEV1 of 35% of predicted 
hospitalised with an acute exacerbation, and demonstrated NTproBNP predicted 
30 day but not 1 year mortality (365). Raised troponin was also associated with 
mortality, and elevation of both markers of cardiac dysfunction was associated 
with a 15 fold increased 30 day mortality. Levels of NTproBNP showed no 
relationship to Pa02 but were not compared to indices of either right or left 
ventricular function. Hosieth et al found that levels of troponin were a stronger 
predictor of long term mortality than NTproBNP in those hospitalised with a COPD 
exacerbation (366), although neither echocardiography nor screening for 
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pulmonary embolism (PE) was performed in the population to determine nature 
of elevation in cardiac markers.  
BNP has also been shown to relate to mortality when measured in a stable 
outpatient population. In COPD patients, Inoue et al demonstrated that BNP levels 
were higher than control subjects, correlated with LVEF, sPAP and shorter time 
to exacerbation, and rose during the acute exacerbation (368). Leutche et al 
demonstrated a raised normalised BNP ratio predicted mortality in a large cohort 
of chronic lung disease patients, and made efforts to exclude those with either PE 
or raised PAWP (367). RHC was performed with severe PH present in over one 
quarter, however the study included patients with connective tissue disease and 
sarcoidosis with therefore a potential alternate aetiology for PH.  
Biomarkers offer an attractive screening tool for detection of PH. The afore 
mentioned limitations of echocardiography in the lung disease population and 
invasive nature of RHC make this ethically unjustifiable as a screening tool when 
treatment option for PH associated with lung disease is not available. 
Prognostically, and also potentially for recruitment to studies, the prevalence and 
detection of PH in lung disease population is desirable. NTproBNP has been proven 
as a marker of RV dysfunction in PAH and as a PH screening tool in connective 
tissue disease (372). As discussed above, levels of NTproBNP have been shown to 
relate to ventricular function and sPAP in chronic lung disease, although not 
consistently depending on population studied and method of determination of 
sPAP. Andersen et al reported on the use of BNP to detect echocardiography 
derived pulmonary hypertension in 117 COPD patients, and reported a NPV 22% 
and PPV 100% using a surprisingly low cut-off level of BNP of <95pg/ml (370). 
However, only 14/117 had PH determined by echo, of which only 6 underwent 
confirmatory RHC (with 3/6 confirmed as having PH). The literature on utility of 
NTproBNP as a screening tool for precapillary PH in chronic lung disease, 
relationship to pure RV dysfunction and survival in PH due to lung disease rather 
than coexistent LV dysfunction is therefore lacking. 
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3.2 Aims. 
As demonstrated by the studies above, the role of pulmonary vasodilator therapy 
in severe PH associated with lung disease is uncertain, clouded by small studies 
with less vigorous criteria for diagnosing PH and utilising mixed populations of 
patients both with and without PH or with co-existent pulmonary venous disease 
and with resultant mix of both positive and negative outcomes. We sought to 
1. Explore diagnostic utility and accuracy of CMR for determining presence 
of PH in comparison to echocardiography and NTproBNP in chronic lung 
disease 
2. Characterise and compare RV structure and function determined by CMR 
and relationship to prognosis in chronic lung disease patients without PH 
(mPAP <25mmHg), with mild-moderate (mPAP 25-34mmHg) and severe PH 
(mPAP ≥ 35mmHg).  
3. Assess response to PH specific therapy in a large cohort of chronic lung 
disease patients with associated severe PH determined by change in 6MWD 
and NTproBNP and further explore impact of lung disease severity and 
phenotype on survival and therapeutic response. 
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3.3 Materials and methods 
3.3.1 Patients in the study 
We retrospectively studied 255 treatment naïve incident cases diagnosed between 
January 2000 and March 2014 at the Scottish Pulmonary Vascular Unit, Glasgow. 
Patients were referred for investigation of unexplained PH, or PH felt 
disproportionate to the degree of lung disease and included after conventional 
multidisciplinary evaluation as described in Methods section 2.1.1. Patients were 
excluded if there was incomplete RHC data, missing CT or lung function data, or 
an alternative aetiology for PH.  Figure 3.1 describes the study population. 
3.3.1.1 IPAH patients 
81 IPAH patients who had no evidence of parenchymal disease of any severity on 
CT of thorax, and no other explanation for PH were included. PH was defined in 
the IPAH group as mPAP ≥25 mmHg with a PAWP ≤15 mmHg and a normal or 
impaired CO (defined as CI ≤4 l/min/m2). 7 patients were excluded whom were 
smokers with airflow obstruction (defined as post bronchodilator FEV1 <80% with 
FEV1/FVC <0.7). The remaining 74 patients were included in the study as a “pure” 
IPAH cohort for comparison. 
 
 
  
 
 
Figure 3.1 Study population
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3.3.1.2 Severe PH in lung disease 
There were 167 patients with pulmonary hypertension and associated lung 
disease. 124 patients met the criteria for severe PH, defined as a mPAP ≥35mmHg 
with a PAWP ≤15mmHg and normal or reduced CO, or a mPAP ≥30 mmHg with 
PAWP ≤15 mmHg and a CI <2 l/min/m2 (n=3).  
Patients were categorised by underlying lung disease into 1 of 4 phenotypes  
(i) emphysema with preserved FEV1, defined as FEV1 >80% predicted 
with evidence of emphysema on CT thorax 
(ii) combined pulmonary fibrosis and emphysema syndrome (CPFE), 
defined by coexistent predominantly apical emphysema and basal 
fibrosis on CT thorax with reduced DLCO. 
(iii) Interstitial lung disease (ILD)  
(iv) COPD, characterized by either post bronchodilator FEV1 <60% 
predicted, or emphysema on CT with FEV1 <80%, in conjunction with 
an FEV1/FVC ratio <0.7 
In addition to the phenotypes described, the effect the severity of associated 
lung disease had on treatment outcome was evaluated. Patients were classified 
into one of two groups using criteria suggested at the Nice world PH symposium 
(253); 
(i) severe PH/mild lung disease – defined as modest parenchymal abnormality 
on CT thorax, COPD with FEV1 ≥60% of predicted or ILD with FVC ≥70% of 
predicted 
(ii)  severe PH/severe lung disease - severe PH-CPFE, severe PH-COPD (defined 
by FEV1<60% of predicted), or severe PH-IPF (defined by FVC <70% of 
predicted). 
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3.3.1.3 PH “in proportion” to lung disease 
Of the remaining patients with lung disease evaluated, 30 had mild-moderate PH 
“in proportion” to lung disease, defined as a mPAP 25-34 mmHg with the same 
PAWP and CO criteria as described above, and 13 had no PH defined as a mPAP 
<25 mmHg in accordance with guidelines.  
3.3.2 Echocardiography 
32 lung disease patients with mPAP <35 mmHg had both demonstrable tricuspid 
regurgitation to allow estimation of sPAP by echocardiogram and had undergone 
CMR. These were included for comparison with 53 severe PH/lung disease patients 
described in section 3.2.1.2 whom also had both echocardiography estimated sPAP 
and a CMR study to evaluate non invasive screening tools for detection of PH in 
lung disease. mPAP estimation by echo was derived from the formula mPAP = 0.61 
sPAP + 2. Thresholds for detection of PH (i.e. mPAP ≥25 mmHg) and severe PH 
(i.e. mPAP ≥35mmHg) by echocardiogram derived sPAP were therefore 38 mmHg 
and 54 mmHg respectively. Unless otherwise stated, RAP was estimated at 5 
mmHg. RV function was assessed by TAPSE (normal function defined by TAPSE 
>1.8cm) and RV dilatation by RVEDD (defined by >4.2cm). 
3.3.3 Cardiac MRI 
35 patients with IPAH and 93 with PH/lung disease underwent cardiac MRI. Of the 
later, 58 had severe PH/lung disease, 23 mild-moderate PH/lung disease and 12 
lung disease patients without PH. Cardiac MRI image acquisition and data analysis 
was carried out as described in section 2.2. Inter-observer variability data has 
previously been published for our centre (373). CMR variables were indexed for 
BSA and adjusted for age.  
3.3.4 Treatment and follow up 
All patients with IPAH were treated with PH targeted therapy in accordance with 
guidelines (332). Patients with lung disease were treated with inhaled 
bronchodilators and LTOT in accordance with UK guidelines (374). Those with 
severe PH/lung disease received a minimum of 3 months compassionate use of PH 
targeted therapy. NYHA FC, 6MWD and NTproBNP were measured at diagnosis, and 
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reassessed at a time point greater than 3 months in those whom received PH 
therapy. As described in section 2.3 survival data was collected until last day of 
the study, 4th August 2014. 
3.3.5 Statistical methods 
Statistical analysis was carried out as described in methods section 2.3. In 
addition, ROC curves were derived to obtain thresholds for detection of both PH 
and severe PH in those with lung disease by level of NTproBNP and CMR indices of 
RVMI, RAC MPA and VMI. Agreement of RV parameters assessed by echocardiogram 
and CMR, and pulmonary artery pressure by echo and RHC was assessed by Pearson 
or Spearman correlation dependent on data distribution, and Bland-Altman 
analysis. Kaplan Meier survival curves were plotted by severity of pulmonary 
hypertension and by lung disease phenotype, and survival compared by logrank 
test.  
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3.4 Results 
3.4.1 Population Characteristics 
Patient characteristics are shown in tables 3-1 and 3-2 for those with lung disease 
and mild – moderate PH or no PH, and severe PH respectively. Whilst the 13 
patients classified by current PH diagnostic guidelines as having “no PH” by mPAP 
<25 mmHg, the average mPAP in this group was mildly elevated in comparison to 
normal (14.7 mmHg ±4) at 21 mmHg (range 13-23). 6MWD was lower in those with 
mild-moderate PH compared to patients without PH (234±108 m vs 364±79 m 
p=0.001) indicating a greater degree of functional impairment associated with the 
development of PH. 
There were 124 patients with severe PH/lung disease of which 84 died during 
follow up, and 74 IPAH patients of whom 25 died. 1 patient with severe PH/lung 
disease and 2 with IPAH underwent lung transplantation. Table 3-2 shows the 
patient characteristics of those with IPAH in comparison to severe PH with lung 
disease. IPAH patients were younger, more often female with less functional 
impairment and lower levels of NTproBNP despite similar haemodynamics.  
In the severe PH/lung disease group, there were 31 patients with 
emphysema/preserved FEV1, 25 patients with CPFE, 23 patients with ILD and 45 
with COPD phenotype. Of these 45 patients, 30 had emphysema, 4 respiratory 
bronchiolitis and 4 bronchiectasis on imaging. 6 had isolated spirometric 
abnormalities. Table 3-3 shows the characteristics of the lung phenotype groups. 
There were 88 patients meeting criteria suggested by Seeger et al. 30 patients 
had marked emphysema on CT but preserved FEV1 and were excluded as this group 
was not considered by this classification. 32 patients met criteria for severe 
PH/mild lung disease, and 58 patients with severe PH/severe lung disease; (22 
CPFE, 26 COPD, 10 ILD). 
In comparison to those with severe PH, those with mild to moderate PH in the 
setting of coexistent lung disease demonstrated preserved RV mass, volumes and 
function, were less hypoxaemic but had similar levels of functional impairment 
(mean 6MWD 234±108 m vs 206±105 m, p= 0.221). 
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3.4.1.1 Lung function 
DLCO was worse in those with severe PH/lung disease in comparison to IPAH 
patients (24 (19-34) v 62 (39-76), p<0.0001) and both in those with lung disease 
with mild-moderate (30 (22-36) p=0.05) or no PH (45 (35-56) p=0.001). Pa02 was 
lower in those with severe PH/lung disease (7.4 ± 1.6 kPa) in comparison to IPAH 
(9.6 ± 2.0 kPa, p<0.0001) and lung disease without PH (10.0 ± 1.9 kPa, p<0.0001), 
but not lung disease mild-moderate PH (8.0 ± 1.7kPa, p=0.08). 
In those with COPD, there was no relationship between FEV1 and mPAP or RVEF 
(r=0.04, P = 0.79 and r = 0.00, p = 1.0 respectively). FEV1:FVC ratio weakly 
correlated with mPAP (r = 0.29, p = 0.05) but not RVEF (r =-0.05, p = 0.79).  
In those with ILD, there was no relationship between FVC and either mPAP or RVEF 
(r =-0.08, p = 0.67 and r = 0.19 p = 0.49 respectively), nor TLC with mPAP or RVEF 
(r = 0.08, p = 0.72 and r = 0.15, p = 0.60 respectively). 
3.4.1.2 Functional Status 
Patients with severe PH lung disease demonstrated greater degree of functional 
impairment than those with IPAH or lung disease without PH. NYHA FC was worse 
with 12% FC II, 71% FC III and 17% FC IV in comparison to 24%, 69% & 7% (p = 0.021) 
in IPAH and 46%, 54% & 0% in lung disease without PH (p = 0.005) respectively. 
There was a trend towards worsening function class in comparison to patients with 
mild-moderate PH with lung disease (21% FCII, 76% FCIII & 3% FCIV, p = 0.099). 
6MWD was lower in severe PH/lung disease patients compared to IPAH patients 
(206±106m v 344±118m, p<0.0001) despite greater degree of PH in the latter 
(mPAP 46 v 54mmHg, p<0.0001). In a multivariate regression model with age, 
mPAP, CO and FEV1, RAP (r = -0.273 p = 0.004), compliance (SV/PP r = 0.282 p = 
0.036) and DLCO (r = 0.281 p = 0.001) were independent determinants of 6MWD. 
Table 3-4 shows univariate regression analysis of determinants of 6MWD in lung 
disease patients. Table 3-5 shows the final multivariate regression model for 
6MWD. In the subgroup with CMR variables, in a multivariate model with age, RAP, 
mPAP, CO & FEV1, neither RVEF nor LVEDVI were independent predictors of 6MWD 
(r = -0.07 p = 0.567 & r =.0.195 p = 0.06 respectively). 
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3.4.1.3 Right ventricular dysfunction in severe PH associated with lung 
disease 
CMR data was available for 58 patients with severe PH/lung disease (17 COPD, 8 
ILD, 15 CPFE, 18 emphysema) and 35 IPAH patients. Table 3-6 displays the 
characteristics of the two groups. There were no significant differences between 
right and left ventricular function. RVMI was lower in severe PH/lung disease group 
(50g/m2 versus 56g/m2 p=0.014). Lung disease patients were older (66 vs 48 
years, p<0.0001) with a more significant smoking history (51/55 previous smokers 
vs 11/35). 
In both IPAH and severe PH/lung disease patients, RVEF was reduced (32 ± 12% 
and 33 ± 13% respectively) with increased RV mass and volumes (RVEDVI 95 ± 28 
ml/m2 and 91 ± 30 ml/m2 respectively). 
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Table 3-1 Characteristics of patients with mild - moderate pulmonary hypertension 
associated with lung disease 
 
n 
All 
(43) 
mPAP 25-34mmHg  
(30) 
mPAP <25mmHg  
(13) 
p value 
Age years 68±10 69±10 66±9 0.395 
Sex % 38♀62♂ 37♀63♂ 46♀54♂  
Smoking history %  
Pack Years 
 
39±18 
86 (25) 
38±21 
100 (12) 
41±13 
 
0.711 
Aetiology % (n) 
COPD 
ILD 
CPFE 
Emphysema 
 
 
40 (12) 
23 (7) 
20 (6) 
17 (5) 
 
23 (3) 
23 (3) 
15 (2) 
39 (5) 
 
Baseline Haemodynamics 
  
  mPAP mmHg 27 ± 5 29 ± 3 21 ± 3 <0.0001*** 
  RAP mmHg 3 ±3 3±3 3±2 0.706 
  CI L/min/m2 2.6 ± 0.6 2.6±0.5 2.6±0.6 0.909 
  PVR Wood units. 4.1 (2.9-5.4) 4.6 (3.8-6.0) 2.6 (2.3-3.0) <0.0001*** 
  PAWP mmHg 8±4 7±4 9±3 0.229 
  SV02 % 68 (65-75) 68 (65-75) (28) 71.8 (65.8-74.4) (11) 0.701 
  SV/PP mL/mmHg 2.28±0.9 1.9 ± 0.6 (28) 3.2 ±0.7 <0.0001*** 
Cardiac MRI N=23 N=12  
  RVEF % 50 ± 11 48 ± 10 54 ± 13 0.139 
  RVEDVI mL/m2 63.0 (56.2-79.9) 62 (52-77) 68 (59-83) 0.260 
  RVMI g/m2 32.9 (27.3-39.5) 35 (30-40) 29 (24-42) 0.172 
  LVEF % 66.2±8 65 ±14 68 ± 11 0.487 
  LVEDVI mL/m2 54.5 (41.5-66.5) 49 (35-60) 67 (54-80) 0.006** 
  LVMI g/m2 50.7 (44.6-58.0) 50 (43-57) 56 (50-61) 0.280 
  SVI mL/m2 38 ± 9 37 ± 10 41 ± 9 0.244 
  RAC MPA % 30.4 (17-42) 23 (17-33) (23) 42 (34-51) (11) 0.006** 
  AoRAC % 18.9 (14-31) (35) 17 (11-31) (22) 22 (16-35)  0.729 
Lung Function 
  FEV1 % 79 (59-96) 72 (52-94) 91 (64-104) 0.212 
  FVC % 100±30 97 ± 32 109 ± 27 0.318 
  DLCO % (n) 33 (23-45) (39) 30 (22-36) (28) 45 (35-56) (11) 0.008** 
  Pa02 kPa (n) 8.6 ± 1.9 (31) 7.8±1.4 (20) 10.0±1.9 (11) 0.001** 
Functional Class % (n) 
   
  I/II 29 (12) 21 (6) 46 (6) 0.140 
  III 69 (29) 76 (22) 54 (7)  
  IV 2 (1) 3 (1) 0 (0)  
6MWD (m)   (n) 275 ± 116 234±108 (26) 364±79 (12) 0.001** 
NTproBNP (pg/ml) 
  (n) 
209 (110 – 426) 218 (112– 412) 
(28) 
200 (91 – 403) 
(12) 
0.750 
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Table 3-2. Population characteristics of severe PH associated with lung disease patients in 
comparison to IPAH. 
 IPAH                
(74) 
 Severe PH/ lung 
disease (124) 
 p value 
Age years 49±18   67±10  <0.0001*** 
Sex % 72♀28♂   45♀55♂  <0.0001*** 
Smoking history % (n) 
Pack years 
32 (22) 
30±15 
  89 (107) 
42±24 
  
0.048* 
Baseline Haemodynamics 
     
  mPAP mmHg 54 (46-62)   46 (40-51)  <0.0001*** 
  RAP mmHg (n) 8±6   8±5   (123) 0.935 
  CI L/min/m2 (n) 2.0±0.5  (73)  2.0±0.5   (119) 0.557 
  PVR w.u. 12.5 (9.2-17.9)   10.6 (8.2-14.2)  0.011* 
  PAWP mmHg 7±4   8±3  0.047* 
  SV02 % (n) 63 (56-69)   (66)  61 (53-67) (112) 0.185 
  SV/PP mL/mmHg 0.94 ± 0.5 (53)  0.98 ± 0.4 (110) 0.582 
Initial PH therapy % (n) 
     
  CCB 9.5 (7)   2 (3)  0.003** 
  PDE-5i 44.6 (33)   68 (84)   
  ETRA 25.7 (19)   23 (28)   
  Prostanoid 14.9 (11)   4 (5)   
  Combination 5.4 (4)   3 (4)   
Lung Function 
     
  FEV1 % 91 (83-97)   75 (58-93)  <0.0001*** 
  FVC % 101 ± 13   96 ± 25  0.076 
  FEV1/FVC % 76 (70-79)   63 (55-71)  <0.0001*** 
  TLC % (n) 93 ± 10  (68)  92 ± 18   (102) 0.602 
  DLCO % (n) 62 (39-76)  (71)  24 (19-34)  (104) <0.0001*** 
  Pa02 kPa (n) 9.6±2  (43)  7.4±1.6  (84) <0.0001*** 
       
Functional Class % (n) 
      
  I/II 24 (17)   12 (14)  0.021* 
  III 69 (49)   71 (85)   
  IV 7 (5)   18 (21)   
6MWD m   (n) 334±118  (62)  206±105  (102) <0.0001*** 
NTproBNP pg/ml  (n)        1128 (508 - 2890) 
 
(46)     2273 (943 – 4506) 
 
(94) 0.019* 
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Table 3-3. Population characteristics of severe PH associated with chronic lung disease 
according to lung disease phenotype 
 
 Emphysema 
(31) 
CPFE 
(25) 
COPD 
(45) 
ILD 
(23) 
p value 
Age years 70±10 68±7 63±11 69±10 0.015 
Sex %    52♀48♂     36♀64 ♂    47♀53♂ 46♀54♂  
Smoking history % 
Pack years 
100 
51±29 
100 
47±23 
89 
36±17 
50 
25±16 
  
0.020* 
LTOT usage %         87           91 60       73 
Baseline Haemodynamics 
  
  mPAP mmHg 46±7 48±8 48±11 46±9 0.678 
  RAP mmHg 7±4 9±5 8±5 10±6 (22) 0.109 
  CI L/min/m2 (n) 1.9±0.4 1.8±0.4 (24) 2.1±0.6 (44) 1.9±0.5 (20)  0.162 
  PVR w.u. 12.2±4 12.9±4 11.1±5 10.0±3 0.119 
  PAWP mmHg 8±3 8±3 9±3 9±3 0.357 
  SV02 %  (n) 61±11  (29) 59±11 (24) 59±10 (39) 62±9 (20) 0.683 
  SV/PP ml/mmHg  0.9 ± 0.3 0.9 ± 0.4 1.1 ± 0.6 (37) 1.0 ± 0.3 0.037* 
Initial PH therapy % (n) 
  
  CCB 0 0 4.4 (2) 4 (1)  
  PDE-5 71.0 (22) 60 (15) 66.7 (30) 74 (17)  
  ETRA 19.4 (6) 24 (6) 24.4 (11) 22  (5)  
  Prostanoid 6.5 (2) 4 (1) 4.4 (2) 0  
  Combination 3.2 (1) 12 (3) 0 0  
Lung Function 
   
  FEV1 % 99±17 81±22 55±16 79±20 <0.0001*** 
  FVC % 117 (105-
139) 
101 (86-124) 84 (75-98) 74 (65-98) <0.0001*** 
  FEV1/FVC % 65±10 62±9 55±11 79±11 <0.0001*** 
  TLC %  (n) 102 ± 14 (27) 89 ± 15 (23) 95 ± 17 (35) 74 ± 16 (17) <0.0001*** 
  DLCO % (n) 26±9  (28) 21±7 (22) 31±14 (35) 28±11 (19) 0.017* 
  Pa02 kPa (n) 7.0±2.1 (22) 7.0±0.8 (15) 7.7±1.4 (32) 7.5±1.7 (15) 0.401 
Function Class % (n) 
    
  I/II 3 (1) 0 21 (9) 18 (4) ns 
  III 81 (25) 79 (19) 65 (28) 59 (13)  
  IV 16 (5) 21 (5) 14 (6) 23 (5)  
6MWD m (n) 224±99 (23) 174±78 (20) 215±110 (39) 199±121 
(20) 
0.409 
NTproBNP pg/ml 
 (n)  
1447 (753–
3881) (22) 
2272 (1203-
6384) 
 (22) 
2335 (650–
4359)  
(32) 
2703 
(1259-
4143) (18) 
0.572 
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Table 3-4. Determinants of functional capacity (defined by 6MWD) in severe PH associated 
with lung disease 
 
Variable Correlation 
coefficient 
95% CI p value 
Age -0.154 -3.50 – 0.138 0.07 
mPAP -0.175 -3.09 - -0.08 0.039 
RAP -0.323 -11.2 - -3.78 <0.0001 
PVR -0.284 -10.5 - -2.88 0.001 
CO 0.377 21.61 – 52.0 <0.0001 
SV/PP 0.428 36.6 – 81.0 <0.0001 
   
FEV1 0.188 0.09 – 1.49 0.027 
DLCO 0.425 2.10 – 4.67 <0.0001 
Pa02 0.442 16.79 – 39.62 <0.0001 
    
RVEF 0.241 0.20 – 3.23 0.027 
LVEF 0.199 -1.22 – 3.10 0.070 
RVEDVI 0.016 -0.75 – 0.87 0.885 
LVEDVI 0.314 0.65 – 3.23 0.004 
SVI 0.308 1.05 – 5.40 0.004 
RVMI -0.096 -1.75 – 0.68 0.385 
RAC MPA 0.343 1.12 – 4.69 0.002 
 
Table 3-5. Multivariate regression model for 6MWD in lung disease patients 
 
R = 0.629, adj r2 = 0.395, p<0.0001 for the model. 
Variable Regression 
coefficient 
95% CI P value 
Age - 0.144 -3.55 – 0.40 0.118 
mPAP 0.261 0.07 – 4.75 0.043 
RAP -0.273 -11.65 - -2.26 0.004 
CO 0.179 -1.74 – 37.50 0.074 
SV/PP 0.282 2.59 – 74.90 0.036 
FEV1 0.154 -0.64 – 1.44 0.073 
DLCO 0.281 0.93 – 3.69 0.001 
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Table 3-6. Characteristics of IPAH and severe PH/lung disease patients with CMR studies. 
 
 
 
n 
IPAH 
 
35 
Severe PH/lung 
disease 
58 
p value 
Age (years) 48 ± 17 65 ± 11 <0.0001*** 
PVR (Wood Units) 14.5 (10 - 18) 10.5 (8 - 15) 0.012* 
mPAP (mmHg) 57 ± 14 48 ± 9 <0.0001*** 
PAWP (mmHg) 8 ± 4 8 ± 4 0.604 
SV/PP 0.89 ± 0.4 (31) 1.05 ± 0.5 (57) 0.105 
    
RVEF (%) 32 ± 12 33 ± 13 0.644 
LVEF (%) 66 (60 -71) 62 (54 -71) 0.470 
RVMI (g/m2) 56 (49-75) 50 (38 - 61) 0.014* 
LVMI (g/m2) 46 (41 -57) 48 (41 - 56) 0.916 
RVEDVI (ml/m2) 95 ± 28 91 ± 30 0.537 
RVESVI (ml/m2) 65 ± 26 62 ± 28 0.609 
LVEDVI (ml/m2) 40 (34 - 53) 44 (37 - 53) 0.414 
SVI (ml/m2) 25 ± 10 28 ± 8 0.182 
RAC MPA (%) 21 (17 - 28) (28) 18 (16 – 22) (53) 0.096 
RAC Ao (%) 24 (14 - 28) (22) 18 (14 - 24) (48) 0.241 
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3.4.2 Screening for pulmonary hypertension in lung disease 
91 of the 167 lung disease patients had both CMR and echocardiography studies, 
12 with no PH, 23 with mild-moderate and 56 with severe PH. It was not possible 
to estimate sPAP by echocardiogram in 10 of 164 patients. 3 patients had a CMR 
performed but had poor quality studies due to respiratory motion artefact and 
were excluded. Only 3 patients were classed as having severe PH phenotype by an 
mPAP 30 -34 (range 32-34mmHg) and CI <2 l/min/m2 (1.5-1.9). None of these had 
a CMR study and were excluded from this analysis. 
Tables 3-7 and 3-8 summarise the sensitivity and specificity for each screening 
tool for the detection of PH and severe PH respectively in patients with lung 
disease. 
3.4.2.1 Echocardiography 
Overall, echocardiography estimated sPAP was available for 154 patients with lung 
disease and 50 IPAH patients. Correlations between echocardiography estimated 
sPAP and invasively measured sPAP were similar in both, Pearson r = 0.53 p<0.0001 
and r= 0.51 p=0.0002 respectively. These values are similar to those published in 
literature in patients with severe lung disease (r=0.69, Arcasoy 2003 (199)) Linear 
regression shown in figure 3.2. 
In those with lung disease, for sPAP estimated by echocardiography versus 
invasive, mean difference was 0.84 mmHg with limits of agreement -36 and 38 
mmHg. In IPAH patients, for sPAP by echo versus invasive, mean difference was -
9 mmHg with limits of agreement -52 and 34 mmHg. Figure 3.3 shows the Bland-
Altman plots of the difference between echo estimated sPAP and invasive sPAP 
against the mean of both values demonstrating poor accuracy of echocardiography 
estimated sPAP. 
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Figure 3.2 Correlation between echocardiogram estimated sPAP and invasive sPAP for [a] 
IPAH [b] lung disease patients.  
Similar correlations were observed in both groups. p<0.0001, with poor R2 values. Whilst statistically 
significant, degree of accuracy between echocardiography estimated and measured sPAP was poor, 
as shown in figure 3.4  
 
 
 
Figure 3.3 Bland Altman plots of the difference between echocardiogram estimated and 
invasive sPAP against mean of both values for [a] IPAH [b] lung disease patients. 
 
Limits of agreement (dashed line) and mean difference (solid line) shown. Plots show large variation, 
up to 50mmHg between echo estimated and invasive measured sPAP in those with lung disease. 
This is in agreement with previous published study showing inaccuracy of echo in chronic lung 
disease were inaccuracies in 52% of echocardiograpy estimated sPAP has been shown (199). 
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Figure 3.4 ROC curves of sensitivity and specificity of echocardiography estimated sPAP 
for [a] mPAP ≥ 25mmHg [b] ≥ 35mmHg 
 
 
A level of sPAP of 38mm Hg was 97% sensitive & 41.7% specific for detection of 
PH, resulting in 7 out of 12 misclassified as having PH, and 1 out of 74 missed (91% 
(83%-96%) PPV and 83% (36%-100%) NPV). A level of sPAP of 54mmHg resulted in 
15/33 false positives and 8/53 false negatives for detection of severe PH 
associated with lung disease (sensitivity 85% specificity 61%). ROC curves are 
shown in figure 3.4. 
Right ventricular end diastolic diameter (RVEDD) was estimated in 8, 20 and 44 
patients with no, mild – moderate and severe PH associated with lung disease 
respectively. RVEDD was increased in those with severe PH/lung disease only (4.6 
± 0.9, P= 0.006, ULN 4.2cm (49) ) and correlated with RVEDVI measured by CMR, 
r= 0.572, p <0.0001.  Figure 3.5 shows mean RVEDD by PH severity, and correlation 
with RVEDVI for the whole group. A RVEDD >3.2cm was 91% sensitive and 38% 
specific for detection of PH, LR 1.45, AUC 0.740 P=0.028, resulting in 5/8 false 
positives and 6/64 false negatives. RVEDD >3.5cm 89% sensitive 46% specific (AUC 
0.787 P<0.0001) for detecting mPAP ≥ 35mmHg. 15/28 patients were misclassified 
as having severe PH and 5/44 cases were missed using this threshold. 
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Figure 3.5 RV end diastolic diameter in patients with lung disease according to severity of 
pulmonary hypertension 
 
[a] RVEDD was similar in patients with mild-moderate PH in comparison to those without PH but 
increased significantly in those with severe PH indicating RV dilatation in this group. [b]. RVEDD 
correlated well with RV end-diastolic volume index determined by gold standard cardiac MRI. 
 
 
 
Figure 3.6 TAPSE in patients with lung disease with mild - moderate and severe PH in 
comparison to those without PH 
 
TAPSE was preserved in those with mild-moderate PH but fell in those with severe PH/lung disease, 
mean value 1.6cm indicative of impaired RV function in this group. [b]. TAPSE showed good 
correlation with cardiac MRI measured RVEF (p<0.0001). 
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TAPSE was estimated in 4, 10 and 53 patients without PH, with mild-moderate and 
severe PH respectively. TAPSE was preserved in those with mild-moderate PH but 
reduced in those with severe PH (2.2 cm vs 1.6 cm, P=0.002, see figure 3.6a). 
Figure 3.6b shows the correlation between TAPSE and CMR derived RVEF (r= 0.548, 
p <0.0001).  
3.4.2.2 NTproBNP 
NTproBNP levels were available for 12, 24 and 46 patients with no, mild to 
moderate and severe PH respectively. Figure 3.7 shows the median NTproBNP by 
severity of PH. Levels of NTproBNP did not differ between those with mild-
moderate and those without PH, 200 vs 218 pg/ml respectively, p= 0.47. NTproBNP 
was elevated in those with severe PH, 2258 pg/ml (416 - 4295) p<0.0001, and 
correlated with RV dilatation and inversely with RVEF (r = 0.484 & r = -0.678 
respectively, both p<0.0001. see figure 3.8) 
A level of NTproBNP of 106 pg/ml was 91% sensitive but only 33% specific (LR 1.37) 
for mPAP ≥25mmHg, resulting in 8/12 false positives and 6/67 false negatives. A 
level of NTproBNP >230 pg/ml was 91% sensitive 58% specific (LR 2.15) for 
detecting severe PH, missing 4/46 cases and misclassifying 14/33 (75% PPV 83% 
NPV). Receiver operator curves are shown in figure 3.9. 
 
 
 
Figure 3.7 NTproBNP levels for patients with chronic lung disease without PH in 
comparison to those with mild-moderate and severe PH. 
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Figure 3.8 Correlation between NTproBNP and [a] RVEF [b] RVEDVI in patients with chronic 
lung disease. 
 
Logarithmic transformation of NTproBNP shown due to data distribution. Increasing levels of 
NTproBNP showed good relationship to falling RVEF and increasing RVEDVI indicative of RV 
dysfunction. p<0.0001 for both. 
 
 
 
 
Figure 3.9 ROC curves for sensitivity and specificity of NTproBNP for detecting [a] mPAP ≥ 
25mmHg [b] ≥ 35mmHg in patients with lung disease  
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3.4.2.3 Cardiac MRI 
Lung disease patients with no PH or mild-moderate PH displayed preserved RV 
function (RVEF 54 ± 13 % and 48 ± 10 %, LLN 45%), with no RV dilatation (RVEDVI 
62 ml/m2 and 66 ml/m2 respectively). In contrast, those with severe PH had 
impaired RVEF (34 ± 13 %) and increased RVEDVI (85 ml/m2). Figure 3.10 shows 
the RVEF and RVEDVI for the groups. Pa02 and FEV1 correlated with RVEF (r=0.328 
p= 0.006, r = 0.237 p = 0.024 respectively) but were not independent determinants 
of RVEF in a model with age and PVR (p = 0.063 and 0.227 respectively). 
RVMI was increased in those with severe PH (50 g/m2) in comparison to both mild-
moderate (36 g/m2 p = 0.003) and no PH patients (29g/m2 p = 0.006). There was a 
trend towards an increase in RVMI between mild-moderate PH and no PH patients, 
but this did not meet statistical significance (p = 0.135). Figure 3.11 shows the 
median RVMI by severity of PH. 
Receiver operator curves for RVMI are shown in figure 3.12. RVMI >26.45 g/m2 was 
89% sensitive and 42% specific for a mPAP ≥25mmHg (7/12 false positives, 8/73 
false negatives. RVMI ≥32.8 g/m2 was 87% sensitive and 57% specific for a mPAP ≥ 
35mmHg (15/35 false positives, 7/53 false negatives). 
 
 
 
Figure 3.10 Right ventricular function and volume in lung disease patients by severity of 
pulmonary hypertension. 
Patients with severe PH displayed reduced RV ejection fraction and RV dilatation in comparison to 
those with mild-moderate or without PH. 
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Figure 3.11 Right ventricular mass in patients with no, mild-moderate and severe PH in 
patients with associated lung disease 
 
Patients with severe PH displayed increased RVM in comparison to those with mild-moderate and 
no PH. Patients with mild-moderate PH did not have statistically significant increase in RVM 
(p=0.135) 
 
 
 
Figure 3.12. Receiver operator curves for sensitivity and specificity of RV mass to detect [a] 
mPAP ≥ 25mmHg and [b] mPAP ≥ 35mmHg.  
 
Optimal thresholds of >26.5 g/m2 and > 32.8g/m2 respectively. 
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VMI (ventricular mass index, ratio of RVM:LVM) showed an increase from 0.53 (0.44 
- 0.84) in those with no PH, to 0.76 (0.64 – 0.89) in patients with mild-moderate 
PH and to 1.01 (0.72 – 1.20) in patients with severe PH. Figure 3.13 shows the 
median VMI for each group. 
A VMI of >0.525 was 97% sensitive and 50% specific for a mPAP ≥ 25mmHg (6/12 
false positives 4/73 false negatives). A VMI >0.6 was 91% sensitive and 44% specific 
for a mPAP ≥35mmHg (18/32 false positives and 5/53 false negatives). Receiver 
operator curves are shown in figure 3.14. 
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Figure 3.13. Ventricular mass index in patients with no, mild-moderate and severe PH and 
chronic lung disease. 
 
VMI, the ratio of RV/LV mass, increased with increasing severity of pulmonary hypertension. Mean 
(SD) shown. 
 
 
 
Figure 3.14 Receiver operator curves displaying sensitivity and specificity of ventricular 
mass index for detecting [a] mPAP ≥ 25mmHg and [b] mPAP ≥35mmHg. 
 
Optimal thresholds of > 0.525 and > 0.60 respectively were identified. 
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3.4.2.4 Vascular stiffness 
Vascular stiffness increased with PH of increasing severity. Compliance (SV/PP = 
1/ vascular stiffness) fell from 3.2 ± 0.7 in those without PH, to 1.9 ± 0.7 in 
patients with mild-moderate PH and 0.98 ± 0.4 in patients with severe PH 
(p<0.0001 for both). RAC MPA fell from 42 (34-51) % to 23 (17-33) % and to 18 (16-
22) respectively. Figure 3.15 shows measures of vascular compliance for each 
group. Pa02 but not FEV1 correlated with RAC MPA (r = 0.265 p = 0.030) and SV/PP 
(r = 0.353 p<0.0001). SV/PP correlated with RAC MPA for the whole cohort, 
p<0.0001 (see figure 3.16) 
Receiver operator curves for RAC MPA for mPAP ≥25mmHg and ≥35mmHg are 
shown in figure 3.17. A RAC of <41.15% was 96% sensitive and 58% specific for a 
mPAP ≥ 25mmHg (5/12 false positives and 3/73 false negatives). A RAC of <32.5% 
was 94% sensitive and 47% specific for a mPAP ≥ 35mmHg (17/32 false positives 
and 3/53 false negatives). 
 
 
 
Figure 3.15 Invasive (SV/PP) and non-invasive (RAC MPA) determined pulmonary vascular 
compliance in patients with no, mild-moderate and severe PH associated with lung disease. 
 
Falling vascular compliance (i.e. increasing stiffness) was demonstrated with increasing severity of 
PH by either method. Median (IQR) shown. 
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Figure 3.16 Correlation of invasive (SV/PP) and noninvasive (RAC MPA) estimates of 
pulmonary artery compliance for lung disease patients 
 
 
 
 
Figure 3.17 Receiver operator curves displaying sensitivity and specificity of RAC MPA for 
detecting [a] mPAP ≥ 25mmHg and [b] ≥ 35mmHg. 
 
Optimal threshold of RAC MPA < 41.15 % and < 32.5% respectively were determined. 
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The combination of echocardiogram estimated sPAP and RAC MPA performed 
superiorly for the detection of a mPAP ≥25 mmHg (100% sensitivity, 83% specificity 
98%PPV 100%NPV). Table 3-7 summarises the sensitivity, specificity, PPV and NPV 
for each screening method. 
 
Table 3-7. Sensitivity and specificity of imaging and biomarker modalities for detection of 
PH in chronic lung disease patients 
 
Variable 
threshold 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Echo estimated 
sPAP >38mmHg 
97 (91-99) 42 (15-72) 91 (83-96) 83 (36-100) 
RVEDD >3.2cm 91 (81-97) 38 (9-76) 92 (82-97) 33 (8-50) 
NTproBNP 
>106pg/ml 
91 (82-97) 33 (10-65) 88 (78-95) 40 (12-74) 
RVMI > 26.45g/m2 89 (80-95) 42 (15-72) 90 (81-96) 39 (14-68) 
VMI >0.525 97 (91-100) 50 (21-79) 92 (84-97) 75 (35-97) 
RAC MPA <41.15% 96 (89-99) 58 (28-85) 93 (85-98) 70 (35-93) 
Echo estimated 
sPAP + RAC 
100 (95-100) 83 (52-98) 98 (91-100) 100 (69-100) 
Echo estimated 
sPAP + VMI 
100 (95-100) 67 (35-90) 95 (87-99) 100 (63-100) 
Echo estimated 
sPAP + NTproBNP 
100 (95-100) 50 (21-79) 93 (84-97) 100 (54-100) 
Combination of imaging modalities, echocardiogram to estimate pressure and CMR to assess 
vascular stiffness (RAC MPA) optimal screening method for presence of pulmonary hypertension. 
And/or analysis used for combined modalities e.g. sPAP >38mmHg AND RAC <41%, or RAC 
<41% /unable to estimate sPAP. 
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The combination of echo estimated sPAP >54 mmHg and RVMI of > 32.8 g/m2 had 
the highest accuracy for the detection of mPAP ≥ 35mmHg (98% sensitivity, 79% 
specificity 88% PPV and 96% NPV). Table 3-8 summarises performance 
characteristics for each screening method for detection of severe PH in lung 
disease patients. 
 
Table 3-8 Sensitivity and specificity of imaging modalities and NTproBNP for detection of 
severe PH in chronic lung disease patients 
 
Variable 
threshold 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Echo estimated 
sPAP >54mmHg 
85 (72-93) 61 (42-77) 78 (65-88) 71 (51-87) 
RVEDD >3.5cm 89 (75-96) 46 (28-66) 72 (58-84) 72 (47-90) 
NTproBNP 
>230pg/ml 
91 (79-98) 58 (39-75) 75 (62-86) 83 (61-95) 
RVMI > 32.8g/m2 87 (76-95) 57 (39-74) 76 (64-86) 74 (54-89) 
VMI >0.6 91 (79-97) 44 (26-62) 73 (60-83) 74 (49-91) 
RAC MPA <32.5% 94 (84-99) 47 (29-65) 75 (63-85) 83 (59-96) 
Echo estimated 
sPAP + RAC 
98 (90-100) 73 (54-87) 85 (74-93) 96 (80-100) 
Echo estimated 
sPAP + RVMI 
98 (90-100) 79 (61-91) 88 (77-95) 96 (81-100) 
Echo estimated 
sPAP + VMI 
96 (87-100) 73 (54-87) 85 (73-93) 92 (75-99) 
Echo estimated 
sPAP + NTproBNP 
96 (87-100) 85 (68-95) 91 (80-97) 93 (78-99) 
Combination of echocardiogram to assess pressure and CMR to measure RV mass optimal 
screening for severe PH in lung disease. And/or analysis used for combined modalities e.g. sPAP 
>54mmHg AND RVMI >32.8g/m2, or RVMI >32.8 g/m2 /unable to estimate sPAP 
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3.4.3 Survival and prognostic factors 
Mean length of follow up for the entire population was 801 ± 722 days (range 17 – 
3582 days). 22 (of 30) patients with mild-moderate PH and 3 (of 13) patients with 
lung disease but no PH died during the follow up period. Survival in those with 
mild-moderate PH in comparison to those with severe PH/lung disease, the latter 
of which were treated with pulmonary vasodilators was no different (1 and 3 year 
estimated survival 67.5% vs 76.6% and 32.1% vs 40.1% respectively, p=0.441). Both 
demonstrated poorer survival in comparison to those without PH (1 and 3 year 
estimated survival 92.3% and 80.8%, p= 0.006 & 0.023 with those with mild-
moderate and severe PH respectively). KM survival curves according to PH severity 
are shown in figure 3.18. 
 
Figure 3.18. Kaplan Meier curves describing survival by severity of pulmonary hypertension 
in lung disease patients. 
 
Survival was comparable in those with mild-moderate PH and severe PH who were treated with 
pulmonary vasodilators (logrank p = 0.441). Both groups displayed reduced survival in comparison 
to lung disease patients without PH (logrank p = 0.006 and p = 0.023 respectively). 
All patients in severe PH group received pulmonary vasodilator therapy until date of death or 
censored due to loss of follow up (n=1). 
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Observed survival was worse in those with severe PH/lung disease, 1 & 3 year 
estimated survival rates compared to IPAH were 75% versus 90% and 40% versus 
72% respectively (p <0.0001). However those with lung disease were significantly 
older, mean age 67 versus 49 years in IPAH (p <0.0001). When the older age of the 
population was considered on multivariate cox, the presence of lung disease 
remained associated with worse survival (HR 0.489 95%CI 0.299-0.798, p=0.004). 
Kaplan Meier curve describing the survival of severe PH/lung disease patients in 
comparison to IPAH patients is shown in figure 3.19. 
 
Figure 3.19. Kaplan Meier survival plot comparing outcome of patients with severe PH and 
lung disease in comparison to IPAH patients. 
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Survival in those with emphysema was reduced in comparison to IPAH (1-year 
survival 74% and 3-year 32% p=0.002). CPFE patients had a comparable 1 year 
survival rate, although the overall survival at 3 years was significantly lower than 
IPAH (1-year survival 88%, 34% at 3 years, p=0.001). ILD patients had the poorest 
survival, 1-year survival 60%, 3-year 19%, worse than IPAH (p <0.0001) and COPD 
patients (p=0.014). Survival between other lung phenotypes did not differ. KM 
curve describing survival of the population according to lung disease phenotype is 
shown in figure 3.20. 
There was no difference in survival observed between those with severe PH/mild 
lung disease and severe PH/severe lung disease (1 and 3 year estimated survival 
rates 87 % versus 76 % and 47 % v 44 % respectively, p = 0.411). KM survival curve 
according to lung disease severity is shown in Figure 3.21 
 
Figure 3.20. Survival according to lung disease phenotype associated with severe PH. 
 
Survival between lung disease phenotypes did not differ, with the exception of poorer survival in 
those with ILD in comparison to COPD diagnoses (logrank p = 0.014). 
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Figure 3.21. Kaplan Meier survival curve for patients with severe PH/severe lung disease in 
comparison to those with mild-moderate lung disease and severe PH. 
 
No significant difference in survival was observed according to severity of associated lung disease 
(logrank p = 0.411) 
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In a multivariate model with age, male sex, higher mPAP and lower LVEDVI were 
independently associated with reduced survival in lung disease patients with mPAP 
<35mmHg (HR 1.153 95% CI 1.003-1.326, p=0.045 and HR 0.944 95% CI 0.907-0.984 
p=0.006 respectively). Table 3-9 shows the univariate and multivariate survival 
analysis. 
Table 3-10 displays prognostic relevance of mPAP and sPAP in comparison to 
indices of RV dysfunction measured by RHC, Echocardiography and CMR on 
univariate survival analysis for all 167 lung disease patients. Only 62 patients had 
all variables available for multivariate analysis. In a model with age, mPAP, and 
RAP, RVEF but not RVEDD on echo remained an independent prognostic factor (HR 
0.965 95%CI 0.934-0.997, p=0.032).  
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Table 3-9. Prognostic variables in mild - moderate pulmonary hypertension associated with 
lung disease. 
 
Variable Univariate model Multivariate model 
 HR (95%CI) P value HR (95%CI) P value 
Age 1.044 (0.997 - 1.092) 0.06 1.038 (0.989 - 1.090) 0.132 
Sex (♂=0) 0.698 (0.308 - 1.583) 0.390 0.201 (0.069 - 0.583) 0.003 
Echo sPAP 1.061 (1.029 – 1.094) <0.001   
mPAP 1.137 (1.033 - 1.252) 0.009 1.153 (1.003 - 1.326) 0.045 
RAP 0.846 (0.703 - 1.017) 0.075   
PVR 1.288 (1.034 - 1.606) 0.024   
SV/PP 0.420 (0.228 – 0.777) 0.006   
DLCO 0.975 (0.954 - 0.997) 0.024   
6MWD 0.997 (0.993 - 1.001) 0.162   
NTproBNP 1.421 (0.935 - 2.162) 0.100   
RVEF 0.964 (0.918 - 1.011) 0.131   
RVEDVI 0.998 (0.974 - 1.024) 0.901   
LVEF 0.973 (0.702 - 1.349) 0.871   
LVEDVI 0.962 (0.930 - 0.994) 0.019 0.944 (0.907 - 0.984) 0.006 
RAC MPA 0.964 (0.931 - 0.999) 0.046   
 
Higher mPAP, male sex and lower LV end diastolic volume were independent predictors of survival 
on multivariate cox proportional regression analysis.  
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Table 3-10. Indices of RV function assessed by 4 modalities (RHC, Echocardiography, CMR 
and NTproBNP) as predictors of survival in all patients with chronic lung disease. 
 
Variable n HR (95%CI) p value 
Right heart catheterisation   
mPAP 167 1.001 (0.987 - 1.015) 0.914 
RAP 167 1.064 (1.026 – 1.104) 0.001** 
CI 167 0.466 (0.313 – 0.694) <0.001*** 
Echocardiography   
PASP 154 1.007 (0.998 – 1.016) 0.144 
TAPSE 70 0.882 (0.457 – 1.702) 0.708 
RVEDD 130 1.297 (1.031 – 1.631) 0.026* 
Cardiac MRI   
RVEF 92 0.971 (0.952 – 0.990) 0.003** 
RVESVI 92 1.013 (1.003 – 1.023) 0.009** 
SVI 92 0.968 (0.940 – 0.996) 0.023* 
    
NTproBNP 126 1.332 (1.139 – 1.559) <0.001*** 
 
Univariate cox proportional regression analysis shown. Echocardiography derived parameters 
performed less well than other modalities in assessing prognosis related to RV dysfunction. The 
severity of PH, assessed by either echocardiography (PASP) or RHC (mPAP) did not relate to 
outcome in comparison. 
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3.4.3.1 Prognostic factors in severe PH associated with lung disease 
A comparative analysis of severe PH/lung disease survivors at 3 years was carried 
out. Table 3-11 shows the characteristics of non survivors and survivors. Survivors 
were characterised by less RV dysfunction (lower RAP and NTproBNP, higher CI 
and RVEF) and lower vascular stiffness (greater SV/PP). 
In a model with age, sex, PVR and NTproBNP, RAP and CI independently predicted 
survival in patients with severe PH/lung disease (HR 1.08195% CI 1.026 – 1.139, HR 
0.350 95% CI 0.167 – 0.696 respectively, both p = 0.003). Table 3-12 shows the 
univariate and multivariate cox survival analysis for IPAH and severe PH/lung 
disease patients. 
Univariate cox survival analysis for severe PH/lung disease patients according to 
phenotype is shown in table 3-13. Haemodynamics but not lung function related 
to outcome.  
In patients with severe PH and ILD, lower CI and higher PAWP were associated 
with death (HR 0.098 95% CI 0.130 – 0.733 p=0.024 and HR 1.254 95% CI 1.006 – 
1.562 p = 0.044 respectively). 
In patients with severe PH and CPFE, increased RAP (HR 1.113 95% CI 1.029 – 1.204 
p = 0.007), PVRI (HR 1.078 95% CI 1.005 – 1.157 p = 0.036) and NTproBNP (HR 1.857 
95% CI 1.149 – 3.00 p = 0.011) and lower CI (HR 0.276 95% CI 0.083 – 0.912 p = 
0.035) or SVO2 (HR 0.936 95% CI 0.898 – 0.977 p = 0.002) were associated with 
worse survival. 
In patients with emphysema/preserved FEV1, lower 6MWD (HR 0.994 95% CI 0.990 
– 0.998 p = 0.003), CI (HR 0.141 95% CI 0.039 – 0.512 p = 0.003) and SV/PP (HR 
0.037 95% CI 0.005 – 0.235 p = 0.001) and increased RAP (HR 1.374 95% CI 1.182 – 
1.597 p <0.0001) and PVRi (HR 1.138 95% CI 1.053 – 1.229 p = 0.001) were 
predictive of worse survival. 
In those severe PH/lung disease patients whom had undergone CMR, in a 
multivariate model with age, sex, PVR and SVI, RVEF was an independent predictor 
of survival (HR 0.946 95% CI 0.907 – 0.986 p = 0.009). Table 3-14 shows the 
univariate and multivariate survival analysis. 
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Table 3-11. Characteristics of survivors and non-survivors at 3 years follow up with severe 
PH/lung disease. 
 Survivors (32) Non-survivors (65) P value 
Age years 64 ± 11 68 ± 9 0.028* 
Sex % 52♀ 48♂ 36♀ 64♂ ns 
Haemodynamics 
  
  mPAP mmHg 48 ± 12 47 ± 8 0.524 
  RAP mmHg 6 ± 4 10 ± 5 <0.0001*** 
  CI  L/min/m2 2.2 ± 0.5 1.7 ± 0.4 <0.0001*** 
  PVR w.u. 10.6 ± 5 12.3 ± 4 0.084 
  PAWP mmHg 9 ± 3 8 ± 3 0.800 
  SV02 % 63 ± 10 58 ±10 0.010* 
  SV/PP 1.2 ± 0.5 0.9 ± 0.4 0.009** 
Ventricular structure & function                n=18                                                                                           n = 29
 
  RVEF % 40 ± 14 29 ± 12 0.003** 
  LVEF % 64 ± 16 59 ± 14 0.347 
  SVI  L/min/m2 32 ± 10 25 ±7 0.010* 
  RVMI g/m2 53 ± 14 57 ± 20 0.446 
  RVEDVI ml/m2 77 ± 21 95 ± 32 0.036* 
  RVESVI ml/m2 48 ± 22 68 ± 28 0.010* 
  MPA RAC (%) 19.7 (17 - 22) 16.4 (15 - 20) 0.112 
Lung Function 
  
  FEV1 % 75 (59 - 102) 77 (60 - 90) 0.759 
  FVC % 101 (80-123) 98 (77 - 114) 0.402 
  TLC % 101 (94-108) 88 (80-103) 0.019* 
  DLCO %  25 (19-42) 24 (18-31) 0.360 
  Pa02 kPa (n) 7.6 ± 1.4 (23) 7.1 ± 1.6 (40) 0.198 
      
Functional Class % (n) 
   
  I/II 16.1 (5) 8.8 (5) ns 
  III 74.2 (23) 63.2 (36)  
  IV 9.7 (3) 28.0 (16)  
6MWD m 
     (n) 
226 ± 114 
(30) 
188 ± 93 
(46) 
0.117 
NTproBNP pg/ml 
     (n) 
1051 (239 – 2741) 
(19) 
2474 (1357 – 6883) 
(49) 
0.002** 
∆ NTproBNP pg/ml 0.0 (-609 - +325) (19) -179 (-1378 - +637) (37) 0.809 
∆ 6MWD m 27 (-29 - +80) (29) 31 (-32 - +73) (30) 0.958 
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Table 3-12. Univariate and multivariate cox proportional hazard analysis of prognostic factors in severe PH/lung disease in comparison to IPAH. 
Variable Univariate model Multivariate model 
 IPAH Severe PH/Lung disease IPAH Severe PH/Lung disease 
 HR(95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Age 1.047 (1.002-1.074) 0.001 1.033 (1.009-1.058) 0.007 1.012 (0.981-1.043) 0.460 1.017 (0.992-1.042) 0.184 
Sex 0.911 (0.383-2.165) 0.833 0.630 (0.430-0.986) 0.043 0.339 (0.120-0.952) 0.040 0.649 (0.402-1.048) 0.077 
6MWD 0.994 (0.990-0.998) 0.003 0.998 (0.995-1.000) 0.056 0.994 (0.998-0.999) 0.020   
NTproBNP 1.066 (0.756 -1.503) 0.717 1.445 (1.152-1.813) 0.001   1.277 (0.990-1.139) 0.059 
Haemodynamic Variables      
mPAP 1.005 (0.976 –1.034) 0.744 0.986 (0.965-1.008) 0.222     
RAP 1.006 (0.942-1.075) 0.855 1.087 (1.044-1.133) <0.0001   1.081 (1.026-1.139) 0.003 
PVR 1.009  (0.950-1.072) 0.767 1.030 (0.986-1.076) 0.185 1.036 (0.964-1.113) 0.335 0.930 (0.864-1.001) 0.052 
PVRI 1.004 (0.970-1.039) 0.813 1.039 (1.011-1.068) 0.006     
CI 0.912 (0.436-1.905) 0.805 0.324 (0.194-0.540) <0.0001   0.350 (0.167-0.696) 0.003 
PAWP 0.964 (0.872-1.066) 0.477 1.000 (0.934-1.071) 0.998     
SV02 0.989 (0.948-1.032) 0.605 0.974 (0.953-0.996) 0.021     
SV/PP 0.537 (0.174-1.650) 0.278 0.517 (0.288-0.929) 0.027     
Lung Function        
DLCO 0.954 (0.934-0.975) <0.0001 0.977 (0.956-0.998) 0.030 0.966 (0.941-0.992) 0.011   
Pa02 0.808 (0.597-1.094) 0.168 0.798 (0.642-0.991) 0.041     
         
CMR data is not included as only 58/124 patients had CMR data. The analysis of this subset can be seen in table 3-14 
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Table 3-13.Univariate cox proportional hazards analysis of prognostic factors according to lung disease phenotype associated with severe PH. 
Variable ILD CPFE Emphysema COPD 
 HR(95%CI) P value HR(95%CI) P value HR(95%CI) P value HR(95%CI) P value 
Age 1.011 (0.964 – 1.061) 0.641 1.015 (0.950 – 1.086) 0.655 1.036 (0.985 - 1.089) 0.173 1.051 (1.003-1.101) 0.037 
Sex  ♂ = 0 0.900 (0.289 – 2.800) 0.856 1.149 (0.458 – 2.881) 0.767 1.022 (0.432 – 2.418) 0.961 0.303 (0.126-0.730) 0.008 
6MWD 0.955 (0.989 - 1.00) 0.061 0.999 (0.991 – 1.008) 0.897 0.994 (0.990-0.998) 0.003 0.999 (0.996-1.003) 0.722 
NTproBNP 1.424 (0.750 – 2.702) 0.280 1.857 (1.149 - 3.000) 0.011 1.514 (0.941 – 2.436) 0.088 1.385(0.898-2.137) 0.140 
Haemodynamics        
mPAP 0.975 (0.916 – 1.038) 0.430 1.024 (0.973 – 1.078) 0.359 1.026 (0.975 – 1.079) 0.323 0.972 (0.939-1.006) 0.107 
RAP 1.094 (0.997 - 1.200) 0.058 1.113 (1.029 - 1.204) 0.007 1.374 (1.182 - 1.597) <0.0001 1.018 (0.941-1.101) 0.654 
PVRi 1.063 (0.959 – 1.177) 0.245 1.078 (1.005 - 1.157) 0.036 1.138 (1.053 - 1.229) 0.001 1.004 (0.960-1.050) 0.853 
CI 0.098 (0.130 - 0.733) 0.024 0.276 (0.083 - 0.912) 0.035 0.141 (0.039 - 0.512) 0.003 0.471 (0.213-1.039) 0.062 
PAWP 1.254 (1.006 - 1.562) 0.044 1.018 (0.879 – 1.179) 0.815 0.909 (0.788 – 1.049) 0.192 0.927 (0.814-1.056) 0.255 
SVO2 0.937 (0.873 - 1.005) 0.068 0.936 (0.898 - 0.977) 0.002 0.972 (0.929 – 1.017) 0.215 0.988 (0.949-1.028) 0.548 
SV/PP 1.853 (0.126 – 26.859) 0.659 0.252 (0.061 - 1.048) 0.058 0.037 (0.005 - 0.235) 0.001 1.174 (0.553-2.493) 0.677 
Lung Function        
FEV1   1.001 (0.982 – 1.021) 0.891 0.995 (0.971 – 1.012) 0.688 1.019 (0.989-1.051) 0.219 
FVC 0.974 (0.938-1.012) 0.177       
DLCO 0.955(0.898-1.046) 0.146 1.022 (0.953 – 1.096) 0.539 0.951 (0.900 - 1.005) 0.077 0.976 (0.945-1.009) 0.152 
CMR data is not included as only 58/124 patients had CMR data. The analysis of this subset can be seen in table 3-14 
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Table 3-14. Indices of right and left ventricular structure & function as prognostic factors in 
severe PH associated with chronic lung disease. 
 
Variable Univariate model Multivariate model 
HR (95%CI) P value HR (95%CI) P value 
RVEF 0.939(0.907-0.972) <0.0001 0.946 (0.907-0.986) 0.009 
RVEDVI 1.014(1.003-1.026) 0.017   
RVESVI 1.019(1.006-1.031) 0.003   
RVMI 1.030(1.009-1.051) 0.004   
LVEF 0.975(0.951-0.999) 0.040   
LVEDVI 0.993(0.972-1.015) 0.525   
LVMI 1.005(0.981-1.030) 0.682   
SVI 0.939(0.897-0.983) 0.007 0.943 (0.888-1.001) 0.053 
In multivariate analysis with age, sex, PVRI and SVI, lower RVEF was an independent predictor of 
poorer prognosis. 
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3.4.4 Response to PH therapies 
In those treated with pulmonary vasodilators due to a diagnosis of either IPAH or 
severe PH/lung disease, 29 patients (9 IPAH, 4 COPD, 5 CPFE, 2 ILD and 9 
emphysema/preserved FEV1) were unable to perform a 6MWT at diagnosis. 18 
patients died prior to their first follow up (4 IPAH, 4 emphysema/preserved FEV1, 
1 CPFE, 6 ILD, 3 COPD). Of these, 9 were unable to carry out a 6MWT at diagnosis. 
Median time to follow up did not differ between IPAH and lung disease groups (111 
(97-150) vs 111(96-148) days p=0.888). Exercise oxygen saturation data was 
available for 47 patients with severe PH/lung disease. No increase in desaturation 
on exercise following PH therapy was observed (-8% (-30 - -6) to -9 %(-15- -6) 
p=0.834). 
Baseline and follow up 6MWD, NTproBNP and NYHA FC for all the groups are shown 
in table 3-15. Figures 3.22 and 3.23 show the median ∆6MWD and ∆NTproBNP 
following PH treatment for each group.  
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Table 3-15. Baseline and follow up 6MWD, NTproBNP and NYHA FC after a minimum of 3 
months of therapy for severe PH/lung disease patients in comparison to IPAH. 
 
Group Baseline Follow up P value 
IPAH 
6MWD (m) n=58 
NTproBNP n=42 
NYHA FC n=63 
 
337±114 
1085 (449-2545) 
17/41/4 
 
376±97 
788 (289-1655) 
30/29/3 
 
<0.0001*** 
0.001** 
0.055 
Lung Disease (all) 
6MWD (m) n=80 
NTproBNP pg/ml n=82 
NYHA FC n=98 
 
224±102 
2245 (850-4295) 
12/75/13 
 
243 ±102 
1667 (614-3590) 
18/74/8 
 
0.032* 
0.008** 
0.302 
COPD 
6MWD (m) n=34 
NTproBNP pg/ml n=28 
NYHA FC n=32 
 
220±112 
2501 (514-4213) 
7/23/4 
 
245±107 
1938 (399-3817) 
11/21/2 
 
0.033* 
0.063 
0.439 
CPFE 
6MWD (m) n=16 
NTproBNP pg/ml n=21 
NYHA FC n=23 
 
191±70 
2258 (1153-5992) 
0/19/4 
 
230±94 
2471 (461-3325)+ 
1/20/2 
 
0.103 
0.015* 
0.429 
Emphysema 
6MWD (m) n=19 
NTproBNP pg/ml n=19 
NYHA FC n=27 
 
237±102 
1378 (440-3881) 
1/23/3 
 
224±88 
1449 (663-3082) 
1/24/2 
 
0.574 
0.365 
0.895 
ILD    
6MWD (m) n=11 261±100 287±119 0.180 
NTproBNP pg/ml n=13 2474 (1085-5540) 1204 (750-3308) 0.011* 
NYHA FC 4/10/2 5/9/2 0.921 
    
    
Severe PH/mild lung disease (n=32)   
6MWD (m) n=22 255±109 259±118 0.788 
NTproBNP pg/ml n=21 1852 (645-5594) 2073(599-3308) 0.110 
NYHA FC 6/19/4 6/19/4 ns 
Severe PH/severe lung disease (n=58)   
6MWD (m) n=36 191±85 224±100 0.009* 
NTproBNP pg/ml n=44 3360 (1233-6831) 2536 (484-4309) 0.0009** 
NYHA FC 2/36/8 7/36/3 0.08 
    
Subgroup analysis according to phenotype of lung disease and severity of lung disease shown. 
Data displayed as mean ± SD or median (IQR) according to data distribution. Paired statistical 
analysis performed. 
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3.4.4.1 Six minute walk test 
58 patients with IPAH and 80 patients with severe PH/lung disease had paired 
6MWT observations for analysis. 6MWD improved in the IPAH cohort, from 337 ± 
114 m at baseline to 376 ± 97 m (p <0.0001) and in those with severe PH/lung 
disease from 224 ± 102 m to 243 ± 102m, p = 0.032). 6MWD improved by 31m after 
3 months of PH targeted therapies in those with IPAH compared with 24m in those 
with severe PH/lung disease. Figure 3.22 shows the median ∆6MWD for IPAH and 
lung disease phenotype groups. There was no significant difference in ∆6MWD 
between the groups with the exception of fall in 6MWD in emphysema group 
(median -17m) in comparison to IPAH (+31m), p = 0.033.  
Significant improvement in 6MWD according to lung disease phenotype was only 
seen in those with COPD, (220 + 112 m to 245 ± 107 m p = 0.033). 6MWD improved 
from 185 ± 85m to 216 ± 100m, p=0.021, in those with severe PH/severe lung 
disease in comparison to those with severe PH/mild lung disease where 6MWD was 
unchanged (255 ± 109 m to 259 ± 118 m). 
6MWD increased in 49/80 severe PH/lung disease patients by average 59m (range 
8 – 200m) and was unchanged or decreased in 31/80 patients, average -33m (range 
-195 to 0m). No baseline characteristic predicted likelihood of an improvement in 
6MWD with therapy, with the exception of a lower baseline 6MWD (203m vs 257m, 
p=0.018). Table 3-16 displays the clinical characteristics of patients according to 
change in 6MWD.
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Figure 3.22 ∆6MWD with PH therapy in IPAH and severe PH/lung disease patients. 
 
Median values shown. No significant difference across groups demonstrated, ANOVA p = 0.170, 
post hoc analysis, no difference in ∆6MWD between IPAH and lung disease patients (p = 0.236). 
only Emphysema group displayed fall in ∆6MWD in comparison to IPAH, p = 0.033. No significant 
difference between lung disease phenotypes demonstrated.
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3.4.4.2 NTproBNP 
42 IPAH patients and 78 patients with severe PH/lung disease had paired NTproBNP 
levels for analysis. NTproBNP fell following introduction of PH therapy in both 
groups, from 1085 (449 - 2545) pg/ml to 788 (289 - 1655) pg/ml (p<0.0001) in 
those with IPAH and from 2245 (850 – 4295) to 1667 (614 – 3590) pg/ml in those 
with severe PH/lung disease (p = 0.008). NTproBNP improved by an average -396 
(-1133 - 97) pg/ml in IPAH and by -211 (-1311 - 205) pg/ml in severe PH/lung 
disease. 
On subgroup analysis by lung disease phenotype, significant improvement in level 
of NTproBNP were seen in those with CPFE (median -596 pg/ml) and ILD (median 
-390 pg/ml) only. Figure 3.23 shows the median ∆NTproBNP following PH therapy 
for each phenotype. There was no significant difference in levels of ∆NTproBNP 
across groups (p = 0.194). Emphysema phenotype showed no improvement in 
NTproBNP (∆NTproBNP +38pg/mL), significant difference in comparison to IPAH 
(p=0.022), ILD (p=0.024) and CPFE (p=0.037) where median ∆NTproBNP were -396, 
-412 and -596 pg/mL respectively.  
NTproBNP levels fell in those classed as having severe PH/severe lung disease from 
3360 (1233-6831) to 2536 (484 – 4309) pg/ml, p = 0.0009 but not those with severe 
PH/mild lung disease. 
NTproBNP fell in 48/82 severe PH/lung disease patients, average -1034 (range -
18101 to -4) pg/ml, and increased or remained static but elevated in 34/82, 
average 333 (range 0 to -17913) pg/ml. No baseline clinical characteristics 
predicted reduction in NTproBNP with PH therapy (data shown in table 3-16).  
167 
 
 
 
Figure 3.23 ∆NTproBNP with PH therapy for IPAH patients in comparison to severe PH/lung 
disease phenotypes 
 
No significant difference was demonstrated across groups (Kruskall Wallace p=0.194). Similar levels 
of ∆NTproBNP observed between IPAH and lung disease patients (-211 and -396pg/mL respectively, 
p=0.526). On post hoc analysis, Emphysema phenotype demonstrated significant increase in 
NTproBNP (median +38pg/mL) in comparison to IPAH (p=0.022), CPFE (p=0.037), ILD (p=0.024) 
with trend in comparison to COPD (p=0.065). There was no difference between other phenotypes. 
 
 Table 3-16 Comparative analysis of baseline characteristics of severe PH/lung disease patients with improvement in 6MWD or NTproBNP after PH therapy 
against nonresponders. 
Variable 6MWD  NTproBNP 
 increase decrease p-value  decrease increase p-value 
n 49 31   48 34  
Age (years) 65 ± 11 65 ± 10 0.707  66 ± 12 68 ± 8 0.499 
Phenotype % (n) 
Emphysema 
COPD 
CPFE 
ILD 
 
16.3 (8) 
50 (24) 
20.4 (10) 
14.3 (7) 
 
35.5 (11) 
32.3 (10) 
19.3 (6) 
12.9 (4) 
 
0.239 
  
16.7 (8) 
33.3 (16) 
29.2 (14) 
20.8 (10) 
 
32.4 (11) 
38.2 (13) 
20.6 (7) 
8.8 (3) 
 
0.200 
mPAP (mmHg) 45 (39-54) 44 (42-51) 0.812  46 (41-51) 43 (39-50) 0.437 
RAP (mmHg) 7 ± 4 8 ± 4 0.187  8 ± 5 8 ± 5 0.749 
PVR (Wood Units) 10 (8-13) 10 (8-13) 0.924  11.3 (9 -15) 9.3 (8-16) 0.451 
CI (l/min/m2) 2.1 ± 0.5 2.1 ± 0.6 0.915  1.9 ± 0.5 2.0 ± 0.7 0.613 
SV/PP 1.0 ± 0.4 1.0 ± 0.4 0.874  1.0 ± 0.5 1.0 ± 0.5 0.947 
FEV1 (%) 69 (54-85) 80 (59-98) 0.168  74 (50 -95) 81 (66-93) 0.220 
FEV1/FVC (%) 58 (49-67) 63 (56-69) 0.171  63 (56-71) 59 (53-68) 0.548 
DLCO (%) 25 (21-36) 29 (21-37) 0.762  26 (18-36) (41) 24 (21-33) (32) 0.938 
Pa02 (KPa) 7.6 ± 1.4 7.7 ± 1.9 0.841  7.6 ± 1.2 7.4 ± 2.2 0.659 
6MWD (m) 203 ± 101 257 ± 94 0.018*  189 ± 86 (40) 231 ± 126 (30) 0.108 
NTproBNP (pg/ml) 1715 (506-3967) (34) 1559 (485-2674) (24) 0.528  2867 (1213 – 6041) 1415 (361-2915) 0.011* 
RVEF(%) 36 ± 14 (26) 33 ± 11 (20) 0.408  30 ± 12 (26) 36 ± 13 (14) 0.126 
RVEDVI (ml/m2) 86 ± 30 93 ± 25 0.397  89 ± 26 99 ± 36 0.288 
SVI (ml/min/m2) 29 ± 9 28 ± 9 0.863  26 ± 6 29 ± 9 0.163 
No variable differed between responders and non responders, defined by improvement in 6MWD or NTproBNP. It was not therefore possible to identify those patients 
likely to benefit from PH specific therapy using baseline characteristics.
169 
 
3.4.4.3 NYHA FC 
Paired functional class status was available for 93 patients with severe PH/lung 
disease and 62 IPAH patients. After a minimum of 3 months of PH treatment, 77% 
(n=72) remained in FC III and 9% (n=8) in FC IV in those with severe PH/lung disease 
with no improvement in comparison to baseline (p=0.421). In IPAH, 47% (n=29) 
remained in FC III and 5% (n=3) in Fc IV at follow up. Although trend toward 
improvement was demonstrated this did not reach statistical significance 
(p=0.055). No improvement in FC was demonstrated on subgroup analysis by either 
lung disease phenotype or severity of the lung disease. 
3.4.4.4 Right ventricular function 
11 patients with PH associated with lung disease underwent CMR at diagnosis and 
after minimum 3 months of PH therapy. Patient demographics are shown in table 
3-17. RVEF remained unchanged, 39 ± 15 % to 40 ± 15 % p=0.72. There was a trend 
towards improvement in LV filling, LVEDVI increased from 48 ± 12 to 53 ± 12 
ml/m2, p = 0.054. SV increased from 53 ± 17 ml to 62 ± 14 ml, p = 0.004. There 
was no relationship between change in SV and change in 6MWD (p = 0.39). Figure 
3.24 displays the paired analysis. 
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Figure 3.24 Change in stroke volume and RV function after PH therapy in patients with severe 
PH and lung disease. 
 
Significant improvement in stroke volume [a] but not RV function (p=0.720) [b] and trend towards 
improved LV filling (LVEDVI [c]) demonstrated in paired analysis. 
  
171 
 
Table 3-17 Characteristics of severe PH/lung disease patients with follow up cardiac MRI 
after PH therapy. 
 
Patient 
ID 
Diagnosis Age Sex mPAP 
mmHg 
PVR 
w.u 
CI 
l/min 
FEV1 
% 
DLCO 
% 
Therapy ∆SV 
mL 
1 COPD 35 M 73 24 1.3 58 61 ERA 16 
2 COPD 61 M 35 5.9 2.9 35 25 ERA -2 
3 COPD 61 F 53 10.2 1.9 59 31 PDE5i 13 
4 Emphysema 80 F 42 10.6 1.8 126 21 PDE5i 11 
5 Emphysema 61 M 50 11 1.9 78 20 PDE5i 8 
6 Emphysema 71 M 42 8.1 2.5 101 40 ERA -7 
7 CPFE 66 M 29 4.9 2.3 97 27 PDE5i 15 
8 CPFE 54 M 65 19.5 1.8 30 15 PDE5i 20 
9 CPFE 70 M 38 6.2 2.2 75 14 PDE5i 15 
10 ILD 74 F 34 4.4 3.1 106 33 PDE5i 4 
11 ILD 42 M 55 10.1 2.3 98 26 PDE5i 10 
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There was no difference in survival between severe PH/lung disease patients with 
an increase in 6MWD on PH therapy at follow up and those without (1 and 3 yr 
survival 87% V 77% and 42% v 46% respectively, p = 0.630). ROC analysis, shown in 
figure 3.26, determined an optimal threshold of 193m walked at follow up (youden 
index 0.45). Distance walked greater than this was not associated with improved 
survival (shown in figure 3.25, p = 0.08), but inability to perform a 6MWT despite 
therapy was significantly predictive of worse survival (p < 0.0001). KM curve for 
survival according to 6MWD at follow up is shown in figure 3.25.  
∆6MWD did not predict survival in those with lung disease on either univariate (p 
= 0.820) or multivariate analysis in a model with age, sex and mPAP (p = 0.427).  
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Figure 3.25. Kaplan Meier survival curves described survival in severe PH/lung disease 
according to 6MWD at follow up in comparison to those unable to perform 6MWT 
 
Patients unable to perform a 6MWT had reduced survival in comparison to both those 6MWD 
≤193m and >193m, logrank p = <0.0001 for both), but similar survival observed in walkers (p = 
0.08). 
 
 
Figure 3.26 Receiver operator curve for sensitivity and specificity of 6MWD whilst 
undergoing PH therapy to determine risk of death at 1 year. 
 
Optimal threshold < 193m walked determined by Youden analysis. 
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Survival did not differ in severe PH/lung disease patients whose NTproBNP fell (by 
any amount) with PH therapy compared to those who did not (1 yr survival 76 % v 
67 % and 3 yr 38 % v 25 % respectively p = 0.430).  
In a model with age, sex, PVR and RAP, ∆NTproBNP independently predicted 
survival in those with severe PH/ lung disease (HR 1.479 95%CI 1.045-2.093, 
p=0.027). 
Receiver operator curve for survival at 1 year (shown in figure 3.28) identified an 
optimal threshold of <1222 pg/ml whilst on therapy (youden index 0.53). 
NTproBNP > 1222 pg/ml 91% sensitive and 62% specific for risk of death. 
A level of NTproBNP < 1222 pg/ml was associated with improved survival (1 and 3 
year survival 95 % versus 54 % and 52 % versus 21% respectively, p < 0.0001). Figure 
3.27 shows KM survival curves. 
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Figure 3.27. Kaplan Meier survival curves describing outcome in severe PH/lung disease 
according to level of NTproBNP at follow up. 
 
 
Figure 3.28. Receiver operator curve to identify optimal threshold level of NTproBNP at 
follow up for increased risk of death at 1 year. 
 
Threshold value of >1222 pg/mL determined by Youden analysis. 
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3.5 Discussion 
The clinical characteristics described in this chapter demonstrate that mild to 
moderate pulmonary hypertension in chronic lung disease is characterised by early 
increases in vascular stiffness with adaptive RVH but preserved RV function in 
agreement with previous small studies (359). The development of elevation in 
pulmonary artery pressure is associated with worse survival, and deterioration in 
functional status defined by a drop in 6MWD. Consequently, survival in mild to 
moderate PH associated with lung disease is predicted by mPAP and pulmonary 
artery compliance (SV/PP). Severe PH associated with lung disease however, 
shares many characteristics with IPAH, with evidence of right ventricular failure. 
In the latter, it is indices of RV function, such as RAP, CI or RVEF rather than 
pulmonary artery pressure that relates to survival. This has implications for 
screening for PH in these populations. As described in results section 3.4.2, non 
invasive screening for PH is best approached by a combination of echo and index 
of vascular stiffness (such as relative area change of the main pulmonary artery 
by CMR) and severe PH by combination of echo and parameters of RV dysfunction, 
such as RV mass or NTproBNP. 
3.5.1 Characteristics and right ventricular dysfunction 
Severe PH in lung disease patients described in this chapter demonstrated severe 
hypoxaemia, grossly impaired DLCO, relatively mild impairment in lung function 
and more severe functional impairment measured by NYHA FC and 6MWD than 
IPAH patients despite similar haemodynamics. Similar characteristics have 
previously been reported in patients with COPD and severe PH (208, 356) and in 
small case series of smokers with emphysema but preserved lung volumes (375). 
The severity of lung function impairment (FEV1 in COPD or FVC in ILD) did not 
correlate with mPAP nor have prognostic value in our study. FEV1 did correlate 
with RVEF, and Pa02 with vascular compliance and RVEF, and inversely with mPAP. 
Correlations between Pa02 or lung function impairment and PAP have been 
described variably in the literature (204, 206, 334). In one study, Pa02 explained 
only 25% of the variance in PAP suggesting impairment of gas exchange is not the 
main determinant in development of PH in chronic lung disease (376). Scharf et al 
showed no relationship between right ventricular EF or volumes with measures of 
airflow obstruction (204) and minimally with Pa02 (r2=0.041). In IPF, poor or no 
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correlation between severity of PH and lung function impairment or CT fibrosis 
score have also been described (219, 377). The limited dispersion of FEV1 and Pa02 
values and use of LTOT in our cohort could have affected correlation. However, 
previous studies suggest only a weak or even no relationship between impaired 
lung function and PAP or RV function. It has been postulated that loss of >80% of 
normal lung function is required to cause a rise in PAP >25mmHg. The severe PH 
seen in or cohort therefore is unlikely to be predominantly driven by lung function 
impairment and alternate explanations for progressive vascular remodelling and 
characteristic similarities with IPAH.  
3.5.1.1 Imaging right ventricular function in chronic lung disease 
Good correlation occurred between echocardiography and CMR imaging of right 
ventricle dilatation, (RVEDD with RVEDVI) and to a lesser extent TAPSE with RVEF, 
in chronic lung disease patients. The latter is not surprising, as TAPSE only assesses 
longitudinal shortening and ventricular ejection, particularly in PH, has significant 
impairment from transverse contraction and TR. The strong relationship between 
RV dysfunction and survival in this chapter demonstrates importance of employing 
imaging modalities to assess RV function when monitoring these patients. 
3.5.1.2 Vascular stiffness 
Good correlation between cardiac MRI index of vascular stiffness (RAC MPA) and 
invasive SV/PP was seen. Both measures were found to have prognostic 
significance and additionally RAC was shown to reliably detect the presence of 
PH. Cardiac MRI therefore cannot only be applied to assess RV function in chronic 
lung disease, but also vascular stiffness in a single sitting. 
3.5.1.3 Functional status 
mPAP, RAP, SV/PP and DLCO independently predicted distance walked on 6MWT 
in all lung disease patients. This suggests that in addition to predicting survival, 
haemodynamics are a better predictor of functional status. This is in agreement 
with previous literature in severe PH/lung disease demonstrating more severe 
exertional dyspnoea than COPD patients with more marked airflow obstruction but 
lower PAP (208), and exhausted circulatory but residual breathing reserve at end 
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exercise (378). mPAP has also been shown to independently predict 6MWD in large 
cohort COPD patients some of whom had PH (207). 
3.5.1.4 NTproBNP 
Levels of NTproBNP were comparable in chronic lung disease patients without PH 
and those with mild-moderate PH, but were markedly elevated in the severe PH 
group. Good correlations with CMR determined RV dilatation and dysfunction 
(RVEDVI and RVEF respectively) in chronic lung disease patients without left 
ventricular dysfunction were demonstrated. Previous studies have shown levels of 
NTproBNP (or BNP) to be elevated in chronic lung disease and relate to left 
ventricular function, or left of right ventricular function during acute 
exacerbations (368, 371).  
NTproBNP was higher in severe PH/lung disease patients than IPAH patients 
despite similar haemodynamics. Furthermore, RVMI was higher in those with IPAH. 
This could suggest a greater degree of right ventricular dysfunction and impaired 
adaptation to afterload in lung disease patients. There was no significant 
difference in renal function to account for the higher NTproBNP (MDRD eGFR 63 
(51-82) vs 71 (53-82) ml/min/1.73m2 p=0.340). Lung disease patients were 
significantly older (67 vs 49 years) and NTproBNP has been shown to increase with 
age, +36% in men and +15% in females per 8.4 years in one study (379). PVR was 
higher (and therefore RV afterload) in the IPAH patients whom underwent MRI, 
and therefore we would expect a greater degree of RV adaptation. Additionally, 
RVMI has been shown to fall with age, a 5% reduction per decade of age has been 
shown (101). Differences in the demographics of the populations may therefore 
account for the apparent difference in NTproBNP and RVMI.   
3.5.2 Imaging the right ventricle to detect PH in chronic lung 
disease 
Echocardiography estimated sPAP has been shown previously to have low 
sensitivity, specificity and predictive values in patients with chronic lung disease, 
with success rates of 24-77% in estimating PAP in the literature (199, 380-383). 
When estimation of sPAP is possible, in COPD and pulmonary fibrosis, positive 
predictive values of 32% and 68% and negative predictive vales 93% and 67% 
respectively have been reported in the literature (199, 384). In our hands, 
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echocardiography estimated sPAP had a 91% PPV and 83% NPV for PH, and 
correlations between echocardiography sPAP and sPAP at right heart 
catheterisation were similar in both IPAH and chronic lung disease patients. It is 
however worth noting that the population described by this chapter is subject to 
selection bias, as all patients were assessed at a tertiary pulmonary hypertension 
centre due to a suspicion of pulmonary hypertension which largely would be as a 
result of echocardiography raised sPAP. There were therefore fewer patients with 
normal pulmonary artery pressures, and fewer still in whom sPAP could not be 
estimated. For severe PH, we found 78% PPV and 71% NPV with echocardiography 
estimated sPAP, reflecting poorer accuracy at higher levels of PH. This can be 
explained by greater degree of functional tricuspid regurgitation as right 
ventricular dilatation and dysfunction develops in severe PH. Regardless of the 
severity of PH, the non invasive detection of either PH or severe PH in chronic 
lung disease patients was improved by the addition of a second imaging method, 
RAC MPA in mild PH, and RVM or addition of biomarker NTproBNP, in severe PH. 
Additionally, cardiac MRI could be used to detect PH in those chronic lung disease 
patients where echocardiography is unable to estimate sPAP as RAC MPA and 
ventricular mass index (VMI) had comparable PPV. In severe PH, NTproBNP >230 
pg/ml or RAC MPA <32.5 % could be useful detection tools as they performed 
superiorly to echocardiography in this population. 
3.5.3 Survival and prognostic variables 
The development of pulmonary hypertension in patients with chronic lung disease 
was associated with significant impairment in prognosis. Interestingly, survival in 
those with mild-moderate PH and those with severe PH treated with pulmonary 
vasodilator therapy did not differ. Chaouat et al previously demonstrated worse 
survival in COPD patients with severe PH (208), which could suggest that 
pulmonary vasodilator therapy improved outcome in those with severe PH. 
Without a control arm it is impossible to conclude this, but suggests need for such 
study to be performed. Survival in patients with severe PH/lung disease in 
comparison to IPAH was reduced, despite age adjustment with ILD patients 
displayed poorer survival in comparison to other lung phenotypes.  
Our results show that pulmonary haemodynamics and right ventricular dysfunction 
are stronger predictors of survival than indices of lung function in chronic lung 
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disease. This is in agreement with previous studies of COPD patients receiving 
LTOT which reported no influence of FEV1 or Pa02 on survival (210, 385, 386). A 
PAP above 25 mmHg in LTOT treated chronic lung disease patients was associated 
with lower survival at 5 years, 33 % vs 66 % p<0.0001 (210) and prognostic 
significance of a raised mPAP in COPD both with and without LTOT has been 
recurrently reported (335, 376, 385) with threshold values of 30 mmHg or 40 
mmHg to define those at significantly increased risk (208, 387). In IPF, even a 
marginally elevated mPAP above 17 mmHg associated with reduced survival (213) 
and mPAP shown to be an independent predictor of survival (214). In the entire 
cohort of chronic lung disease patients included in this chapter, RV dysfunction 
whether assessed by invasive haemodynamics (RAP, CI), echocardiography 
(RVEDD), cardiac MRI (RVEF, RVESVI and SVI) or NTproBNP all related to prognosis. 
In patients with mild-moderate PH, mPAP was an independent predictor of survival 
in agreement with the studies above. In those with severe PH raised right atrial 
pressure and reduced cardiac index and ejection fraction were associated with 
poorer outcome, which is similar to studies of prognostic variables in pulmonary 
arterial hypertension.  
Reduced LVEF as a prognostic variable in severe PH with lung disease occurred 
without clinical left ventricular dysfunction and normal PAWP. Evidence of 
subclinical LV dysfunction on echocardiogram has been reported in COPD (388) 
alongside increased risk of cardiovascular abnormalities including increased 
arterial stiffness, (316, 389, 390) ischaemic heart disease and heart failure. LV 
dysfunction has been shown to relate to fat free mass and IL-6 linking to the 
catabolic-inflammatory COPD phenotype, and increased arterial stiffness (388). 
51/55 patients whom underwent CMR were smokers with an average 40 pack year 
history. Smoking has been shown to have acute effects on aortic pulse wave 
velocity (a measure of vascular stiffness) (391) and LV function (392).  
The ASPIRE registry reported similar 1 year but worse 3 year survival rates of 70% 
and 33% compared to 79% and 47% in our cohort (ILD patients excluded for 
comparison) respectively. 43 of 59 patients received PH therapy, were of similar 
age to our cohort however had a greater degree of pulmonary function impairment 
and included patients with elevated PAWP indicating left ventricular dysfunction. 
In addition severe PH was defined by an mPAP ≥40mmHg. ASPIRE reported SV02, 
age, FC IV and DLCO as independent predictors of survival however included 
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patients with mild and moderate PH in the survival analysis (356). Cottin et al 
reported a 1 year survival rate of 60% in patients with PH and CPFE syndrome, of 
whom 24/40 (60%) received PH therapy (227). Patients with mild to moderate PH 
(mPAP 24-56 mmHg) were also included, higher PVR, lower CI and DLCO were 
shown to predicted worse survival. Direct comparison with this cohort is therefore 
not possible, but both studies agree haemodynamics are more important 
determinants of prognosis. 
3.5.4 Response to PH therapy 
There is no evidence in the literature to support the use of pulmonary vasodilators 
in severe PH with lung disease. As discussed in section 3.1.3 previous studies have 
been of small sample size, did not always include RHC derived mPAP, and included 
patients with mild or even no PH with resultant contradictory conclusions (340, 
342). Concern of inducing worse hypoxaemia has been raised by previous 
vasodilator studies in COPD patients demonstrating a fall in Pa02 due to increased 
VQ mismatch (343). We did not demonstrate a deterioration in oxygen 
desaturation on 6MWT, although this should be interpreted with caution given the 
retrospective analysis of this data.  
Functional capacity defined by 6MWD (but not NYHA FC) improved, but to a lesser 
extent than IPAH patients despite similar haemodynamic characteristics at 
baseline. We did not demonstrate a survival benefit in those with an improved 
6MWD on treatment. This should be interpreted with caution as it possible that 
chronic lung disease patients are more ventilatory limited so an alternate endpoint 
should be considered to determine efficacy. It is also possible that treatment led 
to a stabilisation of the clinical condition as 6MWD did not fall at follow up which 
previous smaller studies in PH associated with lung disease have suggested (355). 
A prospective trial with an untreated control arm could investigate this possibility 
further.   
Improvement in NTproBNP, a marker of RV dysfunction is encouraging. Previous 
studies have not used this biomarker as outcome measure in PH associated with 
lung disease. NTproBNP correlated with RVEF and RVEDVI so we can speculate that 
disease targeted therapy may lead to improved outcome in those with improved 
RV function. Furthermore, in the small subgroup with follow up CMR study, 
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improvement in stroke volume (an indices of RV function) was demonstrated. 
Interestingly in a small study of COPD patients with mild or no associated PH no 
change in SV was seen after sildenafil administration (340), possibly suggesting 
severe PH associated with lung disease does respond differently to PH therapy. In 
IPAH, NTproBNP has been shown to correlate with RV function (297) and changes 
in serial NTproBNP with treatment have been shown to predict survival (301). As 
discussed in section 3.1.4.1 NTproBNP has been shown to predict outcome 
following acute exacerbations of airways disease, (365, 366, 393) identify those 
with concurrent LV dysfunction (393, 394) and as a screening tool for PH in COPD 
(370) and we have shown that RV function predicts survival in the patients 
described in this chapter. ∆NTproBNP but not ∆6MWD predicted survival, and a 
level of NTproBNP below 1222pg/ml whilst on PH therapy was associated with 
improved survival. This could suggest NTproBNP may be a better outcome measure 
than 6MWD in therapeutic trials involving patients with PH associated with lung 
disease where exercise capacity will be ventilatory limited in addition to 
cardiovascular limitation. The negative correlation observed here between FEV1 
and 6MWD in those with COPD could support this ventilatory limitation (378).  
The patients described in this chapter represent the largest treated population of 
severe PH in lung disease and further explores the impact of lung disease 
phenotype and severity on response to vasodilator therapy. The 
Emphysema/preserved FEV1 phenotype responded poorly to PH therapy, with non 
significant fall in 6MWD and increase in NTproBNP. Suggested mechanisms leading 
to the development of PH include vascular ablation, excessive hypoxic pulmonary 
vasoconstriction, pulmonary artery remodelling and endothelial dysfunction from 
inflammation and exposure to cigarette smoke (235). One hypothesis may be that 
the emphysema phenotype demonstrated poorer response to therapy because the 
pathophysiology may relate more to vascular loss than potentially treatment 
responsive vascular dysfunction.  
Surprisingly using the classification suggested by Seeger et al at the 5th world PH 
symposium demonstrated no difference in survival between severe PH/mild lung 
disease and severe PH/severe lung disease groups. In addition, those with severe-
PH/severe lung disease demonstrated improvements in both 6MWD and NTproBNP 
with therapy whereas those who was classified as having co-existent mild lung 
disease did not. Characteristics of patients improving either 6MWD or NTproBNP 
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did not differ. The severity of lung disease in severe PH therefore cannot reliably 
be used to determine therapeutic response to pulmonary vasodilators. 
Pulmonary haemodynamic data of COPD patients exhibiting PH in the literature 
demonstrates moderate elevations in PVR, but RV preload pressures and CO are 
usually in the normal range. In contrast, large increase in PVR and haemodynamic 
signs of RV dysfunction are commonly reported in PAH patients (142, 208, 335, 
395). The severe PH/lung disease patients described in this chapter however, 
share more characteristics with the latter, and improvement in 6MWD and 
NTproBNP with PAH therapies is perhaps therefore not unexpected. Current 
guidelines have suggested differentiating severe PH/lung disease on basis of 
pressure at RHC (mPAP ≥35mmHg) or degree of associated lung disease, but the 
RV characteristics described in this chapter could suggest it may be better to 
define this by the presence of RV dysfunction rather than a level of pressure.  
3.5.5 Limitations 
This study has several limitations. This was a single centre retrospective 
observational study which allowed for variation in therapy used for each cohort, 
and the numbers of patients in each lung disease phenotype were small. There 
was also no control arm with severe PH and lung disease whom did not receive 
therapy to contrast outcomes. It is possibility that changes in outcome measures 
with treatment may represent regression towards the mean as the only predictor 
of improvement in either NTproBNP or 6MWD was a poorer baseline value (see 
table 3-16). CT evidence of lung disease was based on the multidisciplinary report 
as it was not possible to score the severity of emphysema on CT due to the long 
recruitment period scans were performed at multiple sites with varying acquisition 
protocols. Finally, the lung disease cohort was recruited at a PH tertiary referral 
centre and therefore few patients with normal PA pressure were included.  
3.5.6 Clinical implications 
During the 14 year study period, more patients with coexistent lung disease than 
“pure” IPAH were seen. This could possibly be explained by the large proportion 
of smokers (68%) and older age of the study population (mean age 60). The 
demographics of incident IPAH cases has shown a trend towards increasing age at 
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diagnosis, and increasing presence of comorbid diseases in PH registries (147). In 
the REVEAL registry up to 17% of PAH diagnoses had coexistent COPD (252). This 
highlights the importance of assessing impact of coexistent lung disease on PH 
therapy in efforts to develop management strategies for “real life” patients, many 
of which are excluded in drug trials. 
Clinical guidelines recommend consideration of right heart catheterisation in 
chronic lung disease patients for PH diagnosis with disproportionate functional 
limitation to ventilatory impairment, need for accurate prognostic assessment or 
lung transplantation and when severe PH is suspected by noninvasive measures 
and consideration is being made for recruitment into clinical trial of PH therapies 
(253). The non-invasive screening methods described in this chapter potentially 
could improve identification and recruitment of such patients. 
3.5.7 Conclusions 
The studies described in this chapter demonstrate the importance of imaging right 
ventricular function in patients with pulmonary hypertension and chronic lung 
disease to determine prognosis, as a potential screening tool and to assess 
treatment effect in future therapeutic trials of pulmonary vasodilators. Mild to 
moderate PH in lung disease is characterised by increases in vascular stiffness but 
preserved RV function, whereas severe PH associated with lung disease shares 
many of the phenotypic characteristics of significant RV dysfunction associated 
with pulmonary arterial hypertension. NTproBNP reflects RV dysfunction in severe 
PH lung disease patients, can be used to as a screening tool for severe PH, predict 
survival and change in NTproBNP after PH therapy also predicts survival. This may 
reflect improvement in RV function, and be a useful marker of therapy response 
in future studies. 
In comparison to IPAH patients, patients with severe PH associated with lung 
disease have poorer survival which is not abolished by adjusting for age. PH 
therapy lead to improvements in 6MWD and NTproBNP. Survival and response to 
therapy may vary according to lung phenotype. Further studies with an untreated 
control group may establish if PH therapy has a role in delaying the progression of 
the pulmonary hypertension and improving survival. 
185 
 
Chapter 4 - Right Ventricular (RV) – arterial 
coupling in pulmonary hypertension
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4.1 Introduction 
It has been consistently demonstrated that right ventricular function is a major 
determinant of functional state, exercise capacity and survival in patients with 
pulmonary arterial hypertension (260). As discussed in chapter 1, imaging of RV 
function and structure either by CMR or echocardiogram to determine metrics such 
as ejection fraction or SV (41), invasive measures of RV function RAP or CI and 
biomarkers which reflect RV dysfunction such as NTproBNP have all been 
demonstrated in the literature to predict prognosis in PAH. We have also shown in 
chapter 3 that RV function is additionally a major determinant of outcome in 
patients with severe PH and lung disease. However, uncertainty persists about the 
optimal method to evaluate RV function and what variables might be most 
clinically relevant in these patients (396).  
The gold standard measure of RV systolic functional adaptation to increased 
loading conditions is end-systolic elastance (Ees), (or end-systolic pressure (ESP) 
divided by end-systolic volume (ESV)), corrected for arterial elastance (Ea), (or 
stroke volume (SV) divided by ESP). The Ees/Ea ratio defines RV-arterial coupling, 
or the matching of contractility to afterload. Ees is a measure of RV contractility 
and unlike other measures of RV function is load independent. Ees is chamber 
volume dependent and in animal studies shown to relate to myocardial mass (397)  
Emax is the maximal ventricular elastance described by the maximal ratio of 
ventricular pressure to volume during the cardiac cycle (130) and is regarded as 
the gold standard measure of contractility (396). In the LV (characterised by a 
square PV loop) Emax coincides with ESP and therefore equals ESP/ESV. Ees is 
measured at the upper left corner of a square PV loop and therefore Ees 
approximates Emax (398) . In the normal RV where pulmonary vascular impedence 
is low, the PV loop is triangular in shape, and Emax occurs before the end of 
ejection or end systole. Emax is determined by family of PV loops at decreasing 
venous return. RV-arterial coupling can be determined as a measure of volumes 
provided ESV is measured at Emax and not end ejection. The appearance of the 
PV loop in PAH or the systemic RV resembles the normal LV however (399) and 
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therefore contractility can be approximated by ESP/ESV. Increasing discrepancy 
between Ees and Emax may therefore occur at lower levels of RV afterload. 
Ea is a measure of the total afterload faced by the RV and incorporates resistance, 
compliance and impedance of the pulmonary circulation. The optimal balance 
between RV work and oxygen consumption occurs at an Ees/Ea ratio of 1.5-2 (123, 
260). 
4.1.1 Methods of evaluating RV-arterial coupling 
The reference method for the determination of Ees requires instantaneous and 
simultaneous measurements of RV pressure and volume and generation of a family 
of pressure-volume loops at decreasing venous return (123), as shown in figure 
4.1. Experimentally this is achieved by IVC occlusion, which is associated with 
unacceptable risks for widespread clinical application, and is not practical at the 
bedside.  
 
Figure 4.1 RV pressure-volume loops. 
 
[a] shows PV loops at decreasing levels of venous return (usually created by IVC occlusion). Ees is 
then determined from ESP as shown. [b]. Ea determined as slope connecting ESP with EDV. 
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However Ees can also be estimated from a single P-V loop, often referred to as the 
single beat method (125). This method relies on the calculation of a maximum RV 
pressure (Pmax) from the extrapolation of early and late systolic portions of a RV 
pressure curve and the continuous recording of RV pressure and relative change 
in volume to define ESP and ESV. From Pmax, Ees and Ea are easily calculated as 
shown in figure 4.2. Excellent correlation between Pmax estimated by this method 
and values measured directly by clamping the main pulmonary artery in animals 
models has been demonstrated (125). 
 
Figure 4.2 Single beat method.  
 
[a]. Pmax is generated by sine wave extrapolation of RV pressure time curve and plotted on RV 
pressure volume plot as shown in [b] at RV end diastolic volume (EDV) with mPAP at end systolic 
volume (ESV). End systolic elastance (Ees) calculated as slope of pressure/volume relationship, 
V0 as the x axis intercept of this relationship and effective arterial elastance (Ea) as mPAP/(EDV-
ESV) as shown. 
 
As discussed in chapter 1, the estimation of RV-arterial coupling by an Ees/Ea ratio 
can further be simplified for pressure and expressed as SV/ESV (400), i.e. the 
volume method. Alternatively the ratio can be simplified for volumes and 
expressed as Pmax divided by mean pulmonary artery pressure (mPAP), taken as a 
surrogate for ESP, minus 1 (132), i.e. the pressure method. A RV pressure curve is 
easily obtained during a right heart catheterisation. RV volumes are ideally 
determined by cardiac magnetic resonance imaging (CMR) which has been shown 
to have good inter and intra-observer reproducibility in PAH (64). As shown in 
figure 4.3, the volume method (which assumes RV volume is negligible at zero 
pressure, V0=0) results in lower values for RV-arterial coupling. 
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Figure 4.3 Comparison of pressure and volume methods to estimate RV-arterial coupling.  
 
Method (i) volume method where V0 = 0. Ees equates to mPAP/ESV and RV coupling estimated by 
ratio of SV/ESV. Method (ii) pressure method. Ees equates to (Pmax-mPAP)/(EDV-ESV) and RV 
coupling by Pmax/mPAP-1. As shown, method (i) results in lower values for Ees than method (ii). 
 
4.1.2 Estimates of RV-arterial coupling in experimental and 
clinical pulmonary hypertension 
RV-arterial coupling has been investigated in various animal models of acute and 
chronic pulmonary hypertension both with and without evidence of RV failure. In 
acute hypoxia induced models of PH where an acute rise in Ea was demonstrated, 
preserved RV coupling occurred by adaptive increase in RV contractility (125, 401-
403). Preserved RV-arterial coupling has also been reported in acute PH models 
induced by microembolism or PA banding (401), and initially during endotoxic 
shock induced increased PVR, although in the latter deterioration was then 
observed due to unsustained adaptive increase in contractility (404). In a rat 
monocrotaline induced PH model, a decrease in RV-arterial coupling occurred due 
to failure of increase in contractility to match the increased afterload (405). 
Monocrotaline is known to have systemic toxic effects and causes inflammatory 
type pulmonary vascular disease (406). Correlation between some markers of 
inflammation and apoptosis with RV-arterial coupling in both acute and chronic 
models of RV failure have been reported (407-409). 
In experimental models of chronic PH, initial preservation of RV arterial coupling 
was demonstrated at 3 months in a chronic aortopulmonary shunting model (410) 
with subsequent uncoupling at 6 months in association with the development of 
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RV systolic failure (408). In a tachycardiomyopathy model with mild PH induced 
by chronic overpacing, RV arterial uncoupling was also observed due to absence 
of an increase in contractility (411). These experimental studies suggest at least 
initial preservation of RV systolic functional adaptation to an increase in afterload 
in PH, with uncoupling in context of inflammation (i.e. endotoxin or 
monocrotaline), chronic sustained elevation of afterload or in left heart failure. 
Several small studies have reported values of Ees, Ea and RV-arterial coupling 
estimated by varying methods in patients with PH. Using MRI compatible 
conductance catheters Kuehne et al derived P-V loops from instantaneous pressure 
and volume measurements during MRI acquisition in 6 PAH subjects in comparison 
to 6 controls (412). PAH subjects demonstrated significantly higher Ea and Ees in 
comparison to controls. RV-arterial coupling was 1.9 ± 0.4 in controls in 
comparison to 1.1 ± 0.3 in PAH patients. 
Tedford et al reported impaired RV contractility using PV loop analysis in 7 
patients with PAH secondary to systemic sclerosis (SScPAH) in comparison to 5 
IPAH patients (413). Despite similar net afterload (Ea) SScPAH exhibited almost 
70% lower Ees (normalised for RV volume) and lower Ees/Ea ratio (1.0±0.5 vs 2.1±1.0 
mmHg/mL) suggesting differential ability of the RV to adapt to afterload in SScPAH 
in comparison to IPAH. However, other indices of RV function, RVEF, CI and RAP 
or indices of diastolic function did not differ between the groups. Additionally, 
IPAH patients were on chronic PH medications, such as PDE-5i or epoprostenol in 
comparison to only 1/7 SScPAH patients, which may alter RV contractility and 
potentially lead to preservation of RV-arterial coupling demonstrated in the IPAH 
group. 
Trip et al reported a simplified measurement of RV contractility utilising Pmax 
generated by the single beat method from a RV pressure curve obtained at 
standard RHC, and ventricular volumes measured by CMR in 28 IPAH patients (132). 
mPAP was used as a surrogate for ESP. Contractility was then estimated by either 
mPAP/ESV (assuming V0 = 0) or (Pmax - mPAP)/(EDV/ESV). V0 was also estimated by 
the linear extrapolation of the pressure-volume relationship. mPAP/ESV was lower 
by approximately half the value of (Pmax - mPAP)/SV (0.61 vs 1.34 mmHg/mL 
respectively) with increased difference at higher values of Ees. V0 ranged from -8 
to 171mL which correlated with increasing RV volumes. They concluded that V0 is 
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not negligible in PAH patients, and as V0 is dependent on RV dilatation, Ees may be 
more preload dependent than previously regarded. However, the methods 
implemented to estimate V0 relied on a number of surrogate pressures and 
volumes (such as mPAP for ESP) and extrapolation from a linear fit of the PV 
relationship which has been shown in the literature to be curvilinear (414). 
Sanz demonstrated an initial increase in RV contractility (using the simplified ratio 
of mPAP/RVESV) with increasing severity of PH in a large cohort of subjects with 
PH of varied aetiologies (400). With more severe disease, this increase however 
plateaued with a trend towards even a decrease in the most severe group (defined 
by PVRI >14.4 Wood units). RV-arterial coupling (as determined by either 
simplified equations or non-invasive metric SV/ESV) therefore whilst relatively 
maintained in early disease declined with more severe PH. This suggests that the 
ratio of SV/ESV may provide prognostic and functional relevance in patients with 
PH. 
Cardiac CMR studies have shown that decreased SV and RVEF are predictive of 
poor outcome (41), and that a deterioration in RVEF during therapy predicts a 
poor survival irrespective of improvements in PVR (288). However, EF is preload-
dependent while Ees/Ea is theoretically not. Therefore, estimates of RV arterial 
coupling should be superior to other measures of RV function in determining 
outcome. Accordingly, a recent study on a limited number of patients referred for 
investigation of PH of all aetiologies (27/41 with PAH diagnoses), many of whom 
did not receive PH specific therapy, showed RV arterial coupling estimated by 
SV/ESV to be an independent predictor of outcome while RVEF was not (415). RV 
volumes were determined by the inferior gated CT imaging rather than CMR in the 
majority (44/50 patients) which may have influenced this observation.  
Overall, these studies suggest increased RV contractility (Ees) in response to 
increased PVR, with or without preservation of RV-arterial coupling. Additionally, 
the aetiology of the increase in afterload may be important, with potentially 
earlier RV failure and uncoupling in the presence of systemic disease and 
inflammation, such as systemic sclerosis. The extent of RV-arterial uncoupling in 
PH associated with hypoxic lung disease is unknown. Smoking and hypoxia related 
inflammation are known to have roles in both pulmonary and systemic vascular 
stiffness, and LV dysfunction has been linked to catabolic COPD phenotype and IL6 
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(389, 390, 392). Patient characteristics described in chapter 3 suggest possibility 
of greater RV dysfunction (higher NTproBNP) and impaired adaptation (lower RVM) 
in comparison to IPAH patients, although this may relate to demographics of the 
populations. RV-arterial coupling could potentially examine more closely 
differences in RV adaptation to afterload in PH/lung disease. 
4.2 Aims 
As demonstrated by these studies, whilst it is clear that RV functional adaptation 
is the major determinant of outcome in PAH the optimal method for evaluation is 
uncertain. Gold standard measures of RV-arterial coupling may potentially be 
superior to more commonly measured indices of RV function, but are cumbersome 
to perform and invasive, and therefore unlikely to be acceptable for routine 
monitoring of patients. Additionally there is suggestion from small clinical and 
experimental models that RV functional adaptation may differ between PH 
aetiologies. The aims of this chapter are to: 
1. Investigate the prognostic utility of RV-arterial coupling determined by 
both the volume and pressure methods, compared to more usual 
determinations of RV function, CMR RVEF, NTproBNP, and right heart 
catheterisation-derived RAP and SV in a large cohort of patients with PAH. 
2. Explore the potential deterioration in RV-arterial coupling in patients with 
chronic lung disease and PH in comparison to IPAH and connective tissue 
disease PAH.  
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4.3 Materials and methods 
4.3.1 Patient recruitment 
140 treatment naïve incident PAH cases diagnosed between January 2004 and April 
2014 whom had undergone cardiac MRI at diagnosis were identified. 81 patients 
with Group 3 PH secondary to lung disease described in chapter 3 with baseline 
CMR were included for comparison. Patients with lung disease were classified by 
severity of PH as described in section 3.3.1. Patients underwent multidisciplinary 
investigation as described in methods section 2.1.1. CMR image acquisition and 
data analysis was carried out as described in section 2.2. All patients underwent 
cardiac MRI and RV pressure measurement within 72 hours. All PAH patients were 
treated with pulmonary vasodilators in accordance with guidelines. Patients were 
excluded if the RV pressure trace was not available for analysis. 
4.3.2 Right ventricular pressure trace analysis 
Right ventricular pressure traces were available for 61/140 PAH patients and 
32/81 with PH secondary to lung disease. 22 control patients without pulmonary 
hypertension (defined as a mPAP <25mmHg) who had right heart catheterisation 
and CMR to investigate breathlessness were included to provide reference values 
for RV-arterial coupling by the two methods. Of these, 8 had lung disease. 
Analogue traces were manually redigitised using GetData Graph Digitizer 2.26. An 
example is shown in Figure 4.4. 
In those patients for whom an RV pressure trace was available for analysis, Ees was 
calculated using the single beat method (125). Pmax, the maximum theoretical 
pressure the ventricle could generate if isovolumetric contraction occurred, was 
calculated using a manual sine-wave extrapolation of the early systolic and 
diastolic portions of the RV pressure curve. Pmax derivation was carried out by Dr 
R. Vanderpool at Department of Biomedical Engineering, University of Pittsburgh 
and Dr A. Bellofiore University of San Jose State.  
  
194 
 
ESP was approximated by mPAP (132). Ees was calculated as the slope of end-
systolic pressure volume line,  
Ees = (Pmax – mPAP) / (RVEDV – RVESV). 
Arterial elastance (Ea) was estimated by mPAP/(RVEDV – RVESV).  
RV-arterial coupling (Ees/Ea) was simplified for volumes as Pmax/mPAP – 1 
(hereafter referred to as the pressure method, Ees/Ea-P), or simplified for 
pressures as SV/ESV (hereafter referred to as the volume method, SV/ESV) (400). 
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A 
 
 
 
 
 
B  
 
Figure 4.4 Example of digitised RV pressure trace analysis.  
 
A Manual tracing of RV pressure time plot obtained at right heart catheterisation with data 
points exported to excel. Re-constructed digitised trace is shown in blue.  
B. Overlay of original RV pressure/time trace with digitised trace (again shown in blue) 
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On preliminary analysis of 3 beats from a single patient, significant beat to beat 
variation in calculated values for Pmax, Ees and Ees/Ea-P was observed. An example 
is shown in Figure 4.5.  
 
 
Figure 4.5 Beat to beat variation in calculated Pmax.  
 
3 RV pressure time curves for a single patient acquired at right heart catheterisation are indicated 
by blue arrows with the corresponding calculated values for Pmax, Ees and RV-arterial coupling 
Ees/Ea. 
 
An average RV pressure trace was therefore generated for each patient across a 
respiratory cycle, typically 4-6 beats. Figure 4.6 shows the correlation between 
the RV systolic pressure from the average trace, and the average RVSP determined 
by RHC demonstrating good agreement (Pearson r =0.991, p<0.001). The average 
RV pressure trace was used to determine Pmax for each patient as described above. 
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Figure 4.6 Correlation of calculated RVSP from average trace generation with invasively 
measured RVSP. 
 
4.3.3 Statistical methods 
Statistical analysis was carried out as described in section 2.3. Survival was from 
date of diagnostic right heart catheter and endpoint was date of either death, 
lung transplantation or censoring. Patients were censored if they were lost to 
follow up or alive at last day of study (4th August 2014). Only patients who 
received pulmonary vasodilator therapy (92/125) were included in survival 
analysis. 
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4.4 Results 
4.4.1 Patient Characteristics 
Patient haemodynamics, RV indices of structure and function and measures of RV 
arterial coupling are summarised in table 4-1. In comparison to normal subjects, 
PAH patients showed reduced RVEF, SVI and pulmonary arterial compliance 
(measured as either SV/PP or RAC MPA), and increased RV volumes (RVEDVI and 
RVESVI) and mass. 
4.4.2 Estimates of RV-arterial coupling 
4.4.2.1 Effective Arterial Elastance (Ea) 
Ea correlated with increasing levels of pulmonary vascular resistance (r2 = 0.616, 
p<0.001) and inversely with pulmonary artery compliance measured invasively 
(SV/PP, r2 = 0.538, p <0.001) and non invasively by cardiac MRI (RAC MPA, r2 = 
0.252, p <0.001). Correlations are shown in Figures 4.7 – 4.9. 
Ea was increased in PAH patients in comparison to normal subjects, 0.88 (0.63-
1.31) versus 0.23 (0.14 – 0.28) mmHg/mL, p <0.001.  
 
  
 
Table 4-1. Clinical characteristics, haemodynamics, right ventricular dimensions and function in PAH patients in comparison to normal subjects and 
patients with PH secondary to chronic lung disease.  
 No PH  Group 1 PAH p value HLDPH 
n 14 61  42 
Aetiology % (n)  CTDPAH 26 
IPAH 30 
POPH 4 
CHDAPH 1 
  
Age (years) 54 ± 15 52 ± 16 0.637 65 ± 12 
Sex (%female) 71 74  40 
     
mPAP (mmHg) 17 ± 4 49 ± 14 <0.001 44 ± 12 
PVR (Wood Units) 1.8 (1.1 – 2.3) 11.9 (7.5 – 15.5) <0.001 8.9 (5.9 -14.0) 
CI (L/min/m2) 3.3 ± 0.8 2.2 ± 0.7 <0.001 2.2 ± 0.6 
SV/PP (mL/mmHg) 3.23 (3.0 – 5.7) 0.93 (0.65 – 1.20) <0.001 1.09 (0.76-1.42) 
     
RVEF (%) 62 ± 12 34 ± 13 <0.001 37 ± 16 
RVEDVI (mL/m2) 77 ± 27 93 ± 26 0.043 88 ± 35 
RVMI (g/m2) 34 ± 11 53 ± 18 <0.001 50 ± 18 
SVI (mL/m2) 45 (42 – 54) 28 (21-33) <0.001 30 (24-35) 
RAC MPA (%) 45 (36 – 59) 21 (12 – 27) <0.001 19 (14-22) 
     
Ees mmHg/mL 0.31 (0.21 – 0.47) 1.19 (0.81 – 2.26) <0.001 0.89 (0.57 – 1.22) 
Ees (EDV adj) 0.46 (0.30 – 0.58) 1.79 (1.20 – 2.52) <0.001 1.53 (0.80 – 1.97) 
Ea mmHg/mL 0.23 (0.14 – 0.28) 0.88 (0.63 – 1.31) <0.001 0.82 (0.68 – 1.09) 
Ees/Ea-P 1.81 (1.33 – 2.23) 1.33 (0.88 – 1.73) 0.019 1.07 (0.69 – 1.35) 
SV/ESV 1.65 (1.17 – 1.79) 0.53 (0.30 – 0.84) <0.001 0.53 (0.30 – 0.88) 
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Figure 4.7 Correlation of Effective arterial elastance (Ea) with pulmonary vascular 
resistance. 
 
 Ea positively correlated with increasing PVR, R2 = 0.616, p<0.001 
 
 
Figure 4.8 Correlation of Effective arterial elastance (Ea) with pulmonary artery compliance 
(SV/PP).  
 
Ea fell with increasing PA compliance, logarithmic regression r2 = 0.538, p<0.001. y = 1.038 + -
0.682* log(x). 
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Figure 4.9 Correlation of effective arterial elastance (Ea) with pulmonary artery compliance 
estimated MPA RAC.  
 
Ea also fell with increasing PA compliance assessed by CMR MPA RAC, r2 = 0.252, p<0.001. y = 
2.399 + -0.501* log(x). 
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4.4.2.2 RV Contractility (Ees) 
Ees correlated with increasing levels of afterload, measured as either PVR (r2 = 
0.259 p <0.001) or Ea (r2 = 0.354, p <0.001). Correlations are shown in figures 4.10 
and 4.11 respectively. 
Ees was increased in PAH patients in comparison to normal subjects, 1.19 (0.81 – 
2.26) versus 0.31 (0.21 – 0.47) mmHg/mL p <0.001.  
After adjustment for PVR, neither age nor sex were determinants of Ees using 
linear regression analysis. In comparison to IPAH subjects, a diagnosis of HLD 
(despite correction for PVR) was associated with lower Ees. Table 4-2 shows the 
regression analysis. 
 
 
Table 4-2 Determinants of RV contractility (Ees).  
Variable Regression Coefficient P value 
age 0.018 0.827 
Male Sex  -0.063 0.421 
PH aetiology (IPAH control variable)  
CTDPH -0.117 0.214 
HLDPH -0.216 0.029* 
POPH -0.152 0.057 
Normal subjects -0.356 0.002** 
Linear regression of Ees with PVR 
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Figure 4.10 Correlation of RV contractility (Ees) with pulmonary vascular resistance. 
 
Ees increased in response to increasing levels of PVR, r2=0.259, p<0.0001 
 
Figure 4.11 Correlation of RV contractility (Ees) with afterload (Ea) 
 
Ees increased with increasing Ea, r2=0.354, p<0.0001 
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4.4.2.3 Pressure (Ees/Ea-P) and volume (SV/ESV) estimates of RV-arterial 
Coupling 
Both pressure (Ees/Ea-P) and volume (SV/ESV) estimates of RV-arterial coupling 
fell with increasing severity of pulmonary hypertension.  
Ees/Ea-P was lower in PAH patients compared with normal subjects, 1.33 (0.88 – 
1.73) versus 1.81 (1.33 – 2.23), p = 0.019 and inversely correlated with mPAP 
(Pearson r = -0.338, p <0.001) and PVR (Pearson r -0.381, p <0.001).  
SV/ESV was lower in PAH patients, 0.53 (0.30-0.84) in comparison to controls, 1.65 
(1.17 – 1.79), p <0.001. SV/ESV fell with increasing levels of mPAP (spearman r = 
-0.588 p <0.001) and PVR (spearman r = -0.715, p <0.001).  
Ees/Ea-P correlated with other measures of RV function, RVEF (Pearson r = 0.403, 
p <0.001) and negatively with RAP (r = -0.352, p <0.001) and NTproBNP (Spearman 
r = -0.248, p <0.001). SV/ESV more closely related to RAP (Spearman r = -0.449, p 
<0.001) and NTproBNP (Spearman r = -0.723, p <0.001).  
Both Ees/Ea-P and SV/ESV were moderate predictors of 6MWD in the whole cohort, 
r = 0.257 p = 0.002 and r = 0.272 p = 0.001 respectively, after adjustment for age. 
RVEF and SV were both superior predictors of 6MWD r = 0.288 p = 0.001 and r = 
0.453 p <0.001 respectively.  
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Figure 4.12 Regression of SV/ESV with pulmonary vascular resistance.  
 
SV/ESV fell with increasing severity of PH (determined by PVR), logarithmic regression shown, r2 = 
0.484 p<0.001, y = 1.751 + -0.486* log(x) 
 
 
Figure 4.13 Correlation of Ees/Ea-P with RV ejection fraction.  
 
r2 = 0.162, p <0.001. y = 0.73 + 0.02*x 
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4.4.2.4 RV-arterial coupling in pulmonary arterial hypertension 
Population characteristics of CTDPH and IPAH patients are shown in table 4-3. 
Between IPAH and CTDPH patients, there was no difference in Ees/Ea-P, (1.25 ± 
0.7 vs 1.30 ± 0.5 p = 0.759) or SV/ESV (0.48 (0.29 -0.80) vs 0.50 (0.29 – 0.87) 
p=0.637). 14 of the 26 CTDPH patients had systemic sclerosis associated PAH (SSc-
PAH). Ees/Ea-P and SV/ESV in comparison to IPAH patients was similar, 1.39 ± 0.5 
(p = 0.52) and 0.60 (0.30 – 0.89) (p = 0.44) respectively. 
4.4.2.5 RV-arterial coupling in pulmonary hypertension associated with 
chronic lung disease 
Table 4-4 summarises population characteristics and indices of RV function and 
coupling according to severity of associated pulmonary hypertension in patients 
with lung disease. As discussed in chapter 3, lung disease patients were older and 
more often male in comparison to PAH patients. Ees was lower in HLDPH patients 
(0.89 mmHg/mL) in comparison to both all PAH subjects (1.19 mmHg/mL, 
p=0.017) and IPAH (1.23 mmHg/mL p = 0.001) despite similar levels of afterload, 
Ea 0.82 vs 0.88 mmHg/mL p = 0.442 and 0.98 mmHg/mL p = 0.09 respectively. As 
a result, Ees/Ea-P was lower in HLDPH patients in comparison to IPAH subjects (1.07 
mmHg/mL vs 1.37 mmHg/mL p = 0.02) and trend towards lower values in 
comparison to PAH patients (1.33 mmHg/mL p = 0.058). Imaging measures of RV 
function SV/ESV and RVEF did not differ between groups, SV/ESV of 0.53 for all 
groups, p = 0.773 and p = 0.954 respectively, and RVEF 37% vs 34% p = 0.436 with 
PAH and 35%, p = 0.727 with IPAH subjects.  
Figure 4.14 displays RV contractility (Ees) according to severity of PH associated 
with chronic lung disease. Ees was increased in those with PH in comparison to 
controls with lung disease without PH, 0.94 versus 0.41 mmHg/mL, p = 0.021. No 
further increase Ees was demonstrated in those with severe PH, 0.89 mmHg/mL p 
= 0.791. Ea increased in parallel to increasing severity of PH, 0.31 vs 0.66 vs 0.95 
mmHg/mL in those with no, mild-moderate and severe PH respectively. As a 
result, significant decrease in RV-arterial coupling was seen in those with severe 
PH only, whether determined by the pressure or volume method, Ees/Ea-P 1.52 
mmHg/mL versus 1.26 mmHg/mL, p = 0.700 and 1.01 mmHg/mL, p = 0.008 in no, 
mild-moderate and severe PH (shown in Figure 4.15). SV/ESV (shown in Figure 
4.16) did not significantly decline between those with no PH and mild/moderate 
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PH, 1.28 versus 0.84 p = 0.280, but significant uncoupling occurred in the severe 
PH group, 0.37 p = 0.002 and p = 0.001 in comparison to those with no or 
mild/moderate PH respectively. 
 
  
Table 4-3 Characteristics of Idiopathic PAH patients in comparison to Connective tissue disease associated PAH and Systemic Sclerosis associated PAH. 
 
 IPAH CTDPH p-value SSc-PAH p-value 
n 30 26  14  
Age years 49 ± 18 55 ± 14 0.148 61 ± 11 0.024* 
Sex %female 70 85  93  
      
mPAP mmHg 56 ± 16 43 ± 8 0.001** 41 ± 7 0.002** 
PVR Wood Units 12.5 (9.3 – 19.1) 9.1 (5.4 – 13.1 0.011* 9.5 (5.4 – 13.1) 0.021* 
CI L/min/m2 2.1 ± 0.5 2.4 ± 0.7 0.106 2.3 ± 0.5 0.338 
SV/PP mL/mmHg 0.91 (0.65 – 1.11) 0.96 (0.68 – 1.40) 0.293 0.95 (0.75 – 1.35) 0.392 
      
RVEF % 35 ± 12 34 ± 14 0.810 34 ± 13 0.896 
RVEDVI mL/m2 92 ± 28 93 ± 28 0.870 87 ± 30 0.575 
RVMI g/m2 54 ± 18 51 ± 18 0.516 52 ± 20 0.714 
SVI mL/m2 27 (22 – 31) 30 (19 - 35) 0.532 27 (22 – 31) 0.801 
      
Ees mmHg/mL 1.23 (0.98 – 2.06) 1.04 (0.71 – 1.59) 0.068 1.13 (0.86 – 1.61) 0.226 
Ees (EDV adj) 2.04 (1.43 – 2.91) 1.69 (1.03 – 2.23)  1.67 (1.17 – 2.31)  
Ea mmHg/mL 0.98 (0.79 – 1.56) 0.79 (0.57 – 1.25) 0.119 0.70 (0.60 – 1.66) 0.082 
Ees/Ea-P 1.37 (0.72 – 2.01) 1.21 (0.94 – 1.63) 0.532 1.29 (0.98 – 1.79) 0.980 
SV/ESV 0.53 (0.34 – 0.82) 0.50 (0.29 – 0.87) 0.948 0.60 (0.30 – 0.89) 0.762 
NTproBNP pg/mL 886 (448 – 1197) 2989 (595 – 4206) 0.029* 2756 (608 – 4262) 0.039* 
  
 Table 4-4 Haemodynamic, pulmonary and RV function characteristics of chronic lung disease patients with no, mild-moderate and severe pulmonary 
hypertension 
 mPAP <25mmHg mPAP 25-34mmHg mPAP ≥35mmHg 
n 8 12 30 
Aetiology % (n) 
COPD 
CPFE 
ILD 
 
(6) 
- 
(2) 
 
(4) 
(2) 
(6) 
 
(19) 
(10) 
(1) 
Age years 64 ± 9 70 ± 10 63 ± 12 
Sex (% female) 50 50 37 
    
mPAP mmHg 20 ± 3 30 ± 3 49 ± 9 
PVR Wood Units 2.7 (2.4-3.1) 5.0 (3.5-6.9) 10.8 (7.7-15.6) 
CI L/min/m2 2.5 ± 0.4 2.6 ± 0.4 2.0 ± 0.5 
RAP mmHg 4 ± 1 3 ± 4 9 ± 4 
SV/PP mL/mmHg 2.97 (2.63 – 3.88) 1.59 (1.15 -1.77) 0.87 (0.68 – 1.28) 
    
FEV1 % 82 ± 32 77 ± 30 73 ± 20 
FEV1:FVC 64 ± 23 68 ± 19 58 ± 12 
TLCO % 43 (29-65) 33 (26-36) 24 (19-36) 
Pa02 kPa 9 (7.9-11.8) (7) 7.3 (6.9-9.8) (7) 7.3 (6.8-8.5) (23) 
    
RVEF % 52 ± 16 49 ± 14 31 ± 13 
RVEDVI mL/m2 71 ± 20 65 ± 23 97 ± 34 
SVI mL/m2 38 ± 7 35 ± 10 29 ± 8 
    
Ees mmHg/mL 0.41 (0.35-0.63) 0.94 (0.49-1.47) 0.89 (0.64-1.17) 
Ea mmHg/mL 0.31 (0.26 – 0.40) 0.66 (0.44 – 0.81) 0.95 (0.77 – 1.46) 
Ees/Ea 1.52 (1.16 – 2.00) 1.26 (1.08 – 2.14) 1.01 (0.67 -1.18) 
SV/ESV 1.28 (0.64 – 1.98) 0.84 (0.59 – 1.40) 0.37 (0.27 – 0.69) 
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Figure 4.14 RV contractility in chronic lung disease patients with no, mild/moderate and 
severe PH. 
 
Median values 0.41, 0.94 and 0.89 in no, mild/moderate and severe PH groups. * p = 0.021 **p = 
0.002 in comparison to no PH group. p = 0.791 between those with mild/moderate and severe PH. 
 
 
Figure 4.15 Ees/Ea-P in chronic lung disease patients with no, mild/moderate and severe PH  
 
Median values 1.52, 1.26 and 1.01 mmHg/mL for no, mild/moderate and severe PH respectively. ** 
p = 0.008 in comparison to both no PH and mild/moderate PH groups. p = 0.700 between no PH 
and mild/moderate PH groups. 
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Figure 4.16 SV/ESV for chronic lung disease patients with no, mild/moderate and severe PH. 
  
Median values 1.28, 0.84 and 0.37 respectively. ** p = 0.002 in comparison to no PH and p = 0.001 
mild/moderate PH respectively. p = 0.280 between no PH and mild/moderate PH groups. 
 
4.4.3 RV-arterial coupling and prognosis 
41 deaths occurred during the follow up period in the 92 patients who received 
pulmonary vasodilator therapy and were included in this analysis. Higher Ea, RAP, 
RVESVI and NTproBNP, and lower RVEF, SVI, SV/PP and SV/ESV predicted survival 
on bivariate cox proportional hazards regression with age. In a multivariate model 
with age and PVR, RAP and SV/ESV (but not Ees/Ea-P) independently predicted 
outcome (HR 0.329 95%CI 0.165 – 0.656, p = 0.002). In the same multivariate 
model, RVEF independently predicted survival (HR 0.958 95% CI 0.929-0.988 
p=0.006). Table 4-4 shows the bivariate and multivariate cox analysis. 
Youden analysis identified optimal threshold level of 0.463 for SV/ESV and 31.6% 
for RVEF. Figure 4.17 displays the Kaplan Meier survival curves according to these 
threshold values. SV/ESV >0.463 was associated with improved outcome,1 and 3 
year survival 91% vs 80%, and 66% versus 38% respectively, p = 0.011. RVEF >31.6% 
predicted improved survival, 1 and 3 year survival 91% versus 80%, and 65% versus 
37% respectively, p = 0.011. 
 
  
Table 4-5 Bivariate and multivariate cox proportional hazards regression for baseline predictors of survival in patients treated for PAH. 
 
Variable Bivariate model* Multivariate model** 
 HR (95% CI) p-value HR (95% CI) p-value 
mPAP 1.007 (0.979 – 1.035) 0.626   
PVR 1.043 (0.981 – 1.108) 0.179 0.938 (0.861 – 1.022) 0.142 
RAP 1.084 (1.019 – 1.153) 0.011* 1.088 (1.013 – 1.168) 0.020* 
CI 0.600 (0.326 – 1.105) 0.101   
SV/PP 0.379 (0.150 – 0.954) 0.039*   
     
Ees 1.178 (0.795 – 1.745) 0.414   
Ea 2.456 (1.299 – 4.908) 0.011*   
Ees/Ea-P 0.592 (0.316 – 1.107) 0.101   
     
SV/ESV 0.399 (0.228 – 0.700) 0.001** 0.329 (0.165 – 0.656) 0.002** 
RVEF 0.957 (0.931 – 0.984) 0.002** #  
RVESVI 1.016 (1.005 – 1.028) 0.007**   
SVI 0.939 (0.900 – 0.980) 0.004**   
     
NTproBNP  1.491 (1.147 – 1.939) 0.003**   
     
*bivariate model with age ** multivariate model with age & PVR # RVEF 0.958 (0.929 – 0.988) p=0.006 in multivariate model with age, PVR & RAP 
  
Figure 4.17 Kaplan Meier survival curves dichotomised according to [a] SV/ESV >0.463 and [b] RVEF >31.6%. 
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4.4.4 Correlation between pressure and volume methods of 
measuring RV-arterial coupling 
Ees/Ea-P correlated with SV/ESV (r = 0.441, p <0.001), shown in figure 4.18. Bland 
Altman analysis of the two methods bias 0.556, SD 0.683 with limits of agreement 
-0.784-1.9 is shown in figure 4.19. 
V0 estimated by the volume intercept of the pressure-volume regression line 
correlated with RV EDV and ESV (r = 0.607 and r = 0.804 respectively, both 
p<0.001). Correlations are shown in Figures 4.20 and 4.21. Estimated values of V0 
ranged from -129ml to 285ml. 
Figures 4.22 and 4.23 show the difference between pressure and volume methods 
Ees/Ea-P – SV/ESV at increasing levels of mPAP and RV dilatation (RVESV).  
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Figure 4.18 Correlation between pressure (Ees/Ea-P) and volume (SV/ESV) estimates of RV-
arterial coupling. 
 
Linear regression r2 = 0.135, y = 1.01 + 0.41*x. p<0.001 
 
 
Figure 4.19 Bland-Altman analysis of difference in Ees/Ea-P - SV/ESV against mean of both 
values 
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Figure 4.20 Correlation of V0 with RV end diastolic volume. 
 
r2= 0.365 p<0.001. y = -62.1 + 0.68*x. p<0.001 
 
 
Figure 4.21 Correlation of V0 with RV end-systolic volume. 
 
r2 = 0.606, p<0.001. y = -44.4 + 0.9*x. p<0.001 
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Figure 4.22 Difference in pressure and volume estimates of Ees/Ea with increasing levels of 
mPAP. 
 
Greater discrepancy between values seen at lower levels of mPAP. 
 
Figure 4.23 Difference in pressure and volume estimates of Ees/Ea with increasing RV 
dilatation. 
 
Greater discrepancy between values seen at lower RV volume (RVESV) 
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4.5 Discussion 
The results described in this chapter show that effective arterial elastance (Ea) 
estimated by mPAP determined at RHC and CMR imaging to determine RV volumes 
reflects commonly quoted measures of RV afterload PVR or SV/PP. In agreement 
with previous studies, ventricular contractility (Ees) when estimated by the single 
beat method increased in response to this increased afterload in PAH subjects. 
RV-arterial coupling when estimated by the pressure method, Ees/Ea-P was lower 
in PAH subjects but a greater difference when estimated by the volume method, 
SV/ESV was observed. We found comparable estimates of Ees/Ea-P in normal 
subjects, 1.8 mmHg/mL in our study in comparison to 1.9 mmHg/mL in the study 
by Kuehne at al, where gold standard pressure-volume loop analysis was employed 
(412), suggesting validity of the single beat method employed in this chapter.  
RV-arterial coupling estimated by either Ees/Ea-P or SV/ESV related to functional 
status (determined by 6MWD), although this relationship was poorer than other 
measures of RV function such as SV or RVEF. Ees/Ea-P related to other indices of 
RV function determined by imaging (RVEF), RHC (RAP) or by biomarker NTproBNP, 
but this relationship was stronger with SV/ESV. 
4.5.1 Influence of PH aetiology on RV adaptation to afterload. 
Tedford et al have previously reported depressed RV contractility in PAH 
associated with systemic sclerosis in comparison to IPAH (413). In this study, 
Ees/Ea-P were similar in both, and the presence of associated connective tissue 
disease was not a determinant of Ees. Ees/Ea-P was 1.37 mmHg/mL which is similar 
to recent published data in IPAH patients (412, 416). One potential explanation 
for the differences reported by Tedford et al may be that a higher value of 2.1 
mmHg/mL for IPAH patients was a result of PH therapies such as epoprostenol in 
this cohort, and the value of 1.0 mmHg/mL in the Ssc-PAH patients more 
representative of treatment naïve population described in this study regardless of 
aetiology. 
Disproportionate elevation of NTproBNP was observed similar to previous studies 
and potentially still supports evidence for intrinsic myocardial dysfunction in 
CTDPH (417, 418).  
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In patients with PH secondary to chronic lung disease, RV-arterial coupling was 
preserved in early disease (mPAP 25-34mmHg) but uncoupling was demonstrated 
in severe PH characterised by an increase in RV volumes, and no further increase 
in RV contractility. This suggests similarities to IPAH patients where previous 
studies have reported initial preservation of RV-arterial coupling in patients with 
no increase in RV volumes (413). In agreement with the results presented in 
chapter 3, severe PH associated with chronic lung disease is characterised by not 
only RV dysfunction determined by falling RVEF and increasing RV volumes but 
also by impaired RV contractile response to the increased afterload, with resulting 
inefficient RV-arterial coupling whether determined by either pressure or volume 
method. Potentially, intrinsic myocardial dysfunction due to smoking related 
microvascular disease or inflammation which has been linked to LV dysfunction in 
COPD patients could explain impaired contractile response and be a future 
direction for study.  
4.5.2 RV-arterial coupling and relationship to outcome  
The results show that CMR imaging of RV volumes allows for the prediction of 
outcome in PAH by RV function defined either as EF or SV/ESV. Right heart 
catheterisation derived estimates of RV function such as RAP also independently 
predicted survival, but not CI nor measures of afterload such as PVR or SV/PP. 
Furthermore, there was no added value of combining invasive measurements of 
pressure with non-invasive measurements of volumes to assess the prognostic 
value of RV-arterial coupling. 
In agreement with the previous study by Vanderpool et al (415) Ees/Ea estimated 
by the volume method but not the pressure method predicted outcome. The 
pressure method applied to estimate Ees/Ea-P relies on a Pmax calculation based on 
the analysis of a RV pressure curve to estimate maximum pressure of an isovolumic 
beat at EDV (125), and mPAP assumed equal to ESP (132) as described in section 
4.1.1 While the pressure method generated Ees/Ea values that are quantitatively 
in the range of values reported by more robust methods (413, 419), the number 
of assumptions in the method may result in insufficient precision and explain the 
failure to predict outcome. The volume method rests on the indirect assumptions 
that Ees is a volume independent straight line crossing the origin, which is not 
correct (396). However, measurements of ESV and EDV by CMR have a high level 
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of accuracy and precision (64, 357), so that the information content of SV/ESV to 
estimate Ees/Ea is preserved and predicts outcome. 
Mathematically the volume method of estimating RV-arterial coupling, SV/ESV is 
similar to RVEF, where RVEF is the ratio of SV/EDV, so the advantage of SV/ESV 
over the traditionally used RVEF to assess RV adaptation to afterload could 
arguably be unclear. Whilst mathematically linked, they exhibit a non-linear 
relationship. This suggests a possible reason why SV/ESV could be more predictive 
because it widens the physiological range of values thereby increasing resolution 
of SV/ESV in patients with relatively normal RVEF (values of RVEF range 0.14-0.58 
in comparison to 0.18-1.5 for SV/ESV).(420) 
Right heart catheterisation is mandatory for the diagnosis of PH. However, the 
procedure allows for only an indirect description of RV function, with RAP to 
estimate EDV, or preload, SV/PP or PVR to estimate afterload, and SV to reflect 
contractility. In spite of these limitations, RAP, cardiac output and PVR have been 
reported to predict outcome in PAH (144, 269, 286, 287). However, this was in 
studies considering exclusively these invasive measurements. In the work 
presented here which combined right heart catheterisation and CMR 
measurements, only RAP and imaging of RV function (either RVEF or SV/ESV) 
independently predicted outcome. This result agrees with the notion that imaging 
provides a more accurate and relevant definition of RV function than a standard 
right heart catheterisation, without the added benefit of measures of afterload 
such as PVR or SV/PP. Furthermore, repeated invasive RHC to monitor an 
individual throughout the course of disease is likely less acceptable to the patient 
when the option of noninvasive imaging of RV function is equally or even superior 
modality in relation to prognosis. This is in agreement with previous study where 
improvement in PVR at RHC did not lead to improved outcome if RVEF continued 
to deteriorate (288). 
4.5.3 Limitations 
The correlation between pressure and volume estimates (Ees/Ea-P and SV/ESV) 
whilst highly significant displayed wide confidence intervals and limits of 
agreement on Bland Altman analysis (-0.78 to 1.9). This effect appeared more 
significant at greater values and at smaller values of RV ESV. V0 estimated by the 
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regression of the pressure-volume relationship (and therefore reliant on only two 
data points, including mPAP at RVESV (as shown in Figure 4.2b) unsurprisingly 
correlated with ESV in agreement with Trip et al (132), however would therefore 
not account for the greater disagreement between coupling estimates at lower 
values of RVESV. As discussed above, estimates of V0 by this method are likely 
inherently less accurate due to application of a linear regression of a slightly 
curvilinear relationship. The limitations of agreement therefore relates to 
impaired precision as a result of the several assumptions made in the derivation 
of each method as discussed in section 4.5.2. 
This was a single centre retrospective observational study. The invasive RV trace 
analysis required manual digitisation from analogue traces for analysis. The RHC 
and CMR (and therefore pressure and volumes) were not performed 
simultaneously. There were however no changes in therapy between 
measurements. The single beat method employed requires several inherent 
assumptions, such as the use of a sine wave to approximate the waveform of 
isovolumetric contraction (421), but despite this Pmax generated from single beat 
method has shown excellent correlation with Pmax derived from multi-beat PV-loop 
analysis at varying levels of venous return (125), which is regarded as the gold 
standard for measuring RV-arterial coupling and ideally should have been included 
for comparison. These studies however would have required alteration of venous 
return through techniques such as inferior vena cava balloon occlusion with 
potential for complications and were felt unacceptable risk to the patient. 
4.5.4 Clinical Implications 
The results described by this chapter indicate that invasive measures of RV 
function (such as RAP or CI) or pressure estimates of RV arterial coupling do not 
add prognostic advantage over imaging of RV volumes to determine function and 
coupling, when assessed at baseline. Imaging is more acceptable than right heart 
catheterisation to the patient particularly for serial monitoring. The results 
presented herein reinforce previous work that outcomes in PAH should focus on 
RV function, rather than metrics of afterload. 
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4.6 Conclusions 
In this chapter we have shown that RV-arterial coupling is inefficient in patients 
with PAH, relates to functional status and other metrics of RV function, and 
predicts outcome when determined by the volume but not the pressure method. 
Patients with PH related to hypoxic lung disease demonstrate impaired RV 
contractile response to increasing afterload in comparison to PAH subjects. RV 
function to predict outcome in PAH is best evaluated by imaging derived SV/ESV 
or EF. In this study, there was no added value of invasive simplified pressure-
derived estimates of RV-arterial coupling. In the following chapter the effect of 
PAH therapy on the simplified volume estimate of RV-arterial coupling will be 
explored.
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Chapter 5 - Non invasive monitoring of the RV-
pulmonary circulation unit in patients treated for 
pulmonary hypertension
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5.1 Introduction 
The results discussed in chapters 3 and 4 show that RV function at diagnosis is a 
strong prognostic factor in both PAH and severe PH associated with chronic lung 
disease. In this chapter, I propose to examine the effect of PH therapy on RV 
function assessed by both SV/ESV in comparison to other indices such as RV 
ejection fraction and stroke volume, and the prognostic value of this change in 
comparison to other commonly implemented outcome measures such as NTproBNP 
and 6MWD.   
As discussed in section 1.3.1, the ability of the right ventricle to adapt to the 
increased afterload that occurs in patients with pulmonary arterial hypertension 
has been recognised in recent years as the major determinant of functional status, 
exercise capacity and prognosis. Whether determined invasively with measures of 
right atrial pressure or cardiac index at RHC (142, 269), or by use of imaging 
modalities such as echocardiogram (422) or cardiac MRI (41), RV dysfunction both 
at diagnosis and during PAH therapy is associated with poorer outcome. 
Importantly, progressive RV dysfunction despite improvement in PVR with therapy 
has been demonstrated by cardiac MRI and associated with poorer outcome (288), 
highlighting the need for monitoring RV function in these patients. 
5.1.1 Effect of pulmonary vasodilator therapy on RV volumes and 
mass 
As discussed in section 1.3.4, several small pharmacological therapeutic studies 
have demonstrated no improvement in RV volumes or mass (302, 326, 327), with 
the exception of some studies showing a reduction in RV mass with sildenafil, but 
not Bosentan suggesting possibility of a drug class effect (324, 325, 329). Larger 
single or multicentre studies with mixed drug therapies have demonstrated 
improvement in RV EDVI and LVEDVI (41, 288, 373). Reverse remodelling after lung 
transplantation (321) or pulmonary endarterectomy (323) has however been 
demonstrated suggesting ability of the RV to recover if significant improvements 
in afterload are made. Increasing RVEDVI and falling LVEDVI but not change in RVM 
during PAH therapy have been demonstrated to predict worse survival (41). 
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5.1.2 Vascular stiffness 
As discussed in section 1.3.2 reduced vascular compliance (i.e. increased stiffness) 
assessed either invasively by SV/PP (285) or non-invasively by RAC MPA (314) 
measured at diagnosis in PAH is associated with poorer survival. In Chapter 4 RAC 
MPA was shown to inversely correlate with Ea (Figure 4.9, r2 = 0.252, p <0.001), a 
measure of total RV afterload. Invasive studies have demonstrated a reduction in 
PVR with PAH therapy, but the effect of therapy on vascular stiffness as assessed 
by RAC MPA is unknown, and if this is a useful marker of therapeutic response. 
5.1.3 RV function during PH therapy 
Small therapeutic studies have reported consistently on improved SV with PDE-5i, 
and Epoprostenol therapy (302, 324), with mixed outcomes in RV ejection 
fraction, with either no effect (326, 327) or improvement with dual therapy in one 
study (329). Larger single or multicentre studies have demonstrated improvement 
in both measures of RV function after PAH therapy (41, 288, 373). Furthermore, 
any further deterioration in RV function assessed by these indices during therapy 
has been clearly linked to worse prognosis despite improvements in afterload 
(288). 
As discussed in chapter 4, RV-arterial coupling, and in particular SV/ESV may be a 
preferable parameter for monitoring RV function during PH therapy as it is less 
pre-load dependent then RV ejection fraction (SV/EDV). Systemic vasodilatory 
effects of pulmonary vasodilators may increase venous return and therefore 
increase EDV, which decreases EF if SV is unaltered. Alternatively, an increase in 
CO (from either increase in heart rate or preload) may decrease PVR (mPAP – 
PAWP /CO) without any change in functional state of the pulmonary circulation. 
SV/ESV as a measure of RV arterial coupling may clarify cofounding effect of 
preload on longitudinal change in RV systolic function in patients undergoing PAH 
therapy.  
Various experimental animal models have examined the pharmacological effects 
of both inotropic agents and pulmonary vasodilators on RV-arterial coupling. 
Dobutamine has been shown to increase RV-arterial coupling by inotropy (increase 
in contractility, Ees) both with (423) and without a decrease in afterload (125, 
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424). Norepinephrine improves RV-arterial coupling through an exclusively 
inotropic effect (423), whilst levosimendan has been shown to improved coupling 
through combined increase in contractility and reduction in afterload in a 
pulmonary banding model of RV failure (424, 425). Epoprostenol has been shown 
to improve RV-arterial coupling by exclusive pulmonary vasodilatory (i.e. 
reduction in Ea) in both overcirculation induced PH (426) and pulmonary artery 
banding models of RV failure (427). Sildenafil administration improved RV-arterial 
coupling due solely to pulmonary vasodilatory effects in acute hypoxic model of 
PH (428), but additionally through positive inotropic effects in a PA banding 
chronic PH model (429). Bosentan administration in a chronic overcirculatory PH 
model did not demonstrate any improvement in contractility (410). These 
experimental studies suggest overall predominantly vasodilatory rather than 
inotropy related effects, with again the suggestion that PDE-5i may have some 
direct myocardial effects. To date no clinical studies have examined effect of PH 
therapy on RV-arterial coupling in PAH. 
5.1.4 6MWD and NTproBNP, surrogate markers of RV dysfunction. 
Cardiac MRI is regarded as the gold standard modality for interrogating RV 
structure and function due to the complex shape and contractile pattern of the 
RV being better suited to a 3D imaging modality. Cardiac MRI is not however 
available in all centres, and not tolerated by some patients due to claustrophobia 
or breathlessness, whilst 3D echocardiography is still largely limited to the 
research field.  
As discussed in section 1.2.5.3, exercise testing in the form of either a walking 
test or cardiopulmonary exercise test in addition to assessing the patient’s 
functional capacity has been used as a surrogate measure of RV function due to 
the relationships demonstrated with peak VO2, cardiac output, and stroke volume 
(290). The 6MWT is commonly employed as it is easy to perform. Absolute distance 
walked has been shown to predict survival both at diagnosis and whilst undergoing 
therapy (286, 290). However, change in 6MWD does not consistently predict 
survival benefit (430), its utility in less affected individuals is confounded by a 
ceiling effect (295) and distance walked is influenced by a number of confounders 
including patient motivation and comorbidity. 
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As discussed in section 1.2.5.4, the biomarker brain natriuretic peptide (BNP) is 
secreted by ventricular cardiomyocytes in response to increased stretch as a result 
of cardiac wall stress. The BNP precursor is split into a biologically active peptide 
and the more stable N terminal fragment (NTproBNP) (296). Both have been shown 
to reflect RV dysfunction and predict prognosis in PAH (301, 431). Biomarkers have 
the advantages of being independent of interpretation or operator skill, non-
invasive and quick to perform in an outpatient clinic.  
Figure 5.1 shows CMR measured RVEF, RVEDVI, 6MWD and NTproBNP for a patient 
with PAH undergoing pulmonary vasodilator therapy from point of diagnosis. As 
can be seen, whilst 6MWD continues to improve almost to a level considered as a 
treatment goal by current guidelines, this masks continued poor RV ejection 
fraction and increasing RV volume which may have been suspected by the 
persistently raised NTproBNP. 
5.2 Aims 
The results described in chapter 4 show that SV/ESV at diagnosis confers no 
prognostic advantage over RVEF, but both are strong predictors of outcome. As 
discussed earlier in this chapter, 6MWD, whilst a commonly employed outcome 
measure in clinical studies, has a number of limitations as a method of monitoring 
during PH therapy, but NTproBNP could potentially be a stronger prognostic 
variable due to a closer relationship to RV function. The aims of this chapter are: 
1. To examine the effect of PAH therapy on RV-arterial coupling assessed by 
the volume method SV/ESV. 
2. To assess the prognostic relevance of change in SV/ESV in comparison to 
other metrics of RV function, RVEF, SV and volumes, MPA RAC (as a 
noninvasive marker of RV afterload), 6MWD and NTproBNP. 
3. To compare relationship of change in NTproBNP (∆NTproBNP) with change 
in RV function in comparison to change in 6MWD (∆6MWD) during time 
course of the patient’s therapy.
  
 
Figure 5.1. Patient example of serial RV function and volumes in comparison to 6MWD and NTproBNP data from time of diagnosis.  
 
Time points represent 1. Diagnosis. 2. After 4 weeks of drug therapy. 3. At 3 months 4. At 1 year. Reference lines ----- lower limit of normal. ••••• upper limit of normal 
(85). 
Panel A demonstrates RV ejection fraction remains below normal range and B RV volume remains increased, with minimal improvement during therapy. Panel C 
however shows that 6MWD continues to increase, reference line of 440m represents ESC guideline for treatment target as a low risk patient (estimated 1 year mortality 
<5%) (432) and as a means of monitoring may provide false reassurance of treatment efficacy in this patient. Panel D demonstrates NTproBNP levels remain high (in 
agreement with suboptimal RV indices). Reference line 215 pg/mL represents ULN in females (379) (guideline target 300 ng/L). 
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5.3 Materials and methods 
5.3.1 Patient recruitment 
52 PAH patients who had a CMR study performed at diagnosis and at least one 
follow up study after a minimum of 3 months of PH therapy were identified from 
the cohort of 140 incident PAH cases described in chapter 4. Patients underwent 
multidisciplinary investigation as described in section 2.1.1. Cardiac MRI 
acquisition and data analysis were carried out as described in section 2.2. 6MWD 
and/or NTproBNP performed within 1 month of CMR was included for comparison. 
Several patients had undergone multiple CMR studies during PH therapy, (between 
2 and 5 CMR studies) with a total of 126 ∆RV values included in the analysis. All 
patients were treated with pulmonary vasodilators in accordance with guidelines.  
5.3.2 Statistical methods 
Statistical analysis was carried out as described in section 2.3. Survival was from 
date of second CMR study used to calculate ∆RV value, and endpoint was date of 
either death, lung transplantation or censoring. Patients were censored if they 
were lost to follow up or alive at last day of study (1st December 2015). Kaplan-
Meier survival curves were calculated, grouping subjects according to increase or 
decrease in SV/ESV, 6MWD or NTproBNP during PH therapy, with comparison of 
groups using logrank test. 
Correlations were performed to examine relationship between absolute and 
change in 6MWD or NTproBNP with RV volumes, function (SV/ESV and RVEF) and 
SV using Pearson or Spearman r and linear or nonlinear regression dependent on 
data distribution. 
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5.4 Results 
The 52 PAH patients in this study, 33 IPAH, 16 CTDPH and 3 POPH, displayed 
impaired RV function at diagnosis, RVEF 36%, SVI 28 mL/m2 and raised NTproBNP. 
The average time to first follow up study was 5.7 months. Table 5-1 shows the 
population characteristics.  
 
Table 5-1. Population Characteristics 
 
  
Age (years) 53 ± 16 
% Female 64 
Aetiology % (n) 
IPAH 
CTDPH 
POPH 
 
63 (33) 
31 (16) 
6 (3) 
mPAP (mmHg) 47 ± 14 
RAP (mmHg) 6 ± 4 
PVR (Wood Units) 10.0 (5.9 – 15.7) 
CI (mL/m2) 2.2 ± 1.7 
RVEF (%) 36 ± 16 
SV/ESV 0.462 (0.295 – 0.837) 
RVEDVI (mL/m2) 88 ± 29 
RVESVI (mL/m2) 59 ± 30 
SVI (mL/m2) 28 ± 11 
6MWD (m) 312 ± 90 
NTproBNP (pg/mL) 852 (272 – 2657) 
Mean ±SD or median (IQR) shown depending on data distribution. 
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5.4.1 Correlations of NTproBNP and 6MWD with RV function 
At diagnosis, NTproBNP correlated with RAP (r = 0.568, p <0.0001), PVR (r = 0.669, 
p <0.001) and RVMI (r = 0.693, p <0.0001) whilst 6MWD did not (r = -0.130, p = 
0.374, r = 0.079, p = 0.588 and r = 0.175, p = 0.230 respectively). There was no 
significant relationship between NTproBNP levels and 6MWD (r = 0.106, p = 0.494). 
6MWD did not correlate with RVEF (r = 0.052) or SV/ESV (r = -0.077), but weakly 
correlated with SVI (r = 0.296, p <0.0001) and increasing RV volumes, RVEDVI r = 
0.281, p = 0.003 and RVESVI r = 0.193, p = 0.041). Figures 5.2 – 5.5 display the 
correlations. 
NTproBNP strongly correlated with RV volumes, r = 0.504 with RVEDVI and r = 
0.655 with RVESVI, and inversely with RV function, r = -0.665 with SV/ESV, r = -
0.727 with RVEF and r =-0.406 with SVI, all p <0.001. Figures 5.6 to 5.9 describe 
the correlations. 
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Figure 5.2. Correlation of six minute walk distance with RV ejection fraction. 
  
No significant relationship was demonstrated, r2 = 0.003, p = 0.585. 
 
 
Figure 5.3. Correlation of six minute walk distance with stroke volume. 
 
Weak correlation was demonstrated (Pearson r = 0.296), y = 22.19 + 0.03x, r2 = 0.088, p = 0.002. 
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Figure 5.4. Correlation of RV end-diastolic volume with six minute walk distance.  
 
Weak positive correlation was demonstrated, y = 0.09x + 59.15, r2=0.079, p=0.003 
 
 
Figure 5.5 Correlation of RV end-systolic volume with 6MWD. 
 
Weak positive correlation was seen, y = 0.06x + 37.66. r2= 0.037, p = 0.041 
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Figure 5.6 Inverse correlation of RV ejection fraction with NTproBNP. 
 
Logarithmic regression shown, y = 76.19 + -6.05*log(x). r2 = 0.433, p<0.0001. 
 
 
Figure 5.7 Inverse correlation of SV/ESV with NTproBNP. 
 
Logarithmic regression shown, y = 1.79 + -0.16*log(x). r2= 0.209, p<0.0001. 
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Figure 5.8 Correlation of RV end-diastolic volume with NTproBNP. 
 
Y = 35.2 + 8.9*log(x). r2= 0.208 , p<0.0001 
 
Figure 5.9 Correlation of RV end-systolic volume with NTproBNP. 
 
y = -10.1 + 10.97*log(x), r2= 0.350, p<0.0001. 
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5.4.2 Change in RV function with therapy 
48/52 patients had CMR performed at diagnosis, and at less than 1 year of follow 
up. RVEF increased from 35±16 to 39±15, p = 0.008 and SV/ESV from 0.461 (0.295 
– 0.837) to 0.616 (0.341 – 1.066) p = 0.036. There was no improvement in RV 
volumes observed, but SVI increased from 27 ± 9 to 31 ± 10, p = 0.004. Figure 5.8 
– 5.12 display the paired analysis. 
35/48 patients had NTproBNP data at both diagnosis and to coincide with first 
follow up CMR, and 42/48 had 6MWD performed. Significant improvement in 6MWD 
but not NTproBNP was demonstrated. Figure 5.13 displays the analysis. 
23 patients had serial CMR measurements at diagnosis, after 3–8 months and 12-
18 months of therapy. A sustained improvement in both SV/ESV and RVEF was 
demonstrated (shown in figures 5.14 – 5.15), SV/ESV increased from 0.390 (0.317-
0.714) at diagnosis to 0.622 (0.421 – 1.099) at 3-8 months (p = 0.028) and sustained 
(but no further significant increase) at 12-18 months, 0.848 (0.489 – 1.157) p = 
0.354. Friedman test p = 0.006. RV volumes did not improve, RVESVI 63 ± 23 to 57 
± 27 and 59 ± 32 mL/m2 (ANOVA 0.242), RVEDVI 92 ± 29 to 91 ± 28 and 97 ± 34 
(ANOVA 0.206) at 3-8 and 12-18 months respectively. 
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Figure 5.10 Improvement in indices of RV systolic function following PH therapy. 
 
RVEF increased from 34.9 ± 16 to 38.9 ± 15 5, p = 0.008 (mean ± SD shown) and SV/ESV from 
0.481 (0.295 – 0.837) to 0.616 (0.341 – 1.066), p = 0.036 (median (IQR) shown). Paired statistical 
analysis performed. 
 
 
 
 
Figure 5.11. RV volumes at diagnosis and after PH therapy. 
 
No improvement in either RVEDVI (89 ± 28 to 90 ± 29 mL/m2, p=0.555) or RVESVI (61 ± 29 to 58 ± 
28 mL/m2, p=0.233) was observed. Mean and SD shown. Paired statistical analysis performed. 
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Figure 5.12. Change in stroke volume and vascular stiffness with PH therapy. 
 
SVI improved from 27 ± 9 to 31 ± 10 mL/m2, p=0.004 but no improvement in RAC MPA was observed 
(21 ± 10 to 23 ± 10%, p=0.174). mean ± SD shown. Paired statistical analysis performed. 
 
 
 
Figure 5.13. Change in six minute walk distance and NTproBNP following PH therapy. 
 
6MWD increased from 314 to 342 m (p=0.016, n=42) but NTproBNP did not, 998 to 726 pg/mL, 
(p=0.534, n=35). Mean ± SD or median (IQR) shown dependent on data distribution, paired statistical 
analysis performed. 
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Figure 5.14 Serial SV/ESV in patients undergoing PH therapy.  
 
Significant and sustained improvement in SV/ESV demonstrated (Friedman test p = 0.006 across 
series). Median (IQR) shown, n = 23. * p = 0.028 ** p = 0.005. no significant increase between 3-8 
and 12-18 months, p = 0.354. 
 
 
Figure 5.15 Serial RV ejection fraction in patients undergoing PH therapy.  
 
RVEF improved at 3-8 months of therapy and was sustained at 12-18 months (ANOVA p = 0.002), 
mean ± SD shown. * p = 0.02 ** p = 0.001, both in comparison to baseline. No significant further 
improvement between 3-8 months and 12-18 months (p = 0.254).  
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26/48 patients received PDE-5i therapy and 18/48 ETRAs (in the remaining 
patients, 1 received Prostanoid therapy, 1 patient a CCB and 2 patients 
combination therapy with both ETRA & PDE5i). Both groups had similar baseline 
characteristics, shown in table 5-2, although more CTD patients received ETRA 
therapy. Those receiving PDE-5i showed greater improvement in RV function 
assessed by either RVEF (36 ± 16 to 41 ± 15 %, p = 0.03) or SV/ESV (0.486 (0.307 – 
0.850) to 0.710 (0.414-1.111) p = 0.049), whilst those receiving ETRAs greater 
improvement in SVI (27 ±11 mL/m2 to 33 ± 11 mL/m2, p = 0.014) and 6MWD (271 
± 65 to 319 ± 85 m, p = 0.011), shown in table 5-3. There was no change in RVMI 
with PDE-5i (49 ± 17 to 49 ± 15 g/m2, p = 0.805) or ETRA therapy (58 ± 28 to 53 ± 
19 g/m2, p = 0.177). 
Examining those with pure IPAH only (excluding patients with co-existent lung 
disease as a factor), similar differential effects on RV function and SV were still 
present (data shown in table 5-4). 
 
 
 
 
Table 5-2. Characteristics of patients receiving Phosphodiesterase 5 inhibitors in 
comparison to those receiving endothelin receptor antagonists. 
 
 Patients receiving 
PDE-5i (n=26) 
Patients receiving 
ETRA (n=18) 
p value 
Age (years) 55 ± 17 52 ± 16 0.607 
Sex (% F) 62 72  
Aetiology 
IPAH 
CTDPAH 
POPH 
 
73 (19) 
19 (5) 
8 (2) 
 
50 (9) 
50 (9) 
 
mPAP (mmHg) 45 ± 12 50 ± 15 0.285 
PVR (Wood Units) 10.0 (5.5 – 14.2) 9.5 (5.9 – 17.8) 0.583 
CI (mL/m2) 2.2 ± 0.6 2.2 ± 0.6 0.908 
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Table 5-3. Change in right ventricular function according to class of drug therapy. 
 
 At diagnosis During therapy p value 
RVEF 
ETRA 
PDE5i 
 
34 ± 17 
36 ± 16 
 
38 ± 14 
41 ± 15 
 
0.098 
0.031* 
SV/ESV 
ETRA 
PDE5i 
 
0.447 (0.275-0.979) 
0.486 (0.307-0.850) 
 
0.620 (0.338-0.923) 
0.710 (0.414-1.111) 
 
0.396 
0.049* 
SVI 
ETRA 
PDE5i 
 
27 ± 11 
28 ± 9 
 
33 ± 11 
30 ± 10 
 
0.014* 
0.146 
RVEDVI 
ETRA 
PDE5i 
 
91 ± 30 
85 ± 25 
 
89 ± 30 
86 ± 23 
 
0.352 
0.722 
6MWD 
ETRA (14) 
PDE5i (24) 
 
271 ± 65 
325 ± 80 
 
319 ± 85 
347 ± 94 
 
0.011* 
0.154 
NTproBNP 
ETRA (11) 
PDE5i (22) 
 
2989 (434-4278) 
998 (238-2059) 
 
1107 (456-4954) 
490 (87-1784) 
 
0.722 
0.106 
    
Mean ± SD or median (IQR) shown and paired t test or wilcoxon matched pairs analysis depending 
on data distribution. 26 patients treated with PDE5i and 18 with ETRA therapy. Reduced number of 
patients receiving ETRA and PDE5i indicated (n) due to missing data for 6MWD and NTproBNP 
only.  
 
Table 5-4. Change in RV function in IPAH patients receiving either Phosphodiesterase 5 
inhibitors or endothelin receptor antagonists. 
 
 At diagnosis During therapy p value 
RVEF 
ETRA 
PDE5i 
 
30 ± 17 
32 ± 12 
 
33 ± 12 
38 ± 14 
 
0.245 
0.022* 
SV/ESV 
ETRA 
PDE5i 
 
0.317 (0.193-0.844) 
0.390 (0.284-0.781) 
 
0.512 (0.286-0.657) 
0.566 (0.403-0.965) 
 
0.678 
0.031* 
SVI 
ETRA 
PDE5i 
 
24 ± 13 
25 ± 7 
 
34 ± 11 
27 ± 10 
 
0.029* 
0.367 
Mean ± SD or median (IQR) shown. Paired data analysis performed. 15 IPAH patients received 
PDE5i and 9 ETRA, no missing data. 
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5.4.3 Relationship between change in RV function with change in 
NTproBNP and 6MWD. 
105 ∆6MWD, 88 ∆NTproBNP and 126 ∆RV values were derived from serial 
measurements from 52 PAH patients described in table 5-1. Table 5-5 displays the 
population median and range.  
∆6MWD correlated with ∆SVI (r = 0.441, p <0.001), ∆RVEF (r = 0.344, p <0.001) and 
∆SV/ESV (r = 0.272, p = 0.005) and negatively with ∆RVESVI (r = -0.235, p = 0.016) 
but not RVEDVI (r = -0.04, p = 0.632). Figures 5.16 – 5.20 display the correlations. 
∆NTproBNP strongly correlated with ∆RVEDVI (r = 0.372) and ∆RVESVI (r = 0.555) 
and negatively with ∆RVEF (r = - 0.569), ∆SV/ESV (r = -0.469) and ∆SVI (r = -0.545), 
all p <0.001. Figures 5.21 – 5.26 display the correlations with change in NTproBNP 
and log transformation of NTproBNP. 
∆6MWD did not correlate with ∆NTproBNP, Pearson r = - 0.202, p = 0.08. 
 
Table 5-5 Population range and median change in RV indices, 6MWD and NTproBNP. 
  
 n median range 
∆RVEF (%) 126 3.8 -24.8 – 47.2 
∆SV/ESV  0.105 -1.18 – 1.65 
∆SVI (mL/m2)  5.2 -16 – 40 
∆RVEDVI (mL/m2)  -0.31 -59 – 66 
∆RVESVI (mL/m2)  -3.9 -68 – 60 
∆6MWD (m) 105 24 -137 – 224 
∆NTproBNP (pg/mL) 88 -83 -5041 – 3193 
Relative change in NTproBNP (%)  -27 -99 - 412 
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Figure 5.16. Correlation of change in 6MWD with change in RV ejection fraction.  
 
Positive correlation between ∆RVEF and ∆6MWD, y = 3.5 + 0.06x, r2= 0.118, p <0.001 
 
 
Figure 5.17 Correlation of change in SV/ESV with change in 6MWD.  
 
Improvement in SV/ESV weakly correlated with 6MWD improvement, y = 0.09 + 1.52E-3x, r2 = 
0.074, p = 0.005
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Figure 5.18 Correlation of change in stroke volume with change in 6MWD. 
  
An increase in SVI was associated with increase in 6MWD, y = 2.31 + 0.05x, r2 = 0.195, p <0.0001
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Figure 5.19 Change in 6MWD in comparison to change in RV end-diastolic volume. 
 
No significant correlation was observed, r = -0.04, p = 0.682. 
 
 
Figure 5.20 Correlation of change in RV end-systolic volume with change in 6MWD.  
 
Weak relationship only seen, y = -2.67 + -0.07x, r2 = 0.06, p = 0.016  
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Figure 5.21 Correlation of change in RV ejection fraction with change in NTproBNP.  
 
Falling RVEF strongly associated with increased NTproBNP, y = 4.57 + -5.85E-3x, r2 = 0.324, 
p<0.0001 
 
 
Figure 5.22 Correlation of change in RV ejection fraction with change in log transformation 
of NTproBNP. 
y = 2.35 + -5.42x, r2 = 0.299, p<0.0001. 
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Figure 5.23 Correlation of change in SV/ESV with change in NTproBNP.  
 
Fall in SV/ESV strongly associated with increase in NTproBNP, y = 0.12 + -1.59E-4x, r2 = 0.220, 
p<0.0001 
 
Figure 5.24 Correlation of change in SV/ESV with change in log transformation of NTproBNP 
 
y = 0.05 + -0.16x, r2 = 0.255, p<0.0001 
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Figure 5.25 Correlation of change in stroke volume with change in NTproBNP. 
 
y = 4.62 + -3.66E-3x, r2 = 0.189, p <0.0001. 
 
 
Figure 5.26 Correlation of change in stroke volume with change in log transformation of 
NTproBNP. 
 
y = 62.59 + -4.36x, r2 = 0.248, p<0.0001 
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Figure 5.27 Correlation of change in RVEDVI with change in NTproBNP. 
 
Increasing RV end diastolic volume associated with increase in NTproBNP, y = 2.21 + 0.01x, r2 = 
0.297,p <0.0001 
 
 
Figure 5.28 Correlation of change in RV end-diastolic volume with change in log 
transformation of NTproBNP. 
 
y = 3.57 + 6.18x, r2 = 0.149, p<0.0001 
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Figure 5.29 Correlation of change in RV end-systolic volume with change in NTproBNP. 
 
Increasing RV end diastolic volume associated with increase in NTproBNP, y = -2.14 + 0.01x, r2 = 
0.512, p<0.0001 
 
 
Figure 5.30 Correlation of change in RV end-systolic volume with change in log 
transformation of NTproBNP. 
 
y = 0.51 + 9.06x, r2 = 0.337, p<0.0001
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5.4.4 Prognostic significance of change in RV function during PH 
therapy. 
26 deaths (50%) and 1 lung transplantation occurred during the mean follow up 
period of 2626 days. A comparative analysis of survivors and non survivors after 5 
years of follow up is shown in table 5-6. Survivors demonstrated greater 
improvement in 6MWD, NTproBNP and RVESVI. 
There were 7 deaths (50%) in the cohort of 14 patients with a fall in 6MWD at 
follow up in comparison to 16/32 (50%) in those with a stable or increased 6MWD, 
mean estimated survival 1909 versus 2495 days respectively, logrank p = 0.176. 
Figure 5.31 displays the KM survival curve. 
Patients with a decrease in NTproBNP showed a significantly improved outcome 
over those with an increase in levels, mean survival 2788 vs 1451 days, logrank p 
<0.001. 14/15 (93%) versus only 5/22 (23%) died during the follow up period. Figure 
5.32 displays the KM survival curve. 
 
Table 5-6 Comparative analysis of survivors and non survivors at 5 years according to 
change in RV indices, 6MWD and NTproBNP. 
  
 Alive (n=29) Deceased (n=17) p value 
∆RVEF 5 (-3 – 9) -3 (-9 – 9) 0.241 
∆SV/ESV 0.096 (-0.08 – 0.321) -0.069 (-0.156 – 0.146) 0.328 
∆SVI 5 ± 9 2 ± 7 0.266 
∆RVEDVI -0.5 ± 17 10 ± 21 0.062 
∆RVESVI -5 ± 16 8 ± 20 0.026* 
∆6MWD 50 ± 61 -5 ± 72 0.015* 
∆NTproBNP -130 (-615 – 51) 163 (-43 – 1458) 0.013* 
Relative change 
in NTproBNP 
-41 (-74 – 15) 21 (-26 – 66) 0.022* 
Survivors displayed reduction in NTproBNP (expressed as either absolute or %change) and RV 
end-systolic volume and increase in 6MWD in comparison to non-survivors. 
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Figure 5.31 Kaplan Meier survival curve according to change in 6MWD after instigation of 
PH therapy. 
  
No significant difference in outcome observed between those with stable/increase in 6MWD (n = 
32, solid line) and those with decrease in 6MWD (n = 14, dashed line), logrank p = 0.176. 
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Figure 5.32 Kaplan Meier survival curve according to change in NTproBNP after initiation of 
PH therapy. 
 
Patients with reduction in NTproBNP levels (n = 22, solid line) showed improved survival in 
comparison to those with increasing levels (n = 15, dashed line), logrank p<0.0001. 
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15/18 (83%) patients with decrease in SV/ESV died in comparison to 12/34 (35%) 
with a stable or increased SV/ESV after initiation of PH therapy. Mean survival 
estimates 1594 versus 2704 days, p = 0.002. Figure 5.33 displays the KM survival 
curve. All patients with change in RV function according to SV/ESV displayed same 
increase or decrease in function according to RVEF (i.e. KM survival curve 
identical) defined by a ≥3% change (433). 
 
 
 
Figure 5.33. Kaplan Meier survival curve according to change in SV/ESV with PH therapy. 
 
Decreased survival was demonstrated in those patients with a fall in SV/ESV (n = 18, dashed line) 
in comparison to those with a stable or increased in SV/ESV (n = 34, solid line). Logrank p = 0.002. 
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Increasing NTproBNP, RV volumes and decreasing SV/ESV, SVI, RVEF and 6MWD 
were associated with poorer outcome on univariate cox proportional hazards 
regression. Table 5-7 displays the hazard ratios for the analysis. On multivariate 
survival analysis with age and mPAP at diagnosis, ∆NTproBNP (HR 1.622 95%CI 
1.066-2.468, p=0.024) and ∆RVESVI (HR 1.030 95%CI 1.010 – 1.050, p=0.003) but 
not ∆6MWD (HR 0.995 95% CI 0.990-1.001, p=0.129) remained independent 
predictors of outcome. 
 
 Table 5-7. Change in 6MWD, NTproBNP and indices of RV function to predict outcome.  
 
 Univariate model Multivariate model * 
 HR (95%CI) p value HR (95%CI) p value 
∆RVEF 0.949 (0.920 – 0.979) 0.001   
∆SV/ESV 0.316 (0.166 – 0.604) <0.001   
∆SVI 0.959 (0.925 – 0.994) 0.023   
∆RVEDVI 1.020 (1.006 – 1.034) 0.004   
∆RVESVI 1.032 (1.016 – 1.047) <0.001 1.030 (1.01 – 1.05) 0.003 
∆6MWD 0.994 (0.989 – 0.999) 0.016 0.995 (0.990 – 1.001) 0.129 
∆NTproBNP 2.125 (1.452 – 3.111) <0.001 1.622 (1.066 – 2.468) 0.024 
Univariate and multivariate (with age and mPAP at diagnosis) cox proportional hazards regression. Increasing ∆RVESVI and ∆NTproBNP predictive of poorer survival..
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5.4.5 Change in vascular stiffness (RAC MPA) as an outcome 
measure 
At diagnosis, PVR negatively correlated with RAC MPA, r = -0.350, p = 0.013 (n = 
50) suggesting RAC was reasonable measure of RV afterload in this population. 108 
∆RAC values were calculated from 47/50 patients with serial measurements. 
Median ∆RAC -0.20% (range -23 to +42 %). ∆RAC did not correlate with ∆6MWD (n 
= 90, r = 0.173, p = 0.104) nor change in RV function, ∆RVEF (r = 0.169, p = 0.081), 
∆SV/ESV (r = 0.174, p = 0.072).  
∆RAC did not predict survival on univariate cox proportional hazards regression, 
HR 0.992 95%CI 0.971 – 1.013, p = 0.444. There was no associated improvement in 
survival in those whom improved RAC (n = 21) in comparison to those with further 
decrease in RAC (n = 26) after PH therapy, logrank p = 0.917. Figure 5.34 displays 
the Kaplan Meier survival curves. 
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Figure 5.34. Kaplan Meier survival plot according to those with improved RAC MPA in 
comparison to those with further fall during PH therapy. 
 
No significant difference in survival was observed in those with improved (increase) in RAC (n=21, 
solid line) versus further decrease (n=26, dashed line), 1 year and 3 year survival 100 versus 92 % 
and 74 versus 76% respectively, logrank p = 0.917. 
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5.5 Discussion 
The results described by this chapter show improvement in RV-arterial coupling 
determined by the volume method SV/ESV with PAH therapy, and poorer survival 
in those patients with a further fall during therapy. In agreement with previous 
studies, improvement in RVEF and SV but not RV volumes or mass was also seen. 
These results confirm previous studies that parameters of RV dysfunction obtained 
at diagnosis and monitoring of those same variables (i.e. NTproBNP, RV ejection 
fraction and volumes) have prognostic significance in the evaluation of patients 
with PAH undergoing drug therapies. Additionally, changes in NTproBNP were 
shown to more closely parallel changes in RV volumes and systolic function than 
6MWD in patients undergoing PH therapy and independently predict survival. 
5.5.1 Determining change in RV function and afterload with CMR 
PAH specific therapies in current clinical use target one of three pathways 
involved in vascular remodelling and vasoreactivity of the pulmonary vasculature 
resulting in a reduction in PVR. As already discussed, progressive RV dysfunction 
however may occur despite this decrease in PVR. In early PAH, with largely 
preserved RV function and cardiac output, this reduction in PVR results in a fall in 
mPAP (as PVR equals mPAP-PAWP/CO) and therefore RV power output (CO x 
mPAP). In severe PH where RV dysfunction and failure has already ensued, 
therapeutic fall in PVR will translate to improvement in CO rather than fall in 
mPAP and therefore no change in RV work and little/no beneficial impact on the 
RV. Recent meta-analysis looking at pump function across clinical trials 
demonstrated that PAH specific therapies whilst reducing PVR and leading to 
reduction in mPAP and increase in SV are not associated with increase in 
contractility suggesting these therapies have predominantly vasodilatory and little 
or no cardiac specific effects (331). The results here show increase in SVI with 
therapy, but no improvement in RAC MPA with PH therapy, and no relationship to 
outcome in those with increased RAC (i.e. improved vascular stiffness). Due to the 
inverse hyperbolic relationship between compliance and PAP, by the time mPAP 
rises to diagnostic threshold compliance has reached plateau. This may explain a 
lack of effect seen with PH therapy in RAC, and the lack of significance of ∆RAC 
as a prognostic variable. Perhaps the utility of assessing RAC MPA lies in screening 
at risk populations for early pulmonary vascular disease where large falls in RAC 
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(or SV/PP) with minimal rise in PVR or mPAP as shown in chapter 3 for lung disease 
patients with PH. Further fall in either SV/ESV or RVEF however was associated 
with worse survival, but there was no prognostic advantage of SV/ESV over RVEF. 
This again suggests in agreement previous studies that outcome measures to assess 
improvements in RV function rather than afterload with PAH therapy are of more 
prognostic significance. In the situation where CMR is not readily available for this 
purpose, the closer relationship to NTproBNP suggests this is a more suitable 
measure for the clinic than 6MWD, which showed some relationship to SV, but 
poor (or contradictory relationship as 6MWD positively correlated with increased 
RVEDVI) relation to RVEF. 
Whilst RVEF at baseline was a strong predictor of outcome as shown in chapter 4 
and further fall during therapy was associated with poorer survival, ∆RVESVI but 
not ∆RVEF was an independent predictor of outcome. This may reflect the small 
change in RVEF observed (median 4%), although range showed considerable 
variation around this. RV ejection fraction is both a composite measure and 
preload dependent measure of RV systolic function, and perhaps use of ∆RVEF 
lacks sensitivity whilst increasing ∆RVESVI suggests declining contractility and is 
less preload affected. ∆SV/ESV which is proposed as less preload dependent did 
not perform superiorly in this study however.  
5.5.2 Significance of change in NTproBNP during PAH therapy 
Levels of NTproBNP (and BNP) have been shown to inversely correlate with RVEF 
and cardiac output, and correlate with mPAP, RAP, RVM and total pulmonary 
vascular resistance in PAH (297, 298). Changes in levels have been shown to 
parallel haemodynamics and functional status of PAH patients during treatment, 
and relative change in NTproBNP reflect relative change in CMR indices of RV 
structure and systolic function. High NTproBNP levels or in particular increasing 
levels during follow up have been shown to be independent predictors of mortality 
(299-301). The results described here add to the growing evidence in the literature 
that biomarkers such as NTproBNP are strong prognostic variables in PAH and 
reflect RV function, with increasing levels indicative of increasing RV volumes and 
reduction in systolic function. Additionally, in agreement with the recent study by 
Nickel et al (283), the results here show that ∆NTproBNP is an independent 
predictor of outcome in patients undergoing PH therapy, and potentially a superior 
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outcome measure than ∆6MWD. Increasing ∆RVESVI was also an independent 
predictor of outcome. However serial NTproBNP measurements have the added 
benefit of being readily obtained and monitored in a clinical outpatient setting 
unlike cardiac MRI indices of RV function. 
5.5.3 Significance of change in 6MWD during PAH therapy 
6MWD is known to correlate with peak oxygen pulse (which in turn correlates to 
SV and therefore indirectly RV function), CO and total pulmonary resistance, and 
to fall in proportion to worsening FC in PAH (290). Data in the literature is limited 
on the relationship between change in RV function and change in 6MWD during 
therapy. In patients with pulmonary hypertension of varying aetiology, 6MWD has 
been shown to correlate with SVI but not to RV ejection fraction or volume (434). 
Improved RV stroke volume with Epoprostenol therapy has been shown to relate 
to improved 6MWD in one small study, with the most significant increase in SV 
occurring in the first 4 months (302). In a small clinical study of Bosentan treated 
PAH patients, 6MWD improved more in those with an increase in RVEF in 
comparison to those with a stable or decreased RVEF (+98 vs -37 m, p = 0.01) 
(326). Other clinical studies have not however correlated functional improvement 
with improvement in haemodynamic parameters. 6MWD has several important 
limitations as an outcome measure. As discussed in section 1.2.5.3 6MWD is 
influenced by a number of confounders including patient motivation, age, weight 
and comorbidity. A recent study looking at utility of exercise variables including 
6MWT to predict outcome in IPAH versus associated PAH found whilst distance 
walked was of significance in those with IPAH this was not the case in patients 
with PAH associated with other aetiology such as connective tissue disease where 
one would expect limitations related to other factors such as degree of 
musculoskeletal disease (292). Additionally, a ceiling effect may occur whereby 
in those with greater baseline walk distance treatments that improve 
haemodynamics and symptoms may not translate into further additional 
significant increment in distance walked (295). All of these studies provide 
explanations for the poorer or even lack of correlation described here between 
absolute or ∆6MWD with absolute or ∆RVEF and ∆SVI. 
At diagnosis, lower 6MWD, between 250 – 332 m, have been shown to predict poor 
survival in IPAH patients (286, 290, 435). Improvement in absolute 6MWD above 
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380m after 3 months of PH therapy has been shown to confer improved survival, 
but prognostic significance of a change in 6MWD has not been consistently 
demonstrated (430, 436). A pooled analysis of 10 placebo controlled drug trials in 
PAH found that ∆6MWD accounted for only 22.1% of the treatment effect (291), 
with a calculated minimum of 41.8m corresponding to a significant reduction in 
clinical events. These studies however are confounded by select population for 
trial entry including a threshold minimum distance walked. The patients described 
in this chapter reflect treatment in a real life clinical setting, but in agreement 
with previous meta-analyses did not find ∆6MWD to independently predict 
outcome. 
5.5.4 Differential effects of PDE-5i and ETRA therapy on RV 
function 
The results described here suggest the possibility of greater improvement in RV 
function (assessed by either RVEF or SV/ESV) with PDE-5i than ETRAs. This would 
be in agreement with pre-clinical studies in animal models which have raised the 
possibility of direct myocardial effects with improvement in contractility with 
PDE-5i but not ETRAs (429). The conclusions that can be drawn from this study 
however are limited due to the retrospective nature of the study, so whilst 
characteristics of groups were similar this effect would be better examine in case 
matched prospective manner. More patients received PDE-5i than ETRAs which 
could bias the statistical analysis. Differential effects of class of PAH therapy on 
RV function would be important to evaluate further, as it would provide evidence 
for need of patient tailored therapy, such as combination therapy or PDE-5i in 
those with RV dysfunction at diagnosis. 
5.5.5 Limitations 
This was a single centre retrospective observational study. 6MWD and NTproBNP 
levels included for the study were obtained within 1 month of MRI measurements. 
Data on renal function was not collected and therefore unable to examine the 
potential influence of fluctuations in renal function on NTproBNP levels. Despite 
these limitations, correlations between 6MWD and NTproBNP with RV indices were 
comparable to previous work (431, 434). 
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5.6 Conclusion 
Both SV/ESV and RVEF are improved by PAH therapies. Further fall in SV/ESV 
during PAH therapy is associated with poorer survival, but this measure of RV 
function offers no additional prognostic value over RVEF in this study. Both 
absolute and ∆NTproBNP more closely reflect changing RV function and volume 
than 6MWD in patients undergoing PH therapies. ∆NTproBNP but not ∆6MWD is an 
independent predictor of outcome and is an attractive readily accessible method 
for monitoring RV function in a clinic setting. 
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Chapter 6 - General Discussion and Conclusions.
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6.1 Background 
Whilst the initial insult in PAH involves progressive vasculopathy of the pulmonary 
circulation, survival is determined by RV adaptation to the increased afterload 
that occurs, with patients ultimately dying of RV failure. Factors that influence 
this adaptation are complex, and include not only the severity of pulmonary 
vascular disease but rate of onset of PH, underlying disease aetiology, genetics, 
inflammation, neurohormonal activation, coronary perfusion and myocardial 
metabolism. RV afterload is a complex interplay of resistance, compliance and 
wave reflection and whilst commonly quoted measures of PVR are employed 
clinically, this assesses only part of this afterload, perhaps described better by 
effective arterial elastance (Ea). We know from the literature that reduction in 
afterload (defined by PVR) is not indicative of improved outcome in the face of 
continued RV dysfunction, and indeed further fall in RVEF despite improved PVR 
is associated with poorer survival. 
Given the importance of the right ventricle in PAH, preservation and improvement 
of RV function should be an important goal of PH therapy, but to date there is 
little data on the effect of these treatments on RV function and contractility, and 
whether one therapy has benefits over another in the setting of RV dysfunction. 
Simple, reproducible noninvasive measures of RV function may help establish the 
optimal therapeutic approach to RV dysfunction and improve management of PAH 
patients. At present it is unclear what the optimal method of assessing RV function 
is, with hemodynamic studies demonstrating the predictive value of RAP and CI 
(142, 269), echocardiography studies indicating the value of TAPSE and pericardial 
effusion (272, 437), CMR studies highlighting predictive value of RVEF, RV volumes 
and SV (41), and finally the biomarker NTproBNP (299, 300) or 6MWD have been 
linked to RV function and prognosis. Additionally recent research interest has 
focused on RV-arterial coupling, a measure of RV contractility in the context of 
the pulmonary vascular load which ideally requires instantaneous pressure and 
volume measurement determined invasively at increasing levels of preload, which 
therefore has limited clinical application at the bedside. From physiological 
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principles this measure has advantages over other commonly quoted measures of 
RV function and may be a superior metric to monitor RV function in patients 
undergoing therapy. CMR can be used to estimate RV-arterial coupling by the ratio 
of SV to RV ESV, which is a more attractive modality for clinical use. 
Whilst the prognostic significance of RV dysfunction in PAH is well established in 
the literature, less study has focussed on the importance of RV dysfunction in PH 
associated with lung disease, and the utility of imaging the RV with CMR or 
monitoring indirect markers of RV dysfunction such as NTproBNP may be of use in 
a disease where development of PH is associated with significant morbidity and 
mortality, and treatment options other than transplantation or supplementary 
oxygen provision, non-existent.  
6.1.1 Limitations of current methods employed to assess RV 
function and treatment response in PAH 
Right heart catheterisation is essential for the diagnosis of PAH, but invasive in 
nature and a small but real risk of complications limits its use as a regular follow 
up tool to monitor the patient during treatment. Over 20 different 
echocardiography parameters of RV structure and function have been identified, 
with several linked to prognosis in PAH (438). As discussed in section 1.1.2 
however, the complex structure and contractile pattern of the RV is less well 
suited to accurate measurement using 2D methodology, and particularly in PAH 
after onset of RV dilatation and dysfunction, systolic function is less 
representative by TAPSE due to presence of increasing TR and importance of 
transverse shortening in RV ejection. In addition, the technique is operator 
dependent, lacks standardised models for determination of volume or ejection 
fraction and may be difficult to interpret in clinical situations such as lung disease 
or obesity. Despite this, echo is readily available, inexpensive and safe and 
therefore likely to remain an important modality for both detecting PH, and 
assessing the RV. The development and validation of new methods including 
research field of 3D echo may address some of these limitations in the future. 
As discussed in section 1.2.5.3 6MWT is commonly employed in the clinic and as 
endpoint in clinical drug trials to assess both functional status but also indirectly 
RV function due to its relationship with V02max and CO. 6MWD is known to relate 
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to survival (290), but change in 6MWD does not consistently relate to outcome. 
Furthermore, relationship to RV EF has not been demonstrated and distance 
walked is also influenced by a number of factors such as patient co-morbidity or 
effort.  
The biomarker NTproBNP, as discussed in section 1.2.5.4, is known to correlate 
with RV volumes and falling RVEF, and change in levels reflects change in RV 
structure during therapy (297). Additionally, high levels are associated with poorer 
prognosis (300). Levels are affected by LV dysfunction, renal clearance and age, 
and it is uncertain what constitutes a validated threshold for increased risk from 
current literature. It is however easy to monitor in an outpatient setting.  
6.1.2 Potential advantages of cardiac MRI as a clinical outcome 
measure 
The advantages of CMR in assessing RV structure and function were described in 
detail in section 1.3. It is regarded in the literature as the gold standard method 
for assessing the RV due to high inter and intra observer reproducibility, and 3D 
modality is better suited to complex morphology of the RV. RV dilatation, low SV 
and RVEF have all been shown to predict poor outcome in PAH, with further 
decline during therapy particularly associated with poorer survival (41, 288).  
Furthermore, this modality offers the opportunity to study the RV-pulmonary 
circulation as a unit, with flow measurements in the great vessels also available. 
RV-arterial coupling represents matching of RV adaptation to the increased 
afterload that occurs in PAH. As discussed in detail in section 1.1.4.3 it is possible 
to assess this using CMR as SV/ESV ratio. This method of assessing RV function, 
particularly during the monitoring of patients undergoing PAH therapy, should be 
superior based on physiological reasoning to the commonly employed RVEF as it is 
less preload dependent.  
CMR imaging is expensive and not readily available in all PH centres. The 
advantages described above, and the non-invasive nature make this an attractive 
modality to employ in monitoring of patients and is likely more acceptable to the 
patient. 
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6.2 Imaging right ventricular dysfunction in pulmonary 
hypertension 
The aims of this thesis were to identify the optimal non-invasive method of 
monitoring RV dysfunction in PAH where treatment is clearly established, and 
contrast this to PH in chronic lung disease where the right ventricular 
characteristics, particularly with regard to severe or “disproportionate” PH has 
not been previously well studied with CMR.  
In chapter 3 CMR imaging demonstrated that in PH associated with lung disease 
RV function is preserved, however in severe PH/lung disease (defined as mPAP ≥ 
35mmHg) RV dysfunction is prevalent and shows similar characteristics to IPAH 
patients. This RV dysfunction strongly relates to prognosis, and a reduction in 
NTproBNP and improvement in 6MWD was seen with PAH targeted therapy. 
Previous trials of PAH therapy in group 3 disease has not focussed on treating 
severe PH phenotype, which may explain lack of treatment response reported 
previously in the literature (340, 342, 343). Additionally, CMR indices of PA 
stiffness or RVM performed well as screening tools to detect PH associated with 
lung disease where echocardiography to estimate sPAP may be difficult due to 
poor acoustic windows that often result in hyperinflated lung disease patients. 
In chapter 4 we saw that RV-arterial coupling assessed by either the pressure 
(Ees/Ea-P) or volume (SV/ESV) method was reduced in PH in comparison to normal 
subjects. Those with severe PH associated with lung disease potentially had 
disproportionately worse RV adaptation in comparison to PAH subjects (assessed 
by Ees/Ea-P in this chapter, and by higher NTproBNP, lower RV mass in chapter 3) 
which may be a potential explanation (in addition to the lung disease) for the 
significantly worse survival in this group. There was no advantage of SV/ESV over 
RVEF in predicting survival (although arguably the p-value was stronger for 
SV/ESV) suggesting despite physiological reasoning that SV/ESV is a superior 
metric of RV function, that either can be employed to determine outcome. 
Invasive measurements of Ees/Ea-P or RAP/CI had no prognostic advantage over 
CMR imaging of RV function.  
In Chapter 5 we saw improvement in RV-arterial coupling (assessed by SV/ESV) 
with PH therapy, and in agreement with previous studies improvement in other 
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indices of RV function, RVEF and SV. Deterioration in either measure of RV systolic 
function SV/ESV or RVEF during therapy was associated with worse outcome, with 
nether variable having prognostic advantage. NTproBNP closely related to change 
in RV function, whilst 6MWD did not, and change in NTproBNP but not 6MWD 
related to outcome, which was also seen in chapter 3 in patients with severe 
PH/lung disease.  
These studies suggest that CMR imaging of RV function, or use of NTproBNP in the 
clinic, in either PAH or severe PH/lung disease patients has the strongest 
prognostic benefit in monitoring patients undergoing therapy. Invasive 
haemodynamics or estimates of RV-arterial coupling had no additional prognostic 
advantage. 6MWD, whilst a good measure of functional limitation, performed 
inferiorly as an outcome measure in both pulmonary arterial disease, but also in 
a treated population with severe PH and chronic lung disease, and poorly related 
to RV function. This has implications in terms of endpoints for clinical trials where 
RV imaging is not commonly employed as an outcome measure of treatment 
efficacy, and in the clinic where NTproBNP can be readily employed to monitor 
RV response to therapy. 
6.3 Future directions. 
In the past the right heart was largely ignored by researchers or clinicians in 
cardiopulmonary fields. In 2006, the National Heart, lung and Blood Institute 
identified RV physiology as a priority in cardiovascular research (439). It is now 
increasingly evident the fundamental role the right heart plays in cardiopulmonary 
performance in not only pulmonary hypertension, but in normal subjects and those 
with left heart or intrinsic right heart disease. Future treatment advances in 
pulmonary hypertension will not only depend on development of drugs to target 
the molecular pathways involved in pulmonary vascular remodelling, but for the 
reasons drawn together in this thesis, recognise that the RV is an important 
therapeutic target in its own right.  
In chapter 3 we saw that RV performance is of equal significance in severe 
pulmonary hypertension related to lung disease as it is in IPAH, and is a potential 
focus for research in therapies for this poorly studied disease. Significant increase 
in SV was demonstrated in this small cohort, which has not been shown in previous 
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studies of haemodynamic response to pulmonary vasodilators in chronic lung 
disease with mild-moderate PH (340, 349) and may explain why an increase in 
6MWD was seen in this study and not consistently in previous studies of mixed (or 
even no) severity of associated PH. Future study on the role of pulmonary 
vasodilators in severe PH/lung disease could focus on improvement in RV 
performance as an outcome, rather than 6MWD which will also be hampered by 
ventilatory limitation, and whether if such an improvement is demonstrated this 
translates to improved survival. Additionally, the results in both chapter 3 and 4 
suggest impaired RV adaptation to increased afterload in severe PH/chronic lung 
disease in comparison to PAH which would be better addressed in a case matched 
prospective study. 
The work described in chapter 5 may support differential effects of PH therapies 
ETRAs and PDE-5i on RV function. This avenue is of interest in light of recent study 
AMBITION where up front combination therapy at diagnosis was associated with 
improved outcome (440). Focussing future research on pharmacological effects of 
these therapies on RV function may lead to better understanding of therapy 
regimes for those with RV dysfunction. Pre and post therapy studies combining 
RHC and CMR to determine Ees by the single beat method may address differential 
effects on RV contractility between drug classes.  
This work clearly shows that RV function is strongly linked to outcome in both PAH 
and lung disease PH, and that improvement in 6MWD, the most commonly 
employed outcome measure in current PAH therapy clinical trials, does not 
necessarily translate in to improved survival nor reflect RV function. Future 
clinical trials of pulmonary vasodilator therapy should also include RV specific 
functional outcomes, and either SV/ESV or RV ejection fraction determined by 
CMR is an attractive non-invasive endpoint.  
6.4 Conclusions. 
This thesis demonstrates the strong prognostic significance of RV function assessed 
by CMR imaging by either RV-arterial coupling (SV/ESV) or ejection fraction in both 
PAH and severe PH complicating chronic lung disease. Equal focus on RV function 
in addition to pulmonary vascular disease is therefore critical in determining 
clinical response and development of therapeutic avenues. 
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